{"PMC7492708": [["As we already warned in the month of March, there was a rapid expansion of the Sars-CoV-2 coronavirus in Spain, mainly due to the inaction of the Government, allowing numerous mass demonstrations for demands or celebrations, despite knowing, as was shown later, the consequences of having allowed it.1", [["Sars-CoV-2 coronavirus", "ORGANISM", 79, 101], ["CoV-2 coronavirus", "SPECIES", 84, 101], ["Sars-CoV-2 coronavirus", "SPECIES", 79, 101], ["a rapid expansion", "PROBLEM", 54, 71], ["the Sars-CoV", "PROBLEM", 75, 87], ["coronavirus", "PROBLEM", 90, 101], ["celebrations", "PROBLEM", 211, 223], ["rapid", "OBSERVATION_MODIFIER", 56, 61], ["expansion", "OBSERVATION_MODIFIER", 62, 71], ["numerous", "OBSERVATION_MODIFIER", 167, 175], ["mass", "OBSERVATION", 176, 180]]]], "PMC7162629": [["We welcome the G20's recognition that the coronavirus disease 2019 (COVID-19) pandemic \u201ccalls for a transparent, robust, coordinated, large-scale and science-based global response in the spirit of solidarity\u201d and note its commitment to \u201cdo whatever it takes\u201d to overcome the pandemic, along with relevant international organisations.1", [["coronavirus disease", "DISEASE", 42, 61], ["coronavirus", "ORGANISM", 42, 53], ["the coronavirus disease", "PROBLEM", 38, 61], ["coronavirus disease", "OBSERVATION", 42, 61]]]], "6acc31495847986da925c8cbac06c4fbde0c1471": [["W ith the signing of the Pandemic and All-Hazards Preparedness Act into law in December 2006, the Biomedical Advanced Research and Development Authority (BARDA) was created, and given a $1.07-billion budget for the next two years to galvanize the development of new products to counter security threats, including biological threats.", [["Pandemic", "DISEASE", 25, 33], ["new", "OBSERVATION_MODIFIER", 262, 265]]], ["Although it is hoped this will push more products from preclinical research through the clinic, a survey of R&D programs on biodefense reveals that only a very small number of vaccines and therapeutics targeting potential bioterrorism agents are inching their way into the clinic.A survey of biodefenseBiowarfare and bioterrorism have been used for centuries to terrorize, weaken, incapacitate and defeat armies and whole populations of people.", [["people", "ORGANISM", 437, 443], ["people", "SPECIES", 437, 443], ["vaccines", "TREATMENT", 176, 184], ["therapeutics", "TREATMENT", 189, 201], ["bioterrorism agents", "TREATMENT", 222, 241], ["biodefenseBiowarfare", "TREATMENT", 292, 312], ["bioterrorism", "PROBLEM", 317, 329]]], ["Historically, the pathogens used were naturally occurring, such as the plague and smallpox.", [["smallpox", "DISEASE", 82, 90], ["the pathogens", "PROBLEM", 14, 27]]], ["However, with new genetic manipulation technologies and bacterial and viral culturing capabilities, it is possible to engineer organisms with resistance to common antibiotics and antivirals for conducting bioterrorism attacks.A survey of biodefenseIn addition, with advancements in modern travel and trade, diseases endemic to specific geographic regions can be spread across the globe.", [["new genetic manipulation technologies", "TEST", 14, 51], ["bacterial and viral culturing capabilities", "TEST", 56, 98], ["common antibiotics", "TREATMENT", 156, 174], ["antivirals", "TREATMENT", 179, 189], ["conducting bioterrorism attacks", "PROBLEM", 194, 225], ["diseases endemic", "PROBLEM", 307, 323], ["globe", "ANATOMY", 380, 385]]], ["For example, severe acute respiratory syndrome (SARS) spread from Southeast Asia throughout the world within a matter of weeks in 2003 through international travel.", [["acute respiratory syndrome", "DISEASE", 20, 46], ["SARS", "DISEASE", 48, 52], ["severe acute respiratory syndrome", "PROBLEM", 13, 46], ["SARS", "PROBLEM", 48, 52], ["severe", "OBSERVATION_MODIFIER", 13, 19], ["acute", "OBSERVATION_MODIFIER", 20, 25], ["respiratory syndrome", "OBSERVATION", 26, 46]]], ["The resulting worldwide disruptions in international business, travel and daily life were widely reported in the media and created fear in many members of the public.", [["worldwide", "OBSERVATION_MODIFIER", 14, 23], ["disruptions", "OBSERVATION_MODIFIER", 24, 35]]], ["Regional or local dis-eases were once regarded as 'traveler's diseases' that had little probability of spreading through developed countries with advanced public health systems.", [["Regional or local dis-eases", "PROBLEM", 0, 27], ["'traveler's diseases'", "PROBLEM", 50, 71], ["advanced public health systems", "PROBLEM", 146, 176], ["local dis-eases", "OBSERVATION", 12, 27]]], ["However, as the SARS epidemic showed, even cities with advanced hospital and public health systems, such as Hong Kong and Toronto, could not initially contain and control the spread of the disease.A survey of biodefenseTo present a clear picture to those interested in biodefense disease prevention and treatment, we have accessed commercial drug pipeline databases, government publications and websites, company websites and pharmaceutical news reporting services to identify therapeutics and vaccines in development, to sort through inconsistencies and omissions and to determine the stage of development for these products.", [["SARS", "DISEASE", 16, 20], ["the SARS epidemic", "PROBLEM", 12, 29], ["the disease", "PROBLEM", 185, 196], ["biodefense disease prevention", "TREATMENT", 269, 298], ["treatment", "TREATMENT", 303, 312], ["therapeutics", "TREATMENT", 477, 489], ["vaccines", "TREATMENT", 494, 502], ["these products", "TREATMENT", 611, 625], ["disease", "OBSERVATION", 189, 196]]], ["The US Centers for Disease Control and Prevention (CDC)'s list of bioterrorism agents (Box 1) served to define the agents we studied.", [["The US", "TEST", 0, 6], ["Disease Control", "TREATMENT", 19, 34], ["bioterrorism agents", "TREATMENT", 66, 85], ["the agents", "TREATMENT", 111, 121]]], ["We searched for products in development for all Category A and Category B agents, as well as for four Category C agents: Crimean-Congo hemorrhagic fever virus, yellow fever, avian influenza (as a subset of influenza) and SARS-associated corona virus (SARS-CoV).", [["Crimean-Congo hemorrhagic fever", "DISEASE", 121, 152], ["yellow fever", "DISEASE", 160, 172], ["avian influenza", "DISEASE", 174, 189], ["influenza", "DISEASE", 206, 215], ["SARS", "DISEASE", 221, 225], ["SARS", "DISEASE", 251, 255], ["Crimean-Congo hemorrhagic fever virus", "ORGANISM", 121, 158], ["yellow fever", "ORGANISM", 160, 172], ["avian influenza", "ORGANISM", 174, 189], ["SARS-associated corona virus", "ORGANISM", 221, 249], ["SARS-CoV", "ORGANISM", 251, 259], ["Congo hemorrhagic fever virus", "SPECIES", 129, 158], ["yellow fever", "SPECIES", 160, 172], ["avian influenza", "SPECIES", 174, 189], ["corona virus", "SPECIES", 237, 249], ["Crimean-Congo hemorrhagic fever virus", "SPECIES", 121, 158], ["yellow fever, avian influenza", "SPECIES", 160, 189], ["SARS-associated corona virus", "SPECIES", 221, 249], ["SARS-CoV", "SPECIES", 251, 259], ["Category B agents", "TREATMENT", 63, 80], ["Crimean", "TEST", 121, 128], ["Congo hemorrhagic fever virus", "PROBLEM", 129, 158], ["yellow fever", "PROBLEM", 160, 172], ["avian influenza", "PROBLEM", 174, 189], ["influenza", "PROBLEM", 206, 215], ["SARS", "PROBLEM", 221, 225], ["corona virus", "PROBLEM", 237, 249], ["corona virus", "OBSERVATION", 237, 249]]], ["These four were selected as the most likely to have products in development that are biodefense driven.", [["most likely", "UNCERTAINTY", 32, 43], ["biodefense", "OBSERVATION_MODIFIER", 85, 95]]], ["Further details of this study and the basis for all data shown in this article are available elsewhere 1 .A survey of biodefenseThe US CDC list remains the government's best public estimate of current biological threats and provides direction for research and product development.", [["this study", "TEST", 19, 29], ["all data", "TEST", 48, 56], ["The US CDC", "TEST", 128, 138]]], ["However, the list is an active document and should be expected to change over time, as new threats emerge and vaccines or therapeutics are developed for existing threats.", [["vaccines", "TREATMENT", 110, 118], ["therapeutics", "TREATMENT", 122, 134], ["active", "OBSERVATION", 24, 30]]], ["For example, companies are developing vaccines and therapeutics to target existing pathogens, but terrorists may genetically modify existing agents or create new agents that are serious threats.A survey of biodefenseEven when an effective vaccine is available against a possible bioterrorism disease, the agent may remain a threat because the vaccine is not routinely administered.", [["bioterrorism disease", "DISEASE", 279, 299], ["developing vaccines", "TREATMENT", 27, 46], ["therapeutics", "TREATMENT", 51, 63], ["existing pathogens", "PROBLEM", 74, 92], ["new agents", "TREATMENT", 158, 168], ["an effective vaccine", "TREATMENT", 226, 246], ["bioterrorism disease", "PROBLEM", 279, 299], ["the agent", "TREATMENT", 301, 310], ["the vaccine", "TREATMENT", 339, 350]]], ["Thus, if the United States resumed universal administration of a smallpox vaccine, smallpox would no longer be considered a top bioterrorism threat.", [["smallpox", "DISEASE", 83, 91], ["universal administration", "TREATMENT", 35, 59], ["a smallpox vaccine", "TREATMENT", 63, 81], ["smallpox", "TREATMENT", 83, 91]]], ["The existing smallpox vaccines, however, can cause serious complications.", [["The existing smallpox vaccines", "TREATMENT", 0, 30], ["serious complications", "PROBLEM", 51, 72], ["serious", "OBSERVATION_MODIFIER", 51, 58], ["complications", "OBSERVATION", 59, 72]]], ["This issue limits the utility of these vaccines and is driving the development of safer smallpox vaccines.US government spending initiativesIn July 2004, BioShield legislation was signed that would provide $5.6 billion over ten years to purchase vaccines and therapeutics for bioterrorism agents.", [["smallpox", "ORGANISM", 88, 96], ["these vaccines", "TREATMENT", 33, 47], ["safer smallpox vaccines", "TREATMENT", 82, 105], ["vaccines", "TREATMENT", 246, 254], ["therapeutics", "TREATMENT", 259, 271], ["bioterrorism agents", "TREATMENT", 276, 295]]], ["Although this legislation creates a guaranteed market, it was designed for endstage acquisition, not to fund development.", [["endstage acquisition", "TEST", 75, 95]]], ["The first and largest contract awarded under BioShield was announced in November 2004.", [["largest", "OBSERVATION_MODIFIER", 14, 21]]], ["Worth $877.5 million over a five-year period, it was awarded to VaxGen (Brisbane, CA, USA) to manufacture and deliver 75 million doses of anthrax vaccine for the Strategic National Stockpile.", [["anthrax", "ORGANISM", 138, 145], ["anthrax vaccine", "TREATMENT", 138, 153]]], ["The contract was contentious, with product delays and contract modifications; ultimately, the US Department of Health and Human Services terminated the contract inUS government spending initiativesIt is still unclear how successful BioShield will be in promoting development of biodefense products.", [["Human", "ORGANISM", 122, 127], ["BioShield", "SIMPLE_CHEMICAL", 232, 241], ["Human", "SPECIES", 122, 127], ["biodefense products", "TREATMENT", 278, 297]]], ["To date, few large pharmaceutical companies have been attracted to the biodefense market by the promise of BioShield funding.", [["BioShield funding", "TREATMENT", 107, 124], ["few", "OBSERVATION_MODIFIER", 9, 12], ["large", "OBSERVATION_MODIFIER", 13, 18], ["pharmaceutical companies", "OBSERVATION", 19, 43]]], ["The amount of money involved is not great enough to offset concerns about liability and limited market potential.", [["amount", "OBSERVATION_MODIFIER", 4, 10]]], ["Although a second bill, BioShield II, was introduced in April 2005, it has still not been approved.", [["BioShield II", "CHEMICAL", 24, 36]]], ["BioShield II authorizations include tax incentives to spur capital investment, intellectual property protection and liability limits.US government spending initiativesMore than half of the funding we identified for the development of vaccines and therapeutics for bioterrorism agents was targeted to anthrax.", [["BioShield II", "CHEMICAL", 0, 12], ["anthrax", "DISEASE", 300, 307], ["anthrax", "ORGANISM", 300, 307], ["spur capital investment", "TREATMENT", 54, 77], ["intellectual property protection", "TREATMENT", 79, 111], ["vaccines", "TREATMENT", 234, 242], ["therapeutics", "TREATMENT", 247, 259], ["bioterrorism agents", "TREATMENT", 264, 283], ["anthrax", "PROBLEM", 300, 307]]], ["However, the priority for government spending on biodefense products is not always evident.", [["biodefense products", "TREATMENT", 49, 68], ["not always evident", "UNCERTAINTY", 72, 90]]], ["In the fall of 2005, there was a large infusion of funding from the National Institute of Allergy and Infectious Disease (NIAID) for tularemia, which is usually treatable with antibiotics.", [["Allergy and Infectious Disease", "DISEASE", 90, 120], ["tularemia", "DISEASE", 133, 142], ["tularemia", "PROBLEM", 133, 142], ["antibiotics", "TREATMENT", 176, 187], ["large", "OBSERVATION_MODIFIER", 33, 38], ["Infectious", "OBSERVATION", 102, 112]]], ["Cerus (Concord, CA, USA) and the University of New Mexico (Albuquerque, NM, USA) received a $23 million grant to research and develop a tularemia vaccine, whereas DynaPort Vaccine Company (DVC; Frederick, MD, USA) was awarded a fiveyear $35.1 million contract for the development of a tularemia vaccine.", [["tularemia", "DISEASE", 136, 145], ["tularemia", "DISEASE", 285, 294], ["a tularemia vaccine", "TREATMENT", 134, 153], ["a tularemia vaccine", "TREATMENT", 283, 302], ["tularemia", "OBSERVATION", 136, 145], ["tularemia", "OBSERVATION", 285, 294]]], ["The National Biodefense Analysis and Countermeasures Center has completed an assessment and ranking of the bioterrorism threats, which is expected to guide federal spending.", [["an assessment", "TEST", 74, 87]]], ["Although that assessment was delivered to the White House in January 2006, it has been seen only by a small group of individuals with high-level security clearance 3 .US government spending initiativesThe creation of BARDA provides additional product development funding.", [["BARDA", "CHEMICAL", 217, 222], ["BARDA", "PROTEIN", 217, 222], ["The creation of BARDA", "TREATMENT", 201, 222], ["small", "OBSERVATION_MODIFIER", 102, 107]]], ["BARDA's budget was authorized to facilitate the developmentBox 1 Potential bioterrorism diseases and agentsThe CDC classifies agents that could be used in bioterrorism into three categories: category A, B or C (for details, see ref.", [["bioterrorism diseases", "DISEASE", 75, 96], ["BARDA's budget", "TREATMENT", 0, 14], ["Potential bioterrorism diseases", "PROBLEM", 65, 96], ["agents", "TREATMENT", 101, 107]]], ["10).Box 1 Potential bioterrorism diseases and agentsCategory A agents.", [["bioterrorism diseases", "DISEASE", 20, 41], ["Category A agents", "SIMPLE_CHEMICAL", 52, 69], ["Potential bioterrorism diseases", "PROBLEM", 10, 41], ["agents", "TREATMENT", 46, 52], ["bioterrorism diseases", "OBSERVATION", 20, 41]]], ["These nine agents or families of agents are the bioterrorism agents of highest priority for biodefense research.", [["agents", "TREATMENT", 33, 39], ["biodefense research", "TREATMENT", 92, 111]]], ["The CDC defines Category A agents as organisms that pose a risk to national security because they are easily disseminated or transmitted from person to person, result in high mortality rates and have the potential for a major public health impact, might cause public panic and social disruption, and require special action for public health preparedness.Box 1 Potential bioterrorism diseases and agents\u2022 of new products to counter security threats, including biological threats.", [["panic", "DISEASE", 267, 272], ["bioterrorism diseases", "DISEASE", 370, 391], ["person", "SPECIES", 142, 148], ["person", "SPECIES", 152, 158], ["public panic and social disruption", "PROBLEM", 260, 294], ["public health preparedness", "TREATMENT", 327, 353], ["Potential bioterrorism diseases", "PROBLEM", 360, 391], ["new products", "TREATMENT", 407, 419], ["social disruption", "OBSERVATION", 277, 294], ["Potential", "OBSERVATION_MODIFIER", 360, 369], ["bioterrorism diseases", "OBSERVATION", 370, 391]]], ["This is expected to bridge the funding gap between initial research and end product that is particularly challenging for smaller companies.Vaccines in developmentWe identified 152 prophylactic vaccines in development as well as six recently launched vaccines against bioterrorism threats ( Table 1) .", [["Vaccines", "TREATMENT", 139, 147], ["prophylactic vaccines", "TREATMENT", 180, 201]]], ["Among vaccines for Category A agents, development is concentrated on anthrax, with 24 vaccines in development, followed by 19 for smallpox and 13 for plague.", [["anthrax", "DISEASE", 69, 76], ["smallpox", "DISEASE", 130, 138], ["plague", "DISEASE", 150, 156], ["Among vaccines", "TREATMENT", 0, 14], ["Category A agents", "TREATMENT", 19, 36], ["24 vaccines", "TREATMENT", 83, 94], ["plague", "PROBLEM", 150, 156]]], ["There is also significant activity in other categories, with 14 vaccines in development for viral encephalitides and 28 vaccines in development for avian influenza 1 .Vaccines in developmentOf these 152 vaccines, 102 are in preclinical development, 35 are in phase 1, 12 are in phase 2, and only three are in phase 3 clinical trials (Fig. 1) .", [["viral encephalitides", "DISEASE", 92, 112], ["avian influenza", "DISEASE", 148, 163], ["avian influenza 1", "ORGANISM", 148, 165], ["avian influenza", "SPECIES", 148, 163], ["significant activity in other categories", "PROBLEM", 14, 54], ["14 vaccines", "TREATMENT", 61, 72], ["viral encephalitides", "TREATMENT", 92, 112], ["28 vaccines", "TREATMENT", 117, 128], ["avian influenza", "PROBLEM", 148, 163], ["Vaccines", "TREATMENT", 167, 175], ["these 152 vaccines", "TREATMENT", 193, 211], ["significant", "OBSERVATION_MODIFIER", 14, 25], ["activity", "OBSERVATION_MODIFIER", 26, 34]]], ["The pipeline is dominated by products in early stages of development, with few vaccines likely to reach the market in the next few years 1 ( Table 2) .Vaccines in developmentThere are a number of challenges to creating biodefense vaccines, including providing protection against multiple serotypes.", [["few vaccines", "TREATMENT", 75, 87], ["Vaccines", "TREATMENT", 151, 159], ["creating biodefense vaccines", "TREATMENT", 210, 238], ["multiple serotypes", "PROBLEM", 279, 297], ["dominated", "OBSERVATION_MODIFIER", 16, 25], ["early stages", "OBSERVATION_MODIFIER", 41, 53], ["serotypes", "OBSERVATION", 288, 297]]], ["Many of the pathogens have unstable genomes, multiple genotypes or multiple serotypes.", [["the pathogens", "PROBLEM", 8, 21], ["unstable genomes", "PROBLEM", 27, 43], ["multiple genotypes", "PROBLEM", 45, 63], ["multiple serotypes", "PROBLEM", 67, 85], ["pathogens", "OBSERVATION", 12, 21], ["unstable", "OBSERVATION_MODIFIER", 27, 35], ["genomes", "OBSERVATION", 36, 43], ["multiple", "OBSERVATION_MODIFIER", 45, 53], ["genotypes", "OBSERVATION_MODIFIER", 54, 63], ["multiple", "OBSERVATION_MODIFIER", 67, 75], ["serotypes", "OBSERVATION", 76, 85]]], ["As one example, there are seven known serotypes of the Clostridium botulinum neurotoxin that causes botulism.", [["botulism", "DISEASE", 100, 108], ["Clostridium botulinum neurotoxin", "ORGANISM", 55, 87], ["Clostridium botulinum neurotoxin", "SPECIES", 55, 87], ["Clostridium botulinum neurotoxin", "SPECIES", 55, 87], ["the Clostridium botulinum neurotoxin", "TREATMENT", 51, 87], ["botulism", "PROBLEM", 100, 108], ["botulism", "OBSERVATION", 100, 108]]], ["To be completely effective, a vaccine must protect against all seven serotypes of neurotoxin.", [["a vaccine", "TREATMENT", 28, 37], ["neurotoxin", "PROBLEM", 82, 92], ["effective", "OBSERVATION", 17, 26]]], ["There is one vaccine for botulism that is in phase 1 trials, but it is only effective against two of the serotypes.", [["botulism", "DISEASE", 25, 33], ["one vaccine", "TREATMENT", 9, 20], ["botulism", "PROBLEM", 25, 33], ["the serotypes", "PROBLEM", 101, 114], ["serotypes", "OBSERVATION", 105, 114]]], ["The remaining five vaccines are in preclinical development, and only one of those is heptavalent.", [["The remaining five vaccines", "TREATMENT", 0, 27], ["heptavalent", "OBSERVATION", 85, 96]]], ["A heptavalent vaccine that is cost effective may find acceptance outside the biodefense market.", [["A heptavalent vaccine", "TREATMENT", 0, 21]]], ["An additional constraint is the recognition that vaccines created for the Strategic National Stockpile must have other attributes, such as stability, ability to be manufactured on a large scale and high-volume administration.Vaccines in developmentFor some agents on the list, such as hepatitis A, an effective vaccine already exists.", [["hepatitis A", "DISEASE", 285, 296], ["hepatitis A", "SPECIES", 285, 296], ["vaccines", "TREATMENT", 49, 57], ["a large scale", "TREATMENT", 180, 193], ["high-volume administration", "TREATMENT", 198, 224], ["Vaccines", "TREATMENT", 225, 233], ["hepatitis A", "PROBLEM", 285, 296], ["an effective vaccine", "TREATMENT", 298, 318]]], ["In fact, we have identified more than a dozen hepatitis A vaccines on the market worldwide, with three approved in the United States.", [["hepatitis A", "DISEASE", 46, 57], ["hepatitis A", "SPECIES", 46, 57], ["a dozen hepatitis A vaccines", "TREATMENT", 38, 66], ["hepatitis", "OBSERVATION", 46, 55]]], ["Hepatitis A, however, is still a bioterrorism concern, because the vaccine is not routinely administered.", [["Hepatitis A", "DISEASE", 0, 11], ["Hepatitis A", "ORGANISM", 0, 11], ["Hepatitis A", "SPECIES", 0, 11], ["Hepatitis A", "PROBLEM", 0, 11], ["the vaccine", "TREATMENT", 63, 74]]], ["In 2004, the CDC estimated there were 56,000 new infections in the United States, but only 5,683 cases were reported to the National Notifiable Disease Surveillance System.", [["infections", "DISEASE", 49, 59], ["Notifiable Disease", "DISEASE", 133, 151], ["new infections", "PROBLEM", 45, 59], ["new", "OBSERVATION_MODIFIER", 45, 48], ["infections", "OBSERVATION", 49, 59]]], ["According to the CDC, hepatitis A vaccines were more widely used in the late 1990s, and the number of cases reached historic lows 4 .", [["hepatitis A", "DISEASE", 22, 33], ["hepatitis A", "ORGANISM", 22, 33], ["hepatitis A", "SPECIES", 22, 33], ["hepatitis A vaccines", "TREATMENT", 22, 42], ["hepatitis", "OBSERVATION", 22, 31]]], ["Although vaccines have already been approved for several bioterrorism agents, some companies are developing vaccines with greater efficacy, improved safety or easier administration.", [["vaccines", "TREATMENT", 9, 17], ["several bioterrorism agents", "TREATMENT", 49, 76], ["developing vaccines", "TREATMENT", 97, 116]]], ["For example, Hadassah Medical Organization (Jerusalem) has an edible vaccine for hepatitis A in preclinical development.Vaccines in developmentOne substantial change since we surveyed the field in 2005 (ref.", [["hepatitis A", "DISEASE", 81, 92], ["an edible vaccine", "TREATMENT", 59, 76], ["hepatitis A", "PROBLEM", 81, 92], ["Vaccines", "TREATMENT", 120, 128], ["hepatitis", "OBSERVATION", 81, 90], ["substantial", "OBSERVATION_MODIFIER", 147, 158], ["change", "OBSERVATION", 159, 165]]], ["5) is a decrease in the number of vaccines in development for SARS.", [["SARS", "DISEASE", 62, 66], ["a decrease", "PROBLEM", 6, 16], ["vaccines", "TREATMENT", 34, 42], ["SARS", "PROBLEM", 62, 66], ["decrease", "OBSERVATION_MODIFIER", 8, 16]]], ["The SARS-associated coronavirus was added as a Category C agent in August 2004, after an outbreak in 2002-2003 that infected more than 8,000 people.", [["SARS", "DISEASE", 4, 8], ["coronavirus", "ORGANISM", 20, 31], ["people", "ORGANISM", 141, 147], ["people", "SPECIES", 141, 147], ["The SARS-associated coronavirus", "PROBLEM", 0, 31]]], ["In 2005, we identified 18 vaccines in development, but by 2006 this number had dropped to ten 5 .", [["18 vaccines", "TREATMENT", 23, 34]]], ["Active development of SARS products has been delayed or suspended at many companies, because the disease has not F E AT U R E been a major health concern since the 2003 outbreak.", [["SARS", "DISEASE", 22, 26], ["SARS products", "PROBLEM", 22, 35], ["the disease", "PROBLEM", 93, 104], ["SARS", "OBSERVATION", 22, 26]]], ["Berna Biotech (Bern, Switzerland), which had a vaccine in preclinical development, announced that it was abandoning clinical trials of its vaccine because the disease was no longer seen as a priority by global health authorities.Vaccines in developmentOther companies have indicated that the market and epidemiological developments must be evaluated before investing further resources into the development of vaccines or therapeutics for SARS.", [["SARS", "DISEASE", 438, 442], ["a vaccine", "TREATMENT", 45, 54], ["its vaccine", "TREATMENT", 135, 146], ["the disease", "PROBLEM", 155, 166], ["Vaccines", "TREATMENT", 229, 237], ["vaccines", "TREATMENT", 409, 417], ["therapeutics", "TREATMENT", 421, 433], ["SARS", "PROBLEM", 438, 442], ["disease", "OBSERVATION", 159, 166], ["no longer", "UNCERTAINTY", 171, 180]]], ["However, SARS-CoV remains in animal reservoirs and may reemerge.Therapeutics in developmentIn terms of therapeutics, 155 products are in development or recently launched against bioterrorism diseases ( Table 1) .", [["SARS", "DISEASE", 9, 13], ["bioterrorism diseases", "DISEASE", 178, 199], ["SARS-CoV", "ORGANISM", 9, 17], ["SARS-CoV", "SPECIES", 9, 17], ["SARS", "PROBLEM", 9, 13], ["bioterrorism diseases", "PROBLEM", 178, 199], ["CoV", "OBSERVATION_MODIFIER", 14, 17], ["reservoirs", "OBSERVATION", 36, 46]]], ["Among therapeutics for Category A and B agents, development is concentrated on smallpox, with 20 therapeutics in development, followed by 18 for viral encephalitides and 17 for anthrax.", [["smallpox", "DISEASE", 79, 87], ["viral encephalitides", "DISEASE", 145, 165], ["anthrax", "DISEASE", 177, 184], ["B agents", "SIMPLE_CHEMICAL", 38, 46], ["Category A and B agents", "TREATMENT", 23, 46], ["smallpox", "TREATMENT", 79, 87], ["viral encephalitides", "TEST", 145, 165], ["anthrax", "PROBLEM", 177, 184]]], ["Except for therapeutics targeting encephalitide viruses, few products are in development for Category B agents.", [["encephalitide viruses", "ORGANISM", 34, 55], ["Category B agents", "SIMPLE_CHEMICAL", 93, 110], ["therapeutics targeting encephalitide viruses", "TREATMENT", 11, 55], ["Category B agents", "TREATMENT", 93, 110]]], ["There is significant activity against two Category C agents, however, with 14 and 16 therapeutics in development for SARS and avian influenza, respectively 1 .", [["SARS", "DISEASE", 117, 121], ["avian influenza", "DISEASE", 126, 141], ["Category C agents", "TREATMENT", 42, 59], ["SARS", "PROBLEM", 117, 121], ["avian influenza", "PROBLEM", 126, 141], ["significant", "OBSERVATION_MODIFIER", 9, 20], ["activity", "OBSERVATION_MODIFIER", 21, 29]]], ["As for vaccines, the therapeutic pipeline is dominated by products in preclinical development 1 .", [["vaccines", "TREATMENT", 7, 15], ["the therapeutic pipeline", "TREATMENT", 17, 41]]], ["For those working on therapeutics against bioterrorism diseases, the goal is to develop products capable of treating a variety of infections.", [["bioterrorism diseases", "DISEASE", 42, 63], ["infections", "DISEASE", 130, 140], ["bioterrorism diseases", "PROBLEM", 42, 63], ["infections", "PROBLEM", 130, 140], ["infections", "OBSERVATION", 130, 140]]], ["At the outset, many of these diseases present with 'flu-like' symptoms and broadspectrum therapeutics would be of the greatest utility so that treatment can be initiated before identification of the causative agent.", [["flu", "DISEASE", 52, 55], ["these diseases", "PROBLEM", 23, 37], ["'flu-like' symptoms", "PROBLEM", 51, 70], ["broadspectrum therapeutics", "TREATMENT", 75, 101], ["treatment", "TREATMENT", 143, 152], ["the causative agent", "PROBLEM", 195, 214], ["diseases", "OBSERVATION", 29, 37]]], ["Although numerous broad-spectrum antibiotics are already available, few have been tested and approved for the treatment of specific bioterrorism infections.Therapeutics in developmentProducts that are currently used as the standard-of-care include ciprofloxacin (Cipro; Bayer Healthcare, Wuppertal, Germany) for the treatment of anthrax infections and vaccinia immune globulins for the treatment of side effects of smallpox vaccine administration.", [["bioterrorism infections", "DISEASE", 132, 155], ["ciprofloxacin", "CHEMICAL", 248, 261], ["Cipro", "CHEMICAL", 263, 268], ["anthrax infections", "DISEASE", 329, 347], ["ciprofloxacin", "CHEMICAL", 248, 261], ["Cipro", "CHEMICAL", 263, 268], ["ciprofloxacin", "SIMPLE_CHEMICAL", 248, 261], ["Cipro", "SIMPLE_CHEMICAL", 263, 268], ["anthrax", "ORGANISM", 329, 336], ["vaccinia", "ORGANISM", 352, 360], ["immune globulins", "GENE_OR_GENE_PRODUCT", 361, 377], ["vaccinia immune globulins", "PROTEIN", 352, 377], ["anthrax", "SPECIES", 329, 336], ["vaccinia", "SPECIES", 352, 360], ["numerous broad-spectrum antibiotics", "TREATMENT", 9, 44], ["specific bioterrorism infections", "PROBLEM", 123, 155], ["Therapeutics in developmentProducts", "TREATMENT", 156, 191], ["ciprofloxacin", "TREATMENT", 248, 261], ["Cipro", "TREATMENT", 263, 268], ["anthrax infections", "PROBLEM", 329, 347], ["vaccinia immune globulins", "TREATMENT", 352, 377], ["the treatment", "TREATMENT", 382, 395], ["side effects", "PROBLEM", 399, 411], ["smallpox vaccine administration", "TREATMENT", 415, 446], ["numerous", "OBSERVATION_MODIFIER", 9, 17], ["broad", "OBSERVATION_MODIFIER", 18, 23], ["spectrum", "OBSERVATION_MODIFIER", 24, 32], ["antibiotics", "OBSERVATION", 33, 44], ["bioterrorism", "OBSERVATION_MODIFIER", 132, 144], ["infections", "OBSERVATION", 145, 155]]], ["Development of therapeutics for viralF E AT U R Ediseases lags behind that for bacterial diseases, with most recommended care being palliative and nonspecific, such as the administration of liquids, fever reducers (e.g., ibuprofen and acetaminophen) and bed rest.", [["bacterial diseases", "DISEASE", 79, 97], ["fever", "DISEASE", 199, 204], ["ibuprofen", "CHEMICAL", 221, 230], ["acetaminophen", "CHEMICAL", 235, 248], ["ibuprofen", "CHEMICAL", 221, 230], ["acetaminophen", "CHEMICAL", 235, 248], ["ibuprofen", "SIMPLE_CHEMICAL", 221, 230], ["acetaminophen", "SIMPLE_CHEMICAL", 235, 248], ["viralF E AT U R Ediseases lags", "TREATMENT", 32, 62], ["bacterial diseases", "PROBLEM", 79, 97], ["the administration of liquids", "TREATMENT", 168, 197], ["fever reducers", "PROBLEM", 199, 213], ["ibuprofen", "TREATMENT", 221, 230], ["acetaminophen", "TREATMENT", 235, 248], ["bed rest", "TREATMENT", 254, 262]]], ["Many of the therapeutics in development are considered to be therapeutic vaccines.", [["therapeutic vaccines", "TREATMENT", 61, 81]]], ["Therapeutic vaccines are often immune-modulating, agent-specific pharmaceuticals given after exposure, which protect the recipient from contracting the disease or diminish the severity of the disease.", [["Therapeutic vaccines", "TREATMENT", 0, 20], ["agent", "TREATMENT", 50, 55], ["specific pharmaceuticals", "TREATMENT", 56, 80], ["the disease", "PROBLEM", 148, 159], ["the disease", "PROBLEM", 188, 199], ["disease", "OBSERVATION", 152, 159], ["disease", "OBSERVATION", 192, 199]]], ["For example, researchers at the US Army Medical Research Institute of Infectious Diseases (USAMRIID, Fort Detrick, MD, USA) have developed two experimental therapeutic vaccines, which when given after exposure were capable of preventing Ebola and Marburg symptoms and lethality in guinea pigs and rhesus monkeys respectively 6, 7 .", [["Infectious Diseases", "DISEASE", 70, 89], ["Ebola and Marburg symptoms", "DISEASE", 237, 263], ["Ebola", "ORGANISM", 237, 242], ["guinea pigs", "ORGANISM", 281, 292], ["rhesus monkeys", "ORGANISM", 297, 311], ["guinea pigs", "SPECIES", 281, 292], ["rhesus monkeys", "SPECIES", 297, 311], ["guinea pigs", "SPECIES", 281, 292], ["rhesus monkeys", "SPECIES", 297, 311], ["experimental therapeutic vaccines", "TREATMENT", 143, 176], ["Ebola", "PROBLEM", 237, 242], ["Marburg symptoms", "PROBLEM", 247, 263], ["lethality", "PROBLEM", 268, 277], ["Infectious", "OBSERVATION", 70, 80], ["Ebola", "OBSERVATION", 237, 242]]], ["Juvaris BioTherapeutics (Pleasanton, CA, USA) is also developing or codeveloping several therapeutic vaccines against potential bioterrorism agents, such as anthrax, smallpox and the plague.Companies and institutions developing biodefense productsOf the companies, institutions or government entities with some program focused on biodefense, we identified a total of 94 that are developing vaccines and 95 developing therapeutics ( Table 3) .", [["anthrax", "DISEASE", 157, 164], ["smallpox", "DISEASE", 166, 174], ["biodefense products", "PROTEIN", 228, 247], ["Juvaris BioTherapeutics", "TREATMENT", 0, 23], ["therapeutic vaccines", "TREATMENT", 89, 109], ["bioterrorism agents", "TREATMENT", 128, 147], ["smallpox", "TREATMENT", 166, 174], ["biodefense products", "TREATMENT", 228, 247], ["developing vaccines", "TREATMENT", 379, 398]]], ["Groups developing vaccines were identified in 19 different countries and groups developing therapeutics were identified in 14 different countries.", [["Groups developing vaccines", "PROBLEM", 0, 26]]], ["Companies in the United States dominate both lists, representing 61% of the total in vaccine development and 64% of the total in therapeutic development 1 .", [["the total in vaccine development", "TREATMENT", 72, 104]]], ["This result is partially due to the large number of pharmaceutical and biotech companies in the United States, but also partially from the availability of sources in the United States to identify and confirm companies involved in biodefense product development.", [["large", "OBSERVATION_MODIFIER", 36, 41], ["number", "OBSERVATION_MODIFIER", 42, 48], ["pharmaceutical", "OBSERVATION_MODIFIER", 52, 66]]], ["Of the total, three government organizations and eight companies are developing both vaccines and therapeutics.Companies and institutions developing biodefense productsA broad range of companies is represented, including vaccine-focused multinationals Sanofi Pasteur (Lyon, France) and Crucell (Leiden, The Netherlands).", [["biodefense products", "PROTEIN", 149, 168], ["both vaccines", "TREATMENT", 80, 93], ["therapeutics", "TREATMENT", 98, 110], ["biodefense products", "TREATMENT", 149, 168], ["vaccine", "TREATMENT", 221, 228], ["total", "OBSERVATION_MODIFIER", 7, 12], ["broad", "OBSERVATION_MODIFIER", 170, 175]]], ["There are also companies focused on biodefense, such as DVC (Frederick, MD, USA), and small biotech firms such as Vaxin (Birmingham, AL, USA).", [["small", "OBSERVATION_MODIFIER", 86, 91]]], ["These agencies not only provide funding, but frequently have an active role in the development of biodefense vaccines.Companies and institutions developing biodefense productsSome companies are leveraging a proprietary technology to develop multiple products, each for a specific disease target.", [["biodefense products", "PROTEIN", 156, 175], ["biodefense vaccines", "TREATMENT", 98, 117], ["biodefense products", "TREATMENT", 156, 175], ["a specific disease target", "PROBLEM", 269, 294], ["active", "OBSERVATION_MODIFIER", 64, 70]]], ["Acambis (Cambridge, UK) is developing vaccines for West Nile virus, Japanese encephalitis virus and dengue fever using its proprietary ChimeriVax technology, which is based on a live, attenuated 17D strain of the yellow fever virus (the basis for existing yellow fever vaccines) in which the genes encoding antigens conferring immunity to yellow fever virus have been replaced with genes from the virus of interest.Companies and institutions developing biodefense productsAlphaVax (Research Triangle Park, NC, USA) is developing vaccines against botulinum toxin, smallpox, SARS, Marburg virus and viral encephalitis using a proprietary vaccine vector system.", [["Acambis", "CHEMICAL", 0, 7], ["West Nile virus", "DISEASE", 51, 66], ["Japanese encephalitis virus", "DISEASE", 68, 95], ["dengue fever", "DISEASE", 100, 112], ["yellow fever", "DISEASE", 213, 225], ["yellow fever", "DISEASE", 256, 268], ["yellow fever", "DISEASE", 339, 351], ["AlphaVax", "CHEMICAL", 472, 480], ["botulinum toxin", "CHEMICAL", 546, 561], ["smallpox", "DISEASE", 563, 571], ["SARS", "DISEASE", 573, 577], ["Marburg virus", "DISEASE", 579, 592], ["viral encephalitis", "DISEASE", 597, 615], ["West Nile virus", "ORGANISM", 51, 66], ["Japanese encephalitis virus", "ORGANISM", 68, 95], ["yellow fever virus", "ORGANISM", 213, 231], ["yellow fever vaccines", "ORGANISM", 256, 277], ["yellow fever virus", "ORGANISM", 339, 357], ["botulinum toxin", "SIMPLE_CHEMICAL", 546, 561], ["smallpox", "ORGANISM", 563, 571], ["Marburg virus", "ORGANISM", 579, 592], ["antigens", "PROTEIN", 307, 315], ["biodefense products", "PROTEIN", 453, 472], ["Nile virus", "SPECIES", 56, 66], ["Japanese encephalitis virus", "SPECIES", 68, 95], ["yellow fever virus", "SPECIES", 213, 231], ["yellow fever virus", "SPECIES", 339, 357], ["Marburg virus", "SPECIES", 579, 592], ["West Nile virus", "SPECIES", 51, 66], ["Japanese encephalitis virus", "SPECIES", 68, 95], ["yellow fever virus", "SPECIES", 213, 231], ["yellow fever virus", "SPECIES", 339, 357], ["Marburg virus", "SPECIES", 579, 592], ["developing vaccines", "TREATMENT", 27, 46], ["West Nile virus", "PROBLEM", 51, 66], ["Japanese encephalitis virus", "PROBLEM", 68, 95], ["dengue fever", "PROBLEM", 100, 112], ["the yellow fever virus", "PROBLEM", 209, 231], ["existing yellow fever vaccines", "TREATMENT", 247, 277], ["yellow fever virus", "PROBLEM", 339, 357], ["biodefense products", "TREATMENT", 453, 472], ["AlphaVax", "TREATMENT", 472, 480], ["vaccines", "TREATMENT", 529, 537], ["botulinum toxin", "TREATMENT", 546, 561], ["smallpox", "PROBLEM", 563, 571], ["SARS", "PROBLEM", 573, 577], ["Marburg virus", "PROBLEM", 579, 592], ["viral encephalitis", "PROBLEM", 597, 615], ["a proprietary vaccine vector system", "TREATMENT", 622, 657], ["viral encephalitis", "OBSERVATION", 597, 615]]], ["The Alphavaccine Platform System is based on a nonpropagating alphavirus vector engineered to express selected genes from pathogens.", [["alphavirus", "ORGANISM", 62, 72], ["The Alphavaccine Platform System", "TREATMENT", 0, 32], ["a nonpropagating alphavirus vector", "TREATMENT", 45, 79], ["pathogens", "PROBLEM", 122, 131]]], ["Alphavaccine particles that contain the foreign antigen target the lymph nodes and infect the dendritic cells, initiating a strong immune response.", [["lymph nodes", "ANATOMY", 67, 78], ["dendritic cells", "ANATOMY", 94, 109], ["Alphavaccine", "CHEMICAL", 0, 12], ["Alphavaccine", "CHEMICAL", 0, 12], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 67, 78], ["dendritic cells", "CELL", 94, 109], ["dendritic cells", "CELL_TYPE", 94, 109], ["Alphavaccine particles", "TREATMENT", 0, 22], ["the foreign antigen", "TEST", 36, 55], ["the lymph nodes", "PROBLEM", 63, 78], ["the dendritic cells", "PROBLEM", 90, 109], ["foreign antigen", "OBSERVATION", 40, 55], ["lymph nodes", "OBSERVATION", 67, 78], ["dendritic cells", "OBSERVATION", 94, 109], ["strong", "OBSERVATION_MODIFIER", 124, 130], ["immune response", "OBSERVATION", 131, 146]]], ["Funding for AlphaVax's biodefense vaccine program exceeds $23 million, coming primarily from the US federal government 8 .Companies and institutions developing biodefense productsBiotech company AVI BioPharma (Portland, OR, USA) is using its NeuGene antisense technology to develop therapeutics for a variety of biodefense diseases, including anthrax, dengue fever and Ebola.", [["biodefense diseases", "DISEASE", 312, 331], ["anthrax", "DISEASE", 343, 350], ["dengue fever", "DISEASE", 352, 364], ["Ebola", "DISEASE", 369, 374], ["Ebola", "ORGANISM", 369, 374], ["biodefense products", "PROTEIN", 160, 179], ["Ebola", "SPECIES", 369, 374], ["AlphaVax's biodefense vaccine", "TREATMENT", 12, 41], ["biodefense products", "TREATMENT", 160, 179], ["therapeutics", "TREATMENT", 282, 294], ["biodefense diseases", "PROBLEM", 312, 331], ["anthrax", "PROBLEM", 343, 350], ["dengue fever", "PROBLEM", 352, 364], ["Ebola", "PROBLEM", 369, 374]]], ["NeuGene antisense compounds have a synthetic chemical backbone designed to provide stability, specificity, efficacy, functional delivery and safety.", [["a synthetic chemical backbone", "TREATMENT", 33, 62], ["functional delivery", "TREATMENT", 117, 136]]], ["In December 2006, AVI BioPharma signed a two-year $28 million contract with the Defense Threat Reduction Agency (Fort Belvoir, VA, USA) that will fund the development ofConclusionsDespite many products currently in development, the outlook for biodefense vaccines and therapeutics is a bleak one, with few products on the market to counter most bioterrorism agents and only a few in late stages of development.", [["the Defense Threat Reduction", "TREATMENT", 76, 104], ["biodefense vaccines", "TREATMENT", 244, 263]]], ["Even so, the rapidly changing landscape of public health priorities in infectious disease and necessary product attributes, such as high-volume administration, make biodefense a challenging area for development.", [["infectious disease", "DISEASE", 71, 89], ["infectious disease", "PROBLEM", 71, 89], ["high-volume administration", "TREATMENT", 132, 158], ["rapidly", "OBSERVATION_MODIFIER", 13, 20], ["infectious", "OBSERVATION", 71, 81]]], ["The primary market drivers for development of vaccines and therapeutic agents against diseases on the CDC list of bioterror agents are the continued threat posed by domestic and international terrorists and the availability of government funding.", [["vaccines", "TREATMENT", 46, 54], ["therapeutic agents", "TREATMENT", 59, 77], ["diseases", "PROBLEM", 86, 94], ["bioterror agents", "TREATMENT", 114, 130], ["government funding", "TREATMENT", 227, 245]]], ["In this category are diseases, such as yellow fever, dengue fever, Japanese encephalitis and typhoid fever.", [["yellow fever", "DISEASE", 39, 51], ["dengue fever", "DISEASE", 53, 65], ["Japanese encephalitis", "DISEASE", 67, 88], ["typhoid fever", "DISEASE", 93, 106], ["diseases", "PROBLEM", 21, 29], ["yellow fever", "PROBLEM", 39, 51], ["dengue fever", "PROBLEM", 53, 65], ["Japanese encephalitis", "PROBLEM", 67, 88], ["typhoid fever", "PROBLEM", 93, 106], ["diseases", "OBSERVATION", 21, 29], ["yellow", "OBSERVATION_MODIFIER", 39, 45], ["typhoid", "OBSERVATION_MODIFIER", 93, 100]]], ["Several vaccines in development, targeted to travelers, have been designed to protect against a combination of food or waterborne agents.ConclusionsThe development of broad-spectrum antibiotics and antivirals that are tested and approved for use against bioterror diseases remains a pressing need.", [["bioterror diseases", "DISEASE", 254, 272], ["Several vaccines", "TREATMENT", 0, 16], ["waterborne agents", "TREATMENT", 119, 136], ["broad-spectrum antibiotics", "TREATMENT", 167, 193], ["antivirals", "TREATMENT", 198, 208], ["bioterror diseases", "PROBLEM", 254, 272], ["broad", "OBSERVATION_MODIFIER", 167, 172]]], ["These diseases are often diseases endemic to developing countries and are not generally recognized in developed countries.", [["These diseases", "PROBLEM", 0, 14], ["often diseases endemic", "PROBLEM", 19, 41], ["diseases", "OBSERVATION", 6, 14]]], ["Also, many produce generalized 'flu-like' symptoms at the outset and may not be recognized as bioterrorism related until a large number of infected individuals are identified and tracked.", [["individuals", "ORGANISM", 148, 159], ["generalized 'flu-like' symptoms", "PROBLEM", 19, 50], ["bioterrorism", "PROBLEM", 94, 106], ["infected individuals", "PROBLEM", 139, 159], ["generalized", "OBSERVATION_MODIFIER", 19, 30], ["flu", "OBSERVATION", 32, 35], ["may not be", "UNCERTAINTY", 69, 79], ["large", "OBSERVATION_MODIFIER", 123, 128], ["number", "OBSERVATION_MODIFIER", 129, 135], ["infected", "OBSERVATION", 139, 147]]], ["The availability of broad-spectrum antibiotics and antivirals that could be administered before identification of the etiological agent would be beneficial to the general medical community.", [["broad-spectrum antibiotics", "TREATMENT", 20, 46], ["antivirals", "TREATMENT", 51, 61]]], ["Many of the broad-spectrum antibiotics already approved and marketed have never been tested against the diseases on the CDC list of potential bioterror agents and efficacy is not assured.", [["the broad-spectrum antibiotics", "TREATMENT", 8, 38], ["the diseases", "PROBLEM", 100, 112], ["potential bioterror agents", "TREATMENT", 132, 158], ["broad", "OBSERVATION_MODIFIER", 12, 17]]], ["The incentives for the large pharmaceutical companies to test their products against the bioterror diseases are minimal, involving large, protracted clinical trials in remote locations for diseases without large patient populations.", [["patient", "ORGANISM", 212, 219], ["patient", "SPECIES", 212, 219], ["the bioterror diseases", "PROBLEM", 85, 107], ["diseases", "PROBLEM", 189, 197], ["large patient populations", "PROBLEM", 206, 231], ["diseases", "OBSERVATION", 99, 107], ["minimal", "OBSERVATION_MODIFIER", 112, 119], ["large", "OBSERVATION_MODIFIER", 131, 136], ["protracted", "OBSERVATION_MODIFIER", 138, 148], ["large", "OBSERVATION_MODIFIER", 206, 211]]], ["The larger pharmaceutical companies may be leery of liability issues and the negative impact of failed products on the company's stock or venture capital investments.ConclusionsIssues of delivery and stockpiling by federal, state and local governments also remain.", [["liability issues", "PROBLEM", 52, 68], ["venture capital investments", "TREATMENT", 138, 165], ["delivery", "TREATMENT", 187, 195], ["larger", "OBSERVATION_MODIFIER", 4, 10], ["pharmaceutical companies", "OBSERVATION", 11, 35], ["may be", "UNCERTAINTY", 36, 42]]], ["Without guaranteed purchase by these large agencies, companies have little chance of recovering expenditures spent on the development of vaccines or therapeutics for most biodefense applications, and thus have little incentive to pursue them.", [["vaccines", "TREATMENT", 137, 145], ["therapeutics", "TREATMENT", 149, 161]]], ["Smaller pharmaceutical and biotech companies and institutions may have the compounds or technologies of utility in countering bioterrorism agents, but may not have the resources to complete product development and conduct clinical trials without additional support.", [["bioterrorism agents", "TREATMENT", 126, 145], ["additional support", "TREATMENT", 246, 264]]], ["BARDA may address some of these concerns, but it is too early to determine whether it will be effective.", [["BARDA", "SIMPLE_CHEMICAL", 0, 5]]]], "708157cd8e642cbc3071b9af87f2e232437a4205": [["novel coronavirus generation in wild and domesticated animals.", [["coronavirus", "ORGANISM", 6, 17], ["novel coronavirus generation", "PROBLEM", 0, 28], ["coronavirus generation", "OBSERVATION", 6, 28]]], ["Our results list specific high-risk hosts 27 in which our model predicts homologous recombination could occur, our model identifies both wild 28 and domesticated mammals including known important and understudied species.", [["our model predicts homologous recombination", "TREATMENT", 54, 97]]], ["We recommend 29 these species for coronavirus surveillance, as well as enforced separation in livestock markets and 30 agriculture.", [["coronavirus", "ORGANISM", 34, 45], ["coronavirus", "SPECIES", 34, 45], ["coronavirus surveillance", "TEST", 34, 58]]], ["31INTRODUCTION 33The generation and emergence of three novel respiratory coronaviruses from mammalian reservoirs into 34 human populations in the last 20 years, including one which has achieved pandemic status, suggests 35 that one of the most pressing current research questions is: In which reservoirs could the next novel 36 coronaviruses be generated and emerge from in future?", [["respiratory coronaviruses", "DISEASE", 61, 86], ["human", "ORGANISM", 121, 126], ["coronaviruses", "ORGANISM", 328, 341], ["human", "SPECIES", 121, 126], ["human", "SPECIES", 121, 126], ["mammalian reservoirs", "TREATMENT", 92, 112], ["respiratory coronaviruses", "OBSERVATION", 61, 86]]], ["Armed with this knowledge, we may be able to 37 reduce the chance of emergence into human populations or develop potential mitigations in advance, 38 such as by the strict monitoring and enforced separation of the hosts identified here, in live animal 39 markets, farms, and other close-quarters environments.", [["human", "ORGANISM", 84, 89], ["human", "SPECIES", 84, 89], ["human", "SPECIES", 84, 89], ["the strict monitoring", "TEST", 161, 182]]], ["40INTRODUCTION 33Coronaviridae are a family of positive sense RNA viruses which can cause an array of diseases.", [["positive sense RNA viruses", "PROBLEM", 47, 73], ["diseases", "PROBLEM", 102, 110], ["diseases", "OBSERVATION", 102, 110]]], ["In 41 humans, these range from mild cold-like illnesses to the lethal respiratory tract infections mentioned 42 above.", [["respiratory tract", "ANATOMY", 70, 87], ["respiratory tract infections", "DISEASE", 70, 98], ["humans", "ORGANISM", 6, 12], ["respiratory tract", "ORGANISM_SUBDIVISION", 70, 87], ["humans", "SPECIES", 6, 12], ["humans", "SPECIES", 6, 12], ["mild cold-like illnesses", "PROBLEM", 31, 55], ["the lethal respiratory tract infections", "PROBLEM", 59, 98], ["mild", "OBSERVATION_MODIFIER", 31, 35], ["respiratory tract", "ANATOMY", 70, 87]]], ["Seven coronaviruses are known to infect humans 3 , SARS-CoV, MERS-CoV and SARS-CoV-2 43 causing severe disease, while HKU1, NL63, OC43 and 229E tend towards milder symptoms in most 44 patients 4 .", [["coronaviruses", "ORGANISM", 6, 19], ["humans", "ORGANISM", 40, 46], ["SARS-CoV", "ORGANISM", 51, 59], ["MERS-CoV", "ORGANISM", 61, 69], ["SARS-CoV-2 43", "ORGANISM", 74, 87], ["HKU1", "GENE_OR_GENE_PRODUCT", 118, 122], ["patients", "ORGANISM", 184, 192], ["humans", "SPECIES", 40, 46], ["patients", "SPECIES", 184, 192], ["humans", "SPECIES", 40, 46], ["SARS-CoV", "SPECIES", 51, 59], ["MERS-CoV", "SPECIES", 61, 69], ["SARS-CoV", "SPECIES", 74, 82], ["Seven coronaviruses", "PROBLEM", 0, 19], ["SARS", "TEST", 51, 55], ["CoV", "TEST", 56, 59], ["MERS", "TEST", 61, 65], ["CoV", "TEST", 66, 69], ["SARS", "TEST", 74, 78], ["CoV", "TEST", 79, 82], ["severe disease", "PROBLEM", 96, 110], ["HKU1", "TEST", 118, 122], ["NL63", "TEST", 124, 128], ["OC43", "TEST", 130, 134], ["milder symptoms", "PROBLEM", 157, 172], ["coronaviruses", "OBSERVATION", 6, 19], ["severe", "OBSERVATION_MODIFIER", 96, 102], ["disease", "OBSERVATION", 103, 110]]], ["45INTRODUCTION 33Coronaviruses undergo frequent host-shifting events between non-human animal species, or non-human 46 animals and humans 5-7 , a process that may involve changes to the cells or tissues that the viruses infect 47 (virus tropism).", [["cells", "ANATOMY", 186, 191], ["tissues", "ANATOMY", 195, 202], ["humans", "ORGANISM", 131, 137], ["cells", "CELL", 186, 191], ["tissues", "TISSUE", 195, 202], ["humans", "SPECIES", 131, 137], ["humans", "SPECIES", 131, 137], ["frequent host-shifting events", "PROBLEM", 39, 68], ["non-human animal species", "PROBLEM", 77, 101], ["the viruses infect", "PROBLEM", 208, 226]]], ["Such shifts have resulted in new animal diseases (such as bovine coronavirus (BCoV) 48 disease 8 and canine coronavirus (CCoV) disease 9 ), and human diseases (such as OC43 10 and 229E 11 ).", [["bovine coronavirus (BCoV) 48 disease", "DISEASE", 58, 94], ["canine coronavirus (CCoV) disease", "DISEASE", 101, 134], ["human diseases", "DISEASE", 144, 158], ["bovine coronavirus (BCoV) 48 disease 8", "ORGANISM", 58, 96], ["canine coronavirus", "ORGANISM", 101, 119], ["human", "ORGANISM", 144, 149], ["bovine", "SPECIES", 58, 64], ["coronavirus", "SPECIES", 65, 76], ["canine coronavirus", "SPECIES", 101, 119], ["human", "SPECIES", 144, 149], ["bovine coronavirus", "SPECIES", 58, 76], ["BCoV", "SPECIES", 78, 82], ["canine coronavirus", "SPECIES", 101, 119], ["CCoV", "SPECIES", 121, 125], ["human", "SPECIES", 144, 149], ["new animal diseases", "PROBLEM", 29, 48], ["bovine coronavirus (BCoV) 48 disease 8", "PROBLEM", 58, 96], ["canine coronavirus (CCoV) disease", "PROBLEM", 101, 134], ["human diseases", "PROBLEM", 144, 158], ["OC43", "TEST", 168, 172], ["new", "OBSERVATION_MODIFIER", 29, 32], ["animal diseases", "OBSERVATION", 33, 48]]], ["49INTRODUCTION 33The aetiological agent of COVID-19, SARS-CoV-2, is thought to have originated in bats 12 and shifted 50 to humans via an intermediate reservoir host, likely a species of pangolin 13 .", [["COVID-19", "ORGANISM", 43, 51], ["SARS-CoV-2", "ORGANISM", 53, 63], ["humans", "ORGANISM", 124, 130], ["pangolin 13", "ORGANISM", 187, 198], ["pangolin 13", "PROTEIN", 187, 198], ["humans", "SPECIES", 124, 130], ["humans", "SPECIES", 124, 130], ["COVID", "TEST", 43, 48], ["pangolin", "TREATMENT", 187, 195], ["reservoir host", "OBSERVATION", 151, 165]]], ["51INTRODUCTION 33Comparison of the genetic sequences of bat and human coronaviruses has revealed five potentially 52 important genetic regions involved in host specificity and shifting, with the Spike receptor binding 53 domain believed to be the most important 1,5 .", [["bat", "ORGANISM", 56, 59], ["human", "ORGANISM", 64, 69], ["coronaviruses", "ORGANISM", 70, 83], ["Spike receptor binding 53 domain", "PROTEIN", 195, 227], ["human", "SPECIES", 64, 69], ["human coronaviruses", "SPECIES", 64, 83], ["the genetic sequences", "TEST", 31, 52], ["human coronaviruses", "TEST", 64, 83], ["the Spike receptor binding", "PROBLEM", 191, 217], ["host specificity", "OBSERVATION_MODIFIER", 155, 171]]], ["Homologous recombination is a natural process which 54 brings together new combinations of genetic material, and hence new viral strains, from two similar 55 non-identical parent strains of virus.", [["Homologous recombination", "PROBLEM", 0, 24], ["genetic material", "PROBLEM", 91, 107], ["new viral strains", "PROBLEM", 119, 136], ["virus", "PROBLEM", 190, 195], ["new", "OBSERVATION_MODIFIER", 119, 122], ["viral strains", "OBSERVATION", 123, 136], ["virus", "OBSERVATION", 190, 195]]], ["This recombination occurs when different strains co-infect an 56 individual animal, with sequences from each parent strain in the genetic make-up of progeny virus.", [["progeny virus", "ORGANISM", 149, 162], ["different strains co-infect", "PROBLEM", 31, 58], ["progeny virus", "PROBLEM", 149, 162]]], ["57INTRODUCTION 33Homologous recombination has previously been demonstrated in many important viruses such as 58 human immunodeficiency virus 14 , classical swine fever virus 15 , and throughout the Coronaviridae 1,2 , 59 including homologous recombination in Spike being implicated in the generation of SARS-CoV-2 2 .", [["human immunodeficiency virus", "DISEASE", 112, 140], ["swine fever", "DISEASE", 156, 167], ["SARS", "DISEASE", 303, 307], ["58", "ORGANISM", 109, 111], ["human immunodeficiency virus 14", "ORGANISM", 112, 143], ["classical swine fever virus 15", "ORGANISM", 146, 176], ["Spike", "GENE_OR_GENE_PRODUCT", 259, 264], ["SARS-CoV-2 2", "ORGANISM", 303, 315], ["human immunodeficiency virus", "SPECIES", 112, 140], ["swine fever virus", "SPECIES", 156, 173], ["human immunodeficiency virus", "SPECIES", 112, 140], ["swine fever virus 15", "SPECIES", 156, 176], ["SARS-CoV", "SPECIES", 303, 311], ["human immunodeficiency virus", "PROBLEM", 112, 140], ["classical swine fever virus", "PROBLEM", 146, 173], ["homologous recombination", "TREATMENT", 231, 255], ["viruses", "OBSERVATION", 93, 100]]], ["60INTRODUCTION 33As well as instigating host-shifting, homologous recombination in other regions of the virus genome 61 could also introduce novel phenotypes into coronavirus strains already infectious to humans.", [["coronavirus", "ORGANISM", 163, 174], ["humans", "ORGANISM", 205, 211], ["virus genome 61", "DNA", 104, 119], ["humans", "SPECIES", 205, 211], ["humans", "SPECIES", 205, 211], ["homologous recombination", "TREATMENT", 55, 79], ["the virus genome", "PROBLEM", 100, 116], ["novel phenotypes into coronavirus strains", "PROBLEM", 141, 182]]], ["There are 62 at least seven potential regions for homologous recombination in the replicase and Spike regions of the 63 SARS-CoV genome alone, with possible recombination partner viruses from a range of other 64 mammalian and human coronaviruses 16 .", [["Spike", "GENE_OR_GENE_PRODUCT", 96, 101], ["SARS-CoV", "ORGANISM", 120, 128], ["human", "ORGANISM", 226, 231], ["replicase and Spike regions", "DNA", 82, 109], ["63 SARS-CoV genome", "DNA", 117, 135], ["human", "SPECIES", 226, 231], ["SARS-CoV", "SPECIES", 120, 128], ["human coronaviruses", "SPECIES", 226, 245], ["homologous recombination in the replicase", "PROBLEM", 50, 91], ["Spike regions", "PROBLEM", 96, 109], ["recombination partner viruses", "PROBLEM", 157, 186], ["homologous recombination", "OBSERVATION", 50, 74]]], ["Recombination events between two compatible partner strains 65 in a shared host could thus lead to future novel coronaviruses, either by enabling pre-existing 66 mammalian strains to infect humans, or by adding new phenotypes arising from different alleles to pre-67 existing human-affecting strains.", [["coronaviruses", "ORGANISM", 112, 125], ["humans", "ORGANISM", 190, 196], ["human", "ORGANISM", 276, 281], ["humans", "SPECIES", 190, 196], ["human", "SPECIES", 276, 281], ["humans", "SPECIES", 190, 196], ["human", "SPECIES", 276, 281], ["novel coronaviruses", "PROBLEM", 106, 125], ["new phenotypes", "PROBLEM", 211, 225], ["affecting strains", "PROBLEM", 282, 299]]], ["68INTRODUCTION 33The most fundamental requirement for homologous recombination to take place is the co-infection of a 69 single host with multiple coronaviruses.", [["coronaviruses", "ORGANISM", 147, 160], ["homologous recombination", "TREATMENT", 54, 78], ["the co-infection", "PROBLEM", 96, 112], ["multiple coronaviruses", "PROBLEM", 138, 160], ["multiple", "OBSERVATION_MODIFIER", 138, 146], ["coronaviruses", "OBSERVATION", 147, 160]]], ["However, our understanding of which hosts are permissive to 70 which coronaviruses, the pre-requisite to identifying which hosts are potential sites for this 71 recombination (henceforth termed 'recombination hosts'), remains extremely limited.", [["coronaviruses", "ORGANISM", 69, 82]]], ["Here, we utilise 72 a similarity-based analytical pipeline to address this significant knowledge gap.", [["analytical pipeline", "TREATMENT", 39, 58]]], ["Our approach predicts 73 associations between coronaviruses and their potential mammalian hosts by integrating three 74 perspectives or points of view encompassing: 1) genomic features depicting different aspects of 75 coronaviruses (e.g. secondary structure, codon usage bias) extracted from complete genomes 76 (sequences = 3,271, virus strains = 411); 2) ecological, phylogenetic and geospatial traits of potential 77 mammalian hosts (n=876); and 3) characteristics of the network that describes the linkage of 78 coronaviruses to their observed hosts, which expresses our current knowledge of sharing of 79 coronaviruses between various hosts and host groups.", [["coronaviruses", "ORGANISM", 46, 59], ["coronaviruses", "ORGANISM", 517, 530], ["coronaviruses", "ORGANISM", 611, 624], ["coronaviruses", "PROBLEM", 46, 59], ["genomic features", "PROBLEM", 168, 184], ["75 coronaviruses", "PROBLEM", 216, 232], ["secondary structure", "PROBLEM", 239, 258], ["codon usage bias", "PROBLEM", 260, 276], ["virus strains", "TEST", 333, 346]]], ["Here we capture this topology, and 83 relations between coronaviruses and hosts in our network, by means of node (coronaviruses and hosts) 84 embeddings using DeepWalk 23a deep learning method that has been successfully used to predict 85 drug-target 24 , and IncRNA-disease associations 25 .", [["node", "ANATOMY", 108, 112], ["node", "MULTI-TISSUE_STRUCTURE", 108, 112], ["coronaviruses", "PROBLEM", 56, 69], ["node", "OBSERVATION", 108, 112]]], ["Our 88 framework then ensembles its constituent learners to produce testable predictions of mammalian hosts 89 of multiple coronaviruses.", [["coronaviruses", "ORGANISM", 123, 136], ["multiple coronaviruses", "PROBLEM", 114, 136], ["multiple", "OBSERVATION_MODIFIER", 114, 122], ["coronaviruses", "OBSERVATION", 123, 136]]], ["90INTRODUCTION 33In this study we address the following three questions: 1) Which species may be unidentified 91 mammalian reservoirs of coronaviruses? 2) What are the most probable mammalian host species in 92 which coronavirus homologous recombination could occur?", [["coronaviruses", "ORGANISM", 137, 150], ["coronavirus", "ORGANISM", 217, 228], ["this study", "TEST", 20, 30], ["coronaviruses", "PROBLEM", 137, 150], ["mammalian host species", "PROBLEM", 182, 204], ["coronavirus homologous recombination", "TREATMENT", 217, 253], ["most probable", "UNCERTAINTY", 168, 181], ["mammalian host species", "OBSERVATION", 182, 204]]], ["And 3) Which coronaviruses are most 93 likely to co-infect a single host, and thus act as sources for future novel viruses? 9496Our model to predict unobserved associations between coronaviruses and their mammalian hosts 97 indicated a total of 126 (ensemble mean probability cut-off >0.5, when subtracting/adding SD from the 98 mean the number of predicted hosts is 85/169.", [["coronaviruses", "ORGANISM", 13, 26], ["coronaviruses", "ORGANISM", 181, 194], ["future novel viruses", "PROBLEM", 102, 122], ["coronaviruses", "PROBLEM", 181, 194], ["viruses", "OBSERVATION", 115, 122]]], ["For simplicity, we report SD hereafter as -/+ from 99 predicted values at reported probability cut-offs, here: SD=-41/+43) non-human mammalian species in 100 which SARS-CoV-2 could be found.", [["SARS", "DISEASE", 164, 168], ["non-human", "ORGANISM", 123, 132], ["SARS-CoV", "SPECIES", 164, 172], ["non-human mammalian species", "PROBLEM", 123, 150]]], ["The breakdown of these hosts by order was as follows (values in 101 brackets represent SD from ensemble mean): Carnivora: 37 (0/0); Rodentia: 32 (-9/3); Chiroptera: 25 102 (-19/38); Artiodactyla: 20 (-8/2); Eulipotyphla: 5 (-4/0); Primates: 4 (0/0); Lagomorpha: 2 (-1/0) and 103 Pholidota: 1 (0/0).", [["Chiroptera", "ORGANISM", 153, 163], ["Eulipotyphla", "ORGANISM", 207, 219], ["breakdown", "OBSERVATION_MODIFIER", 4, 13]]], ["Figure 1 illustrates these predicted hosts, the probability of their association with 104 SARS-COV2, as well as numbers of known and unobserved (predicted) coronaviruses that could be 105 found in each potential reservoir of SARS-CoV-2 (Supplementary results table SR1 lists Predicted hosts are grouped by order (inner circle).", [["SARS", "DISEASE", 90, 94], ["SARS", "DISEASE", 225, 229], ["inner circle", "MULTI-TISSUE_STRUCTURE", 313, 325], ["SARS-CoV", "SPECIES", 225, 233], ["coronaviruses", "PROBLEM", 156, 169], ["SARS", "PROBLEM", 225, 229], ["CoV", "TEST", 230, 233]]], ["Middle circle presents probability of association between 114 host and SARS-CoV-2 (>0.5 light grey to 1 dark grey).", [["SARS-CoV-2", "ORGANISM", 71, 81], ["SARS-CoV", "SPECIES", 71, 79], ["SARS", "TEST", 71, 75], ["CoV", "TEST", 76, 79]]], ["Yellow bars represent number of coronaviruses 115 (species or strains) observed to be found in each host.", [["coronaviruses 115", "ORGANISM", 32, 49], ["coronaviruses", "PROBLEM", 32, 45], ["strains", "PROBLEM", 62, 69], ["number", "OBSERVATION_MODIFIER", 22, 28]]], ["Blue stacked bars represent other coronaviruses 116 predicted to be found in each host by our model.", [["Blue stacked bars", "PROBLEM", 0, 17], ["other coronaviruses", "PROBLEM", 28, 47]]], ["Predicted coronaviruses per host are grouped by prediction 117 probability into five categories (from inside to outside): >0.9, 0.9-0.9, 0.8-0.7, 0.7-0.6, and 0.", [["coronaviruses", "ORGANISM", 10, 23]]], ["Gammacoronaviruses and unclassified coronaviruses.", [["coronaviruses", "ORGANISM", 36, 49], ["Gammacoronaviruses", "PROBLEM", 0, 18], ["unclassified coronaviruses", "PROBLEM", 23, 49], ["unclassified coronaviruses", "OBSERVATION", 23, 49]]], ["Yellow cells represent observed associations 131 between the host and the coronavirus.", [["Yellow cells", "ANATOMY", 0, 12], ["Yellow cells", "CELL", 0, 12], ["coronavirus", "ORGANISM", 74, 85], ["Yellow cells", "CELL_TYPE", 0, 12], ["coronavirus", "SPECIES", 74, 85], ["Yellow cells", "PROBLEM", 0, 12], ["the coronavirus", "PROBLEM", 70, 85]]], ["Blue cells present predicted associations (predicted probability 132 ranging from >0.5 (light blue) to 1 (dark blue)).", [["Blue cells", "ANATOMY", 0, 10], ["Blue cells", "CELL", 0, 10], ["Blue cells", "CELL_TYPE", 0, 10], ["Blue cells", "TEST", 0, 10], ["light blue", "TEST", 88, 98]]], ["White cells represent no association between host and 133 virus (beneath cut-off probability of 0.5).", [["White cells", "ANATOMY", 0, 11], ["White cells", "CELL", 0, 11], ["133 virus", "ORGANISM", 54, 63], ["White cells", "CELL_TYPE", 0, 11], ["White cells", "PROBLEM", 0, 11], ["host and 133 virus", "PROBLEM", 45, 63], ["no association", "UNCERTAINTY", 22, 36]]], ["Give that coronaviruses frequently undergo homologous recombination when they co-infect a host, and 177 that SARS-CoV-2 is highly infectious to humans, the most immediate threat to public health is 178 recombination of other coronaviruses with SARS-CoV-2.", [["SARS", "DISEASE", 109, 113], ["SARS", "DISEASE", 244, 248], ["coronaviruses", "ORGANISM", 10, 23], ["SARS-CoV-2", "ORGANISM", 109, 119], ["humans", "ORGANISM", 144, 150], ["coronaviruses", "ORGANISM", 225, 238], ["SARS-CoV-2", "ORGANISM", 244, 254], ["humans", "SPECIES", 144, 150], ["SARS-CoV-2", "SPECIES", 109, 119], ["humans", "SPECIES", 144, 150], ["SARS-CoV", "SPECIES", 244, 252], ["coronaviruses", "PROBLEM", 10, 23], ["homologous recombination", "TREATMENT", 43, 67], ["CoV", "TEST", 114, 117], ["other coronaviruses", "PROBLEM", 219, 238], ["infectious", "OBSERVATION", 130, 140]]], ["Our prediction of these species' potential interaction with SARS-CoV-2 and considerable 230 numbers of other coronaviruses, as well as the latter three species' close association to humans, identify 231 them as high priority underestimated risks.", [["SARS", "DISEASE", 60, 64], ["SARS-CoV-2", "ORGANISM", 60, 70], ["coronaviruses", "ORGANISM", 109, 122], ["humans", "ORGANISM", 182, 188], ["humans", "SPECIES", 182, 188], ["SARS-CoV", "SPECIES", 60, 68], ["humans", "SPECIES", 182, 188], ["SARS", "TEST", 60, 64], ["CoV", "TEST", 65, 68], ["other coronaviruses", "PROBLEM", 103, 122]]], ["In addition to these human-associated species, both the 232 chimpanzee (Pan troglodytes) and African green monkey (Chlorocebus aethiops) have large numbers 233 of predicted associations (51, 46 at 0.5; and 16, 11 at 0.9, respectively), and given their relatedness to 234 humans and their importance in the emergence of viruses such as DENV 37 and HIV 38 , also serve as 235 other high priority species for surveillance.", [["human", "ORGANISM", 21, 26], ["chimpanzee", "ORGANISM", 60, 70], ["Pan troglodytes", "ORGANISM", 72, 87], ["African", "ORGANISM", 93, 100], ["green monkey", "ORGANISM", 101, 113], ["Chlorocebus aethiops", "ORGANISM", 115, 135], ["humans", "ORGANISM", 271, 277], ["DENV 37", "ORGANISM", 335, 342], ["HIV 38", "ORGANISM", 347, 353], ["human", "SPECIES", 21, 26], ["chimpanzee", "SPECIES", 60, 70], ["Pan troglodytes", "SPECIES", 72, 87], ["green monkey", "SPECIES", 101, 113], ["Chlorocebus aethiops", "SPECIES", 115, 135], ["humans", "SPECIES", 271, 277], ["HIV", "SPECIES", 347, 350], ["human", "SPECIES", 21, 26], ["Pan troglodytes", "SPECIES", 72, 87], ["African green monkey", "SPECIES", 93, 113], ["Chlorocebus aethiops", "SPECIES", 115, 135], ["humans", "SPECIES", 271, 277], ["DENV", "SPECIES", 335, 339], ["HIV", "SPECIES", 347, 350], ["these human-associated species", "PROBLEM", 15, 45], ["chimpanzee (Pan troglodytes)", "TREATMENT", 60, 88], ["African green monkey (Chlorocebus aethiops", "TREATMENT", 93, 135], ["DENV", "PROBLEM", 335, 339], ["HIV", "TEST", 347, 350], ["surveillance", "TEST", 406, 418], ["large", "OBSERVATION_MODIFIER", 142, 147]]], ["23696The most prominent result in figure 1 is the common pig (Sus scrofa), having the most predicted 237 associations, in addition to SARS-CoV-2, of all included mammals (121 and 73 coronaviruses predicted 238 at 0.5 and 0.9 cut-offs).", [["23696", "CHEMICAL", 0, 5], ["pig", "ORGANISM", 57, 60], ["Sus scrofa", "ORGANISM", 62, 72], ["pig", "SPECIES", 57, 60], ["Sus scrofa", "SPECIES", 62, 72], ["23696", "SPECIES", 0, 5], ["pig", "SPECIES", 57, 60], ["Sus scrofa", "SPECIES", 62, 72], ["SARS-CoV", "SPECIES", 134, 142], ["SARS", "TEST", 134, 138], ["CoV", "TEST", 139, 142], ["coronaviruses", "TEST", 182, 195], ["most prominent", "OBSERVATION_MODIFIER", 9, 23], ["common pig", "ANATOMY", 50, 60]]], ["The pig is a major known mammalian coronavirus host, harbouring both a large 239 number (26) of observed coronaviruses, as well as a wide diversity ( figure 2, supplementary results 240 table SR4).", [["pig", "ORGANISM", 4, 7], ["mammalian coronavirus", "ORGANISM", 25, 46], ["coronaviruses", "ORGANISM", 105, 118], ["pig", "SPECIES", 4, 7], ["coronavirus", "SPECIES", 35, 46], ["pig", "SPECIES", 4, 7], ["observed coronaviruses", "PROBLEM", 96, 118], ["a wide diversity", "PROBLEM", 131, 147], ["mammalian coronavirus host", "OBSERVATION", 25, 51], ["large", "OBSERVATION_MODIFIER", 71, 76], ["coronaviruses", "OBSERVATION", 105, 118]]], ["Given the large number of predicted viral associations presented here, the pig's close 241 association to humans, its known reservoir status for many other zoonotic viruses 39 , and it being 242 involved in genetic recombination of some of these viruses 40 , the pig is predicted to be one of the 243 foremost candidates for an important recombination host.", [["zoonotic viruses", "DISEASE", 156, 172], ["pig", "ORGANISM", 75, 78], ["humans", "ORGANISM", 106, 112], ["viruses 40", "ORGANISM", 246, 256], ["pig", "ORGANISM", 263, 266], ["pig", "SPECIES", 75, 78], ["humans", "SPECIES", 106, 112], ["pig", "SPECIES", 75, 78], ["humans", "SPECIES", 106, 112], ["pig", "SPECIES", 263, 266], ["many other zoonotic viruses", "PROBLEM", 145, 172], ["these viruses", "PROBLEM", 240, 253], ["large", "OBSERVATION_MODIFIER", 10, 15], ["viral associations", "OBSERVATION", 36, 54]]], ["24496In addition to the more immediate threat of homologous recombination directly with SARS-CoV-2, we 245 also present our predicted associations between all mammals and all coronaviruses (figures 2 and 3).", [["SARS-CoV", "SPECIES", 88, 96], ["homologous recombination", "TREATMENT", 49, 73], ["all coronaviruses", "ANATOMY", 171, 188]]], ["24696These associations represent the longer-term potential for background viral evolution via homologous 247 recombination in all species.", [["24696", "CHEMICAL", 0, 5], ["24696", "SPECIES", 0, 5], ["background viral evolution", "PROBLEM", 64, 90], ["longer-term potential", "OBSERVATION_MODIFIER", 38, 59], ["viral", "OBSERVATION", 75, 80]]], ["These data also show that there is a 11.54-fold underestimation in the 248 number of associations, with 421 observed associations and 4438 predicted at 0.5 cut-off (5.72-fold 249 increase with 1989 associations predicted at 0.9 cut-off).", [["a 11.54-fold underestimation", "PROBLEM", 35, 63]]], ["This is visually represented in figure 3, which 25096shows the bipartite network of virus and host for observed associations (A), and predicted associations 251 (B-D); with a marked increase in connectivity between our mammalian hosts and coronaviruses, even 252 at the most stringent 0.95 confidence cut-off.", [["coronaviruses", "ORGANISM", 239, 252], ["a marked increase in connectivity", "PROBLEM", 173, 206], ["coronaviruses", "PROBLEM", 239, 252], ["marked", "OBSERVATION_MODIFIER", 175, 181], ["increase", "OBSERVATION_MODIFIER", 182, 190]]], ["This indicates that the potential for homologous 253 recombination between coronaviruses is substantially underestimated using just observed data.", [["coronaviruses", "ORGANISM", 75, 88], ["coronaviruses", "PROBLEM", 75, 88]]], ["254 Furthermore, our model shows that the associations between more diverse coronaviruses is also 255 underestimated, for example, the number of host species with four or more different subgenera of 256 coronaviruses increases by 41.57-fold from seven observed to 291 predicted (Table S4, We acknowledge certain limitations in our methodology, primarily pertaining to current incomplete 283 datasets in the rapidly developing but still understudied field.", [["coronaviruses", "ORGANISM", 76, 89], ["coronaviruses", "ORGANISM", 203, 216], ["more diverse coronaviruses", "PROBLEM", 63, 89], ["host species", "PROBLEM", 145, 157], ["diverse", "OBSERVATION_MODIFIER", 68, 75], ["coronaviruses", "OBSERVATION", 76, 89], ["host species", "OBSERVATION", 145, 157]]], ["1) The inclusion only of coronaviruses 284 for which complete genomes could be found limited the number of coronaviruses (species or strain) for 285 which we could compute meaningful similarities, and therefore predict potential hosts.", [["coronaviruses", "ORGANISM", 25, 38], ["coronaviruses", "ORGANISM", 107, 120], ["coronaviruses", "PROBLEM", 25, 38], ["coronaviruses", "PROBLEM", 107, 120]]], ["The same 286 applies for our mammalian specieswe only included mammalian hosts for which phylogenetic, 287 ecological, and geospatial data were available.", [["geospatial data", "TEST", 123, 138]]], ["2) Research effort, centering mainly on coronaviruses found in 290 humans and their domesticated animals, can lead to overestimation of the potential of coronaviruses to 291 recombine in frequently studied mammals, such as lab rodents which were excluded from the results 292 reported here (similar to previous work 18 ), and significantly, domesticated pigs and cats which we have 293 found to be important recombination host species of coronaviruses.", [["coronaviruses", "ORGANISM", 40, 53], ["humans", "ORGANISM", 67, 73], ["coronaviruses", "ORGANISM", 153, 166], ["pigs", "ORGANISM", 354, 358], ["cats", "ORGANISM", 363, 367], ["coronaviruses", "ORGANISM", 438, 451], ["humans", "SPECIES", 67, 73], ["pigs", "SPECIES", 354, 358], ["cats", "SPECIES", 363, 367], ["humans", "SPECIES", 67, 73], ["pigs", "SPECIES", 354, 358], ["coronaviruses", "PROBLEM", 40, 53], ["coronaviruses", "PROBLEM", 153, 166], ["coronaviruses", "PROBLEM", 438, 451]]], ["Firstly, in our results, other 'overstudied' mammals such as cows and sheep, were not 295 highlight by our model, which is consistent with them being considered less important hosts of 296 coronaviruses, and certain under-studied bats were highlighted as major potential hosts; together, these 297 indicate that research effort is not a substantial driver of our results.", [["cows", "ORGANISM", 61, 65], ["sheep", "ORGANISM", 70, 75], ["coronaviruses", "ORGANISM", 189, 202], ["bats", "ORGANISM", 230, 234], ["cows", "SPECIES", 61, 65], ["sheep", "SPECIES", 70, 75], ["sheep", "SPECIES", 70, 75], ["consistent with", "UNCERTAINTY", 123, 138]]], ["Secondly, methodologically, the 298 effect of research effort has been mitigated by capturing similarities from our three points of view (virus, 299 host and network) and multiple characteristics therein.", [["network", "MULTI-TISSUE_STRUCTURE", 158, 165]]], ["30096In this study we demonstrate that the potential for homologous recombination in mammalian hosts of 301 coronaviruses is highly underestimated.", [["mammalian hosts", "ORGANISM", 85, 100], ["301 coronaviruses", "ORGANISM", 104, 121], ["this study", "TEST", 8, 18], ["homologous recombination", "TREATMENT", 57, 81], ["coronaviruses", "PROBLEM", 108, 121]]], ["The ability of the large numbers of hosts presented here to be 302 hosts of multiple coronaviruses, including SARS-CoV-2, demonstrated the capacity for homologous 303 recombination and hence production of further novel coronaviruses.", [["coronaviruses", "ORGANISM", 85, 98], ["SARS-CoV-2", "ORGANISM", 110, 120], ["coronaviruses", "ORGANISM", 219, 232], ["SARS-CoV", "SPECIES", 110, 118], ["multiple coronaviruses", "PROBLEM", 76, 98], ["SARS-CoV", "TEST", 110, 118], ["the capacity", "PROBLEM", 135, 147], ["homologous 303 recombination", "TREATMENT", 152, 180], ["further novel coronaviruses", "PROBLEM", 205, 232], ["large", "OBSERVATION_MODIFIER", 19, 24]]], ["Our methods deployed a meta-304 ensemble of similarity learners from three complementary perspectives (viral, mammalian and 305 network), to predict each potential coronavirus-mammal association.", [["305 network", "MULTI-TISSUE_STRUCTURE", 124, 135], ["coronavirus", "ORGANISM", 164, 175], ["coronavirus", "OBSERVATION", 164, 175]]], ["30696The current consensus is that SARS-CoV-2 was generated by homologous recombination; originally 307 derived from coronaviruses in bats 12 and then shifted to humans via an intermediate reservoir host, 308 likely a species of pangolin 13 .", [["30696", "CHEMICAL", 0, 5], ["SARS", "DISEASE", 35, 39], ["SARS-CoV-2", "ORGANISM", 35, 45], ["coronaviruses", "ORGANISM", 117, 130], ["humans", "ORGANISM", 162, 168], ["SARS-CoV-2", "DNA", 35, 45], ["pangolin 13", "DNA", 229, 240], ["humans", "SPECIES", 162, 168], ["30696", "SPECIES", 0, 5], ["humans", "SPECIES", 162, 168], ["SARS-CoV", "TEST", 35, 43], ["coronaviruses", "PROBLEM", 117, 130], ["pangolin", "TREATMENT", 229, 237]]], ["Importantly, the lineage of SARS-CoV-2 was deduced only after the 309 outbreak in humans.", [["SARS", "DISEASE", 28, 32], ["SARS-CoV-2", "ORGANISM", 28, 38], ["humans", "ORGANISM", 82, 88], ["humans", "SPECIES", 82, 88], ["SARS-CoV", "SPECIES", 28, 36], ["humans", "SPECIES", 82, 88], ["lineage", "OBSERVATION_MODIFIER", 17, 24], ["SARS", "OBSERVATION", 28, 32]]], ["With the greater understanding of the extent of mammalian host reservoirs and the 310 potential recombination hosts we identify here, a targeted surveillance program is now possible which 311 would allow for this generation to be observed as it is happening and before a major outbreak.", [["mammalian host reservoirs", "TREATMENT", 48, 73], ["host reservoirs", "OBSERVATION", 58, 73]]], ["Such 312 information could help inform mitigation strategies and provide a vital early warning system for future 313 novel coronaviruses.", [["coronaviruses", "ORGANISM", 123, 136], ["mitigation strategies", "TREATMENT", 39, 60]]], ["314316Viruses and mammalian data 317 Viral genomic data: Complete sequences of coronaviruses were downloaded from Genbank 43 .", [["314316", "CHEMICAL", 0, 6], ["coronaviruses", "ORGANISM", 79, 92], ["314316", "SPECIES", 0, 6], ["mammalian data", "TEST", 18, 32], ["Viral genomic data", "TEST", 37, 55], ["coronaviruses", "PROBLEM", 79, 92]]], ["In addition, we removed these associated with experimental infections were possible.", [["infections", "DISEASE", 59, 69], ["experimental infections", "PROBLEM", 46, 69], ["infections", "OBSERVATION", 59, 69]]], ["This 320 resulted in total of 3,264 sequences for 411coronavirus species or strain (i.e. viruses below species level 321 on NCBI taxonomy tree).", [["coronavirus species", "ORGANISM", 53, 72], ["411coronavirus species", "PROBLEM", 50, 72], ["strain (i.e. viruses below species level", "PROBLEM", 76, 116]]], ["Of these 88 were sequences of coronavirus species, and 307 of strains (in 25 322 coronavirus species, with total number of species included=92).", [["coronavirus", "ORGANISM", 30, 41], ["coronavirus", "ORGANISM", 81, 92], ["coronavirus species", "TEST", 30, 49], ["strains", "PROBLEM", 62, 69], ["coronavirus species", "TEST", 81, 100]]], ["323Selection of potential mammalian hosts of coronaviruses:We processed meta-data accompanying 324 all sequences (including partial sequences but excluding vaccination and experimental infections) of 325 coronaviruses uploaded to GenBank to extract information on hosts (to species level) of these 326 coronaviruses.", [["infections", "DISEASE", 185, 195], ["coronaviruses", "ORGANISM", 45, 58], ["coronaviruses", "ORGANISM", 302, 315], ["partial sequences", "TEST", 124, 141], ["vaccination", "PROBLEM", 156, 167], ["experimental infections", "PROBLEM", 172, 195], ["mammalian hosts", "OBSERVATION", 26, 41], ["coronaviruses", "OBSERVATION", 45, 58]]], ["We supplemented these data species-level hosts of coronaviruses extracted from 327 scientific publications via the Enhanced Infectious Diseases Database (EID2) 44 .", [["Infectious Diseases", "DISEASE", 124, 143], ["coronaviruses", "ORGANISM", 50, 63], ["these data species", "TEST", 16, 34], ["coronaviruses", "PROBLEM", 50, 63], ["Infectious", "OBSERVATION", 124, 134]]], ["This resulted in 328 identification of 313 known terrestrial mammalian hosts of coronaviruses (regardless of whether a 329 complete genome was available or not, N=185 mammalian species for which an association with a 330 coronaviruses with complete genome was identified).", [["coronaviruses", "ORGANISM", 80, 93], ["329 complete genome", "DNA", 119, 138], ["coronaviruses", "PROBLEM", 80, 93], ["mammalian species", "PROBLEM", 167, 184], ["a 330 coronaviruses", "PROBLEM", 215, 234], ["terrestrial mammalian hosts", "OBSERVATION", 49, 76]]], ["We expanded this set of potential hosts by 331 including terrestrial mammalian species in genera containing at least one known host of coronavirus, 332 and which are known to host one or more other virus species (excluding coronaviruses, information of 333 whether the host is associated with a virus were obtained from EID2).", [["coronavirus", "ORGANISM", 135, 146], ["terrestrial mammalian species in genera", "PROBLEM", 57, 96], ["coronavirus", "PROBLEM", 135, 146], ["other virus species", "PROBLEM", 192, 211], ["coronaviruses", "PROBLEM", 223, 236], ["a virus", "PROBLEM", 293, 300], ["terrestrial mammalian species", "OBSERVATION", 57, 86], ["coronavirus", "OBSERVATION", 135, 146]]], ["335Selection of potential mammalian hosts of coronaviruses:Quantification of viral and mammalian similarities 336 We computed three types of similarities between each two viral genomes as summarised below.", [["coronaviruses", "ORGANISM", 45, 58], ["viral genomes", "DNA", 171, 184], ["coronaviruses", "PROBLEM", 45, 58], ["viral and mammalian similarities", "PROBLEM", 77, 109], ["mammalian hosts", "OBSERVATION", 26, 41], ["viral genomes", "OBSERVATION", 171, 184]]], ["337 Biases and codon usage: We calculated proportion of each nucleotide of the total coding sequence 338 length.", [["nucleotide", "CHEMICAL", 61, 71]]], ["We computed dinucleotide and codon biases 45 and codon pair bias, measured as the codon pair 339 score (CPS) 45,46 in each of the above sequences.", [["dinucleotide", "CHEMICAL", 12, 24], ["dinucleotide", "CHEMICAL", 12, 24], ["computed dinucleotide and codon biases", "TEST", 3, 41], ["codon pair bias", "TEST", 49, 64], ["CPS", "TEST", 104, 107], ["the above sequences", "TEST", 126, 145]]], ["This enabled us to produce for each genome sequence 340 (N=3,271) the following feature vectors: nucleotide bias; dinucleotide bias; codon biased; and codon-341 pair bias.", [["nucleotide", "CHEMICAL", 97, 107], ["dinucleotide", "CHEMICAL", 114, 126], ["nucleotide", "CHEMICAL", 97, 107], ["dinucleotide", "CHEMICAL", 114, 126], ["genome sequence", "DNA", 36, 51], ["each genome sequence", "TEST", 31, 51], ["nucleotide bias", "TEST", 97, 112], ["dinucleotide bias", "TEST", 114, 131], ["codon biased", "PROBLEM", 133, 145], ["codon", "TEST", 151, 156]]], ["342Selection of potential mammalian hosts of coronaviruses:Secondary structure: Following alignment of sequences (using AlignSeqs function in R package 343Selection of potential mammalian hosts of coronaviruses:Decipher 47 ), we predicted the secondary structure for each sequence using PredictHEC function in the 344 R package Decipher 47 .", [["coronaviruses", "ORGANISM", 45, 58], ["coronaviruses", "ORGANISM", 197, 210], ["PredictHEC function", "TEST", 287, 306], ["mammalian hosts", "OBSERVATION", 26, 41]]], ["We obtained both states (final prediction), and probability of secondary 345 structures for each sequence.", [["each sequence", "TEST", 92, 105]]], ["This enabled us to generate six vectors (length = 100) for each genome 348Selection of potential mammalian hosts of coronaviruses:representing: mean probability and coverage for each of three possible structures -Helix (H), Beta-349Sheet (E), or Coil (C).", [["coronaviruses", "ORGANISM", 116, 129], ["Beta-349Sheet", "GENE_OR_GENE_PRODUCT", 224, 237], ["genome 348Selection", "DNA", 64, 83], ["length", "TEST", 41, 47], ["coronaviruses", "PROBLEM", 116, 129], ["mean probability", "PROBLEM", 144, 160], ["Beta", "TEST", 224, 228], ["mammalian hosts", "OBSERVATION", 97, 112]]], ["350We set this function to penalise gap-to-gap and gap-to-letter mismatches.", [["gap", "TEST", 36, 39], ["gap", "TEST", 51, 54]]], ["350Similarity quantification We transformed the feature (traits) vectors described above into similarities 354 matrices between coronaviruses (species or strains).", [["coronaviruses", "ORGANISM", 128, 141], ["coronaviruses", "PROBLEM", 128, 141], ["strains", "PROBLEM", 154, 161]]], ["This was achieved by computing cosine similarity 355 between these vectors in each category (e.g. codon pair usage, H coverage, E probability).", [["these vectors", "TREATMENT", 61, 74], ["codon pair usage", "TREATMENT", 98, 114]]], ["350for each genomic feature (N=10) presented by vector as described above, this similarity was calculated 357 as follows: 358359Where and are two genomic sequences presented by two feature vectors and from the 360 genomic feature space (e.g. codon pair bias) of the dimension d (e.g. d= 100 for H-coverage).", [["genomic sequences", "DNA", 146, 163], ["360 genomic feature space", "DNA", 210, 235], ["codon pair bias", "TEST", 242, 257]]], ["361359We then calculated similarity between each pair of virus strains or species (in each category) as the 362 mean of similarities between genomic sequences of the two virus strains or species (e.g. mean 363359nucleotide bias similarity between all sequences of SARS-CoV-2 and all sequences of MERS-CoV 364 presented the final nucleotide bias similarity between SARS-CoV-2 and MERS-CoV).", [["nucleotide", "CHEMICAL", 212, 222], ["SARS", "DISEASE", 264, 268], ["nucleotide", "CHEMICAL", 329, 339], ["nucleotide", "CHEMICAL", 212, 222], ["SARS-CoV-2", "ORGANISM", 264, 274], ["MERS-CoV", "ORGANISM", 296, 304], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 364, 374], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 379, 387], ["SARS-CoV-2", "DNA", 264, 274], ["MERS-CoV 364", "DNA", 296, 308], ["SARS-CoV", "SPECIES", 264, 272], ["MERS-CoV", "SPECIES", 296, 304], ["SARS-CoV", "SPECIES", 364, 372], ["MERS-CoV", "SPECIES", 379, 387], ["virus strains", "PROBLEM", 57, 70], ["species", "PROBLEM", 74, 81], ["the two virus strains", "PROBLEM", 162, 183], ["nucleotide bias", "TEST", 212, 227], ["all sequences", "TEST", 247, 260], ["SARS", "TEST", 264, 268], ["CoV", "TEST", 269, 272], ["MERS", "TEST", 296, 300], ["CoV", "TEST", 301, 304], ["nucleotide bias", "TEST", 329, 344], ["SARS", "TEST", 364, 368], ["CoV", "TEST", 369, 372], ["virus strains", "OBSERVATION", 57, 70]]], ["This enabled us 365 to generate 11 genomic features similarity matrices (the above 10 features represented by vectors + 366 genomic similarity matrix) between our input coronaviruses.", [["matrix", "CELLULAR_COMPONENT", 143, 149], ["coronaviruses", "ORGANISM", 169, 182], ["11 genomic features similarity matrices", "PROBLEM", 32, 71]]], ["367368Similarity network fusion (SNF): We applied similarity network fusion (SNF) 48 to integrate the 369 following similarities in order to reduce our viral genomic feature space: 1) Nucleotide, dinucleotide, 370 codon, and codon pair usage biases were combined into one similarity matrix -genome bias similarity.", [["dinucleotide", "CHEMICAL", 196, 208], ["dinucleotide", "CHEMICAL", 196, 208], ["similarity network fusion (SNF)", "TREATMENT", 50, 81], ["Nucleotide, dinucleotide, 370 codon", "TREATMENT", 184, 219], ["codon pair usage biases", "TREATMENT", 225, 248]]], ["371368And 2) Helix (H), Beta-Sheet (E), or Coil (C) mean probability and coverage similarities (six in total) 372 were combined into one similarity matrix -secondary structure similarity.", [["Coil (C) mean probability", "PROBLEM", 43, 68], ["secondary structure", "OBSERVATION", 156, 175]]], ["373 SNF applies an iterative nonlinear method that updates every similarity matrix according to the other 374 matrices via nearest neighbour approach and is scalable and is robust to noise and data heterogeneity.", [["an iterative nonlinear method", "TREATMENT", 16, 45]]], ["375368The integrated matrix captures both shared and complementary information from multiple similarities.", [["375368", "CHEMICAL", 0, 6], ["matrix", "CELLULAR_COMPONENT", 21, 27], ["375368", "SPECIES", 0, 6]]], ["Quantification of topological features: The above constructed network summarises our knowledge to 391 date of associations between coronaviruses and their hosts, and its topology expresses patterns of 392 sharing these viruses between various hosts and host groups.", [["coronaviruses", "ORGANISM", 131, 144], ["coronaviruses", "PROBLEM", 131, 144], ["topological features", "OBSERVATION", 18, 38]]], ["Our analytical pipeline captures this 393 topology, and relations between nodes in our network, by means of node (vertex) embeddings.", [["node", "ANATOMY", 108, 112], ["node", "MULTI-TISSUE_STRUCTURE", 108, 112], ["nodes", "OBSERVATION", 74, 79], ["node", "OBSERVATION", 108, 112]]], ["This 394 approach encodes each node (here either a coronavirus or a host) with its own vector representation in 395 a continuous vector space, which in turns enable us to calculate similarities between two nodes based 396 on this representation.", [["node", "ANATOMY", 31, 35], ["node", "MULTI-TISSUE_STRUCTURE", 31, 35], ["a coronavirus", "PROBLEM", 49, 62], ["a continuous vector space", "TREATMENT", 116, 141], ["node", "OBSERVATION", 31, 35], ["nodes", "OBSERVATION", 206, 211]]], ["397368We adopted DeepWalk 23 to compute vectorised representations for our coronaviruses and hosts from 398 the network connecting them.", [["coronaviruses", "ORGANISM", 75, 88], ["our coronaviruses", "PROBLEM", 71, 88]]], ["DeepWalk uses truncated random walks to get latent topological 399 information of the network and obtains the vector representation of its nodes (in our case coronaviruses, Similarity learning meta-ensemblea multi-perspective approach 411 Our analytical pipeline stacks 12 similarity learners into meta-ensembles and selects the best performing 412 ensemble following internal and external validation processes.", [["nodes", "ANATOMY", 139, 144], ["meta-ensembles", "DNA", 298, 312], ["its nodes", "PROBLEM", 135, 144], ["Our analytical pipeline stacks", "TREATMENT", 239, 269], ["internal and external validation processes", "TREATMENT", 368, 410], ["nodes", "OBSERVATION", 139, 144]]], ["The constituent learners based on 413 different data and points of views and can be categorised as follows: 414368Coronavirusesthe viral point of view: we assembled three models derived from a) genome similarity, 415 b) genome biases, and c) genome secondary structure.", [["views", "TEST", 67, 72], ["genome biases, and c) genome secondary structure", "PROBLEM", 220, 268], ["secondary structure", "OBSERVATION", 249, 268]]], ["Each of these learners gave each coronavirus-416 mammalian association ( \u2192 ) a score, termed confidence, based on how similar the coronavirus 417 is to known coronaviruses of mammalian species , compared to how similar is to all included 418 coronaviruses 24,25 .", [["coronavirus", "ORGANISM", 33, 44], ["coronavirus 417", "ORGANISM", 130, 145], ["coronaviruses", "ORGANISM", 158, 171], ["coronaviruses", "ORGANISM", 242, 255], ["known coronaviruses of mammalian species", "PROBLEM", 152, 192], ["coronaviruses", "TEST", 242, 255], ["coronaviruses", "OBSERVATION", 158, 171], ["mammalian species", "OBSERVATION", 175, 192]]], ["In other words, if is more similar (e.g. based on genome secondary structure) to 419 coronaviruses observed in host than it is similar to those coronaviruses not observed in , then the 420 association \u2192 is given a higher confidence score.", [["coronaviruses", "PROBLEM", 85, 98]]], ["Conversely, if is somewhat similar to 421 coronaviruses observed in , and also somewhat similar to viruses not known to infect this particular 422 mammal, then the association \u2192 is given a medium confidence score.", [["coronaviruses", "PROBLEM", 42, 55], ["viruses", "OBSERVATION", 99, 106]]], ["The association \u2192 423 is given a lower confidence score if is more similar to coronaviruses not known to infect than it 424 is similar to coronaviruses observed in this host.", [["coronaviruses", "ORGANISM", 78, 91], ["coronaviruses", "ORGANISM", 138, 151], ["a lower confidence score", "PROBLEM", 31, 55], ["coronaviruses", "PROBLEM", 78, 91], ["coronaviruses", "PROBLEM", 138, 151]]], ["425 Ensemble construction: We combined the above described leaners by stacking them into ensembles 452 (meta-ensembles) using Stochastic Gradient Boosting (GBM).", [["GBM", "CANCER", 156, 159], ["meta-ensembles)", "TREATMENT", 104, 119], ["Stochastic Gradient Boosting (GBM", "TREATMENT", 126, 159]]], ["The purpose of this combination is to 453 incorporate the three points of views descried above, as well as varied aspects of the coronaviruses and 454 their mammalian potential hosts, into a generalisable, robust model 50 .", [["coronaviruses", "ORGANISM", 129, 142], ["views", "TEST", 74, 79]]], ["We selected GBM as our stacking 455 algorithm due to its ability to handle non-linearity and high-order interactions between constituent 456 learners 51 .", [["GBM", "ANATOMY", 12, 15], ["GBM", "DISEASE", 12, 15], ["GBM", "CANCER", 12, 15], ["GBM", "OBSERVATION", 12, 15]]], ["We performed the training and optimisation (tuning) of these ensembles using the caret R 457368Package 52 .", [["caret R 457368Package 52", "DNA", 81, 105], ["the training", "TREATMENT", 13, 25]]], ["458368Ensemble sampling: our gbm ensembles comprised 100 replicate models.", [["458368", "CHEMICAL", 0, 6], ["458368", "SPECIES", 0, 6], ["Ensemble sampling", "TEST", 6, 23], ["gbm", "OBSERVATION", 29, 32]]], ["Each model was trained with 459 balanced random samples using 10-fold cross validation.", [["samples", "ANATOMY", 48, 55], ["10-fold cross validation", "TREATMENT", 62, 86]]], ["Standard deviation (SD) from mean probability 461 was also generated and its values subtracted/added to predictions.", [["Standard deviation (SD) from mean probability", "PROBLEM", 0, 45], ["deviation", "OBSERVATION", 9, 18]]], ["462368Validation and performance estimation: We validated the performance of our analytical pipeline 463 externally against 5 held-out test-sets. each test-set was generated by splitting the set of observed 464 associations between coronaviruses and their hosts into two random sets: a training-set comprising 85% 465 of all known associations and a test-set comprising 15% of known associations.", [["462368", "CHEMICAL", 0, 6], ["coronaviruses", "ORGANISM", 232, 245], ["462368", "SPECIES", 0, 6], ["each test", "TEST", 146, 155], ["a training", "TREATMENT", 284, 294], ["a test", "TEST", 348, 354]]], ["These test-sets were 466 held-out throughout the processes of generating similarity matrices; similarity learning, and assembling 467 our learners, and were only used for the purposes of estimating performance metrics of our analytical 468 pipeline.", [["These test", "TEST", 0, 10]]], ["This resulted in 5 runs in which our ensemble learnt using only 85% of observed associations 469 between our coronaviruses and their mammalian hosts.", [["coronaviruses", "ORGANISM", 109, 122]]], ["For each run calculated three performance 470 metrics based on the mean probability across each set of 100 replicate models of the gbm meta-471 ensembles: AUC, true skills statistics (TSS) and F-score.", [["the gbm meta", "TEST", 127, 139], ["AUC", "TEST", 155, 158]]]], "1f04e27ad51b6f85f0696b21c808852d78e1d5ca": [["For instance,\u00afightlessness has evolved repeatedly in island populations of birds and insects (Williamson, 1981) .", [["birds", "ORGANISM", 75, 80]]], ["Island populations also frequently differ from mainland relatives in colour, behaviour, morphology, fecundity, and even longevity (Crowell & Rothstein, 1981; Williamson, 1981; Austad, 1993; Adler & Levins, 1994) .", [["Island populations", "CELL", 0, 18], ["Crowell & Rothstein, 1981; Williamson, 1981; Austad, 1993; Adler & Levins, 1994)", "SPECIES", 131, 211], ["Island populations", "PROBLEM", 0, 18]]], ["Speci\u00aecally, such differences were assumed to derive from selection for traits associated with rapid population growth (r-selection) during the early phase of island colonization and subsequent selection for competitive ability (K-selection) under the typical island conditions of a more equable physical environment and consequent lower densityindependent mortality, dense populations of extant species, as well as reduced numbers of predator and competitor species.", [["traits", "PROBLEM", 72, 78], ["rapid population growth", "PROBLEM", 95, 118], ["island colonization", "PROBLEM", 159, 178], ["consequent lower densityindependent mortality", "PROBLEM", 321, 366], ["extant species", "PROBLEM", 389, 403], ["reduced numbers of predator and competitor species", "PROBLEM", 416, 466], ["lower densityindependent", "OBSERVATION_MODIFIER", 332, 356], ["dense", "OBSERVATION_MODIFIER", 368, 373], ["populations", "OBSERVATION_MODIFIER", 374, 385], ["extant species", "OBSERVATION", 389, 403], ["reduced", "OBSERVATION_MODIFIER", 416, 423], ["numbers", "OBSERVATION_MODIFIER", 424, 431], ["competitor species", "OBSERVATION", 448, 466]]], ["Other authors (Davis, 1983; Berry, 1996) have noted that because island colonization events constitute signi\u00aecant genetic bottlenecks, many of the differences between mainland and island populations (as well as among island populations themselves) may derive from the chance subset of mainland genotypes which island colonizers happen to possess.", [["island colonization events", "PROBLEM", 65, 91], ["signi\u00aecant genetic bottlenecks", "PROBLEM", 103, 133], ["mainland genotypes", "PROBLEM", 285, 303]]], ["Insular animal populations often exhibit extremes of body size, and may be considerably larger or smaller than their closest mainland relatives (Case, 1978) .", [["body", "ANATOMY", 53, 57], ["body", "ORGANISM_SUBDIVISION", 53, 57], ["Insular animal populations", "PROBLEM", 0, 26], ["animal", "OBSERVATION_MODIFIER", 8, 14], ["populations", "OBSERVATION", 15, 26], ["extremes", "OBSERVATION_MODIFIER", 41, 49], ["body", "OBSERVATION_MODIFIER", 53, 57], ["size", "OBSERVATION_MODIFIER", 58, 62], ["may be", "UNCERTAINTY", 68, 74], ["considerably", "OBSERVATION_MODIFIER", 75, 87], ["larger", "OBSERVATION_MODIFIER", 88, 94], ["smaller", "OBSERVATION_MODIFIER", 98, 105]]], ["In mammals generally, a trend has been identi\u00aeed for large species to become smaller on islands and small species to become larger (Lomolino, 1985) .", [["large species", "PROBLEM", 53, 66], ["smaller on islands", "PROBLEM", 77, 95], ["small species", "PROBLEM", 100, 113], ["large", "OBSERVATION_MODIFIER", 53, 58], ["species", "OBSERVATION", 59, 66], ["smaller", "OBSERVATION_MODIFIER", 77, 84], ["small", "OBSERVATION_MODIFIER", 100, 105], ["species", "OBSERVATION", 106, 113], ["larger", "OBSERVATION_MODIFIER", 124, 130]]], ["However, the sample of mammals from which this trend was deduced was decidedly biased toward temperate, as opposed to tropical, islands and may not hold when the effects of latitude are controlled for.", [["islands", "OBSERVATION", 128, 135]]], ["For instance, in house mice Mus musculus, the mammal most broadly characterized in terms of latitudinal trends in insular body size, populations at low latitudes are frequently small (typically 9\u00b114 g: Tomich, Wilson & Lamourex, 1968; Berry, Sage et al., 1981) and at high latitudes are frequently large (20+ g: Berry, Jakobson & Peters, 1978; Barnett & Dickson, 1989) , although exceptions occur (Tomich et al., 1968; Berry & Peters, 1975) possibly as a result of founder effects and/or unusual combinations of predator or competitor species (Angerbjorn, 1986; Berry, 1996) .", [["insular body", "ANATOMY", 114, 126], ["house", "ORGANISM", 17, 22], ["mice Mus musculus", "ORGANISM", 23, 40], ["insular", "MULTI-TISSUE_STRUCTURE", 114, 121], ["body", "ORGANISM_SUBDIVISION", 122, 126], ["mice", "SPECIES", 23, 27], ["Mus musculus", "SPECIES", 28, 40], ["Mus musculus", "SPECIES", 28, 40], ["musculus", "ANATOMY", 32, 40], ["insular body", "OBSERVATION_MODIFIER", 114, 126], ["size", "OBSERVATION_MODIFIER", 127, 131], ["low latitudes", "OBSERVATION_MODIFIER", 148, 161], ["small", "OBSERVATION_MODIFIER", 177, 182]]], ["Because animals from populations with statistically distinct body sizes are seldom reared under standardized conditions, the extent to which observed size differences represent genetic or environmental differences is unclear.INTRODUCTIONEcological conditions typical of many islands also have relevance to the evolution of ageing rate.", [["body", "ANATOMY", 61, 65], ["body", "ORGANISM_SUBDIVISION", 61, 65], ["statistically distinct body sizes", "PROBLEM", 38, 71], ["distinct", "OBSERVATION_MODIFIER", 52, 60], ["body", "OBSERVATION_MODIFIER", 61, 65], ["sizes", "OBSERVATION_MODIFIER", 66, 71], ["size", "OBSERVATION_MODIFIER", 150, 154], ["many", "OBSERVATION_MODIFIER", 270, 274], ["islands", "OBSERVATION", 275, 282]]], ["Several comparative studies support this prediction (Keller & Genoud, 1997; Ricklefs, 1998) .", [["Several comparative studies", "TEST", 0, 27]]], ["Thus in the relatively safe environments typi\u00aeed by many islands, evolutionary processes are expected to gradually slow the ageing rate relative to an initially similar population on the mainland.", [["many", "OBSERVATION_MODIFIER", 52, 56], ["islands", "OBSERVATION", 57, 64], ["similar", "OBSERVATION_MODIFIER", 161, 168], ["population", "OBSERVATION", 169, 179]]], ["This prediction has been veri\u00aeed in Virginia opossums (Austad, 1993) .INTRODUCTIONUnder the assumption that genetic comparison of populations of the same species which age at different rates would yield insight into the genetics of ageing (Austad, 1996) , we sought to determine whether this same pattern of retarded ageing among island populations might hold for house mice M. musculus introduced to islands within historical times.", [["Virginia opossums", "ORGANISM", 36, 53], ["mice", "ORGANISM", 370, 374], ["M. musculus", "ORGANISM", 375, 386], ["mice", "SPECIES", 370, 374], ["M. musculus", "SPECIES", 375, 386], ["Virginia opossums", "SPECIES", 36, 53], ["M. musculus", "SPECIES", 375, 386], ["the same species", "PROBLEM", 145, 161]]], ["We collected mice from two tropical islands and introduced them into the laboratory in order to compare their ageing rate with two other groups of mice: wild mice from a mainland population and laboratory mice.", [["mice", "ORGANISM", 13, 17], ["mice", "ORGANISM", 147, 151], ["mice", "ORGANISM", 158, 162], ["mice", "ORGANISM", 205, 209], ["mice", "SPECIES", 13, 17], ["mice", "SPECIES", 147, 151], ["mice", "SPECIES", 158, 162], ["mice", "SPECIES", 205, 209], ["mice", "SPECIES", 13, 17], ["mice", "SPECIES", 147, 151], ["mice", "SPECIES", 158, 162], ["mice", "SPECIES", 205, 209]]], ["Domestication, like insular life, is expected to produce changes in many traits within a species (Bronson, 1984) .", [["insular", "OBSERVATION_MODIFIER", 20, 27]]], ["Therefore a comparison between wild and domesticated mainland mice might also be of interest.INTRODUCTIONAlthough mice have been introduced to hundreds of islands around the world (Berry, 1986) , we chose to investigate the populations of two tropical islands, because of the greater climatic constancy in the tropics relative to temperate or polar islands.", [["mice", "ORGANISM", 62, 66], ["mice", "ORGANISM", 114, 118], ["mice", "SPECIES", 62, 66], ["mice", "SPECIES", 114, 118], ["mice", "SPECIES", 62, 66], ["mice", "SPECIES", 114, 118], ["two tropical islands", "PROBLEM", 239, 259], ["tropical islands", "OBSERVATION", 243, 259], ["greater", "OBSERVATION_MODIFIER", 276, 283], ["climatic constancy", "OBSERVATION", 284, 302], ["polar islands", "OBSERVATION", 343, 356]]], ["Greater climatic constancy is assumed to correlate with lower mortality rates from environmental hazards.", [["Greater climatic constancy", "PROBLEM", 0, 26]]], ["Speci\u00aecally, we chose two islands that had previously been reported to harbour house mice with reduced body size and small litters compared with wild mainland animals.", [["body", "ANATOMY", 103, 107], ["mice", "ORGANISM", 85, 89], ["body", "ORGANISM_SUBDIVISION", 103, 107], ["mice", "SPECIES", 85, 89], ["mice", "SPECIES", 85, 89], ["reduced body size", "PROBLEM", 95, 112], ["small litters", "PROBLEM", 117, 130], ["reduced", "OBSERVATION_MODIFIER", 95, 102], ["body", "OBSERVATION_MODIFIER", 103, 107], ["size", "OBSERVATION_MODIFIER", 108, 112], ["small", "OBSERVATION_MODIFIER", 117, 122], ["litters", "OBSERVATION", 123, 130]]], ["We interpreted these insular traits as an indication that signi\u00aecant evolutionary change had occurred to the mice since the time of their introduction to the islands.INTRODUCTIONAlthough data on ageing rate in our mouse populations are not yet available, we present data herein to verify that these mouse populations are now wellestablished in the laboratory and that even under identical laboratory conditions, substantial differences occur among the populations.Trapping of mice from mainland and island locationsWe compared mice from 3 free-living populations with 1 population of laboratory-selected mice.", [["mice", "ORGANISM", 109, 113], ["mouse", "ORGANISM", 214, 219], ["mouse", "ORGANISM", 299, 304], ["mice", "ORGANISM", 476, 480], ["mice", "ORGANISM", 527, 531], ["mice", "ORGANISM", 604, 608], ["mice", "SPECIES", 109, 113], ["mouse", "SPECIES", 214, 219], ["mouse", "SPECIES", 299, 304], ["mice", "SPECIES", 476, 480], ["mice", "SPECIES", 527, 531], ["mice", "SPECIES", 604, 608], ["mice", "SPECIES", 109, 113], ["mouse", "SPECIES", 214, 219], ["mouse", "SPECIES", 299, 304], ["mice", "SPECIES", 476, 480], ["mice", "SPECIES", 527, 531], ["mice", "SPECIES", 604, 608], ["signi\u00aecant evolutionary change", "PROBLEM", 58, 88], ["these mouse populations", "PROBLEM", 293, 316]]], ["Free-living mainland mice were trapped near livestock barns in Moscow, Idaho, U.S.A. (478N lat., 1178W long.)", [["mice", "ORGANISM", 21, 25], ["mice", "SPECIES", 21, 25], ["mice", "SPECIES", 21, 25], ["livestock barns", "OBSERVATION", 44, 59]]], ["Tropical island mice came from in and around human dwellings at 2 locations, Pohnpei Island (78N lat., 1588E long.) in the Federated States of Micronesia and Majuro Island (88N lat., 1728E long.) in the Republic of the Marshall Islands.", [["mice", "ORGANISM", 16, 20], ["human", "ORGANISM", 45, 50], ["mice", "SPECIES", 16, 20], ["human", "SPECIES", 45, 50], ["mice", "SPECIES", 16, 20], ["human", "SPECIES", 45, 50], ["Marshall Islands", "OBSERVATION", 219, 235]]], ["These 3 groups of wild-trapped mice are referred to respectively as IdWC, PoWC, and MaWC.", [["mice", "ORGANISM", 31, 35], ["IdWC", "GENE_OR_GENE_PRODUCT", 68, 72], ["PoWC", "GENE_OR_GENE_PRODUCT", 74, 78], ["MaWC", "GENE_OR_GENE_PRODUCT", 84, 88], ["mice", "SPECIES", 31, 35], ["mice", "SPECIES", 31, 35]]], ["All wild house mice were live-trapped using Sherman traps (868616 cm) baited with either peanut butter or seared, grated coconut.Production of laboratory born populations from wildcaught miceMice trapped in Idaho, Pohnpei, or Majuro were shipped to the University of Michigan.", [["mice", "ORGANISM", 15, 19], ["coconut", "ORGANISM_SUBDIVISION", 121, 128], ["mice", "SPECIES", 15, 19], ["peanut", "SPECIES", 89, 95], ["mice", "SPECIES", 15, 19], ["peanut", "SPECIES", 89, 95]]], ["Upon arrival the mice were housed in polycarbonate cage bottoms with pine shavings, wire bar lids, and polycarbonate cage tops with \u00aelters to minimize cage-to-cage spread of potential pathogens.", [["polycarbonate", "CHEMICAL", 37, 50], ["polycarbonate", "CHEMICAL", 103, 116], ["mice", "ORGANISM", 17, 21], ["mice", "SPECIES", 17, 21], ["mice", "SPECIES", 17, 21], ["polycarbonate cage bottoms", "TREATMENT", 37, 63], ["pine shavings", "TREATMENT", 69, 82], ["wire bar lids", "TREATMENT", 84, 97], ["polycarbonate cage tops", "TREATMENT", 103, 126], ["\u00aelters", "TREATMENT", 132, 138], ["potential pathogens", "PROBLEM", 174, 193], ["pine shavings", "OBSERVATION", 69, 82], ["pathogens", "OBSERVATION", 184, 193]]], ["Cages were changed every 14 days for individually housed mice, and every 7\u00b18 days for breeding pairs or lactating dams with litters.", [["mice", "ORGANISM", 57, 61], ["dams", "ORGANISM_SUBDIVISION", 114, 118], ["mice", "SPECIES", 57, 61], ["mice", "SPECIES", 57, 61], ["breeding pairs", "PROBLEM", 86, 100]]], ["Temperature was maintained at 74 4 8F., and the room lighting cycle was 14 :10 light : dark.Production of laboratory born populations from wildcaught miceBreeding pairs were established from each shipment of WC mice shortly after arrival.", [["mice", "ORGANISM", 211, 215], ["wildcaught miceBreeding pairs", "CELL_LINE", 139, 168], ["mice", "SPECIES", 211, 215], ["mice", "SPECIES", 211, 215], ["Temperature", "TEST", 0, 11], ["the room lighting cycle", "TEST", 44, 67]]], ["The progeny of these WC6WC matings are termed IdG0, PoG0, or MaG0 mice; they have known birthdays and have lived from birth under laboratory conditions but are not known to be speci\u00aec pathogen-free (DC' stock.", [["DC", "ANATOMY", 199, 201], ["WC6WC", "GENE_OR_GENE_PRODUCT", 21, 26], ["IdG0", "GENE_OR_GENE_PRODUCT", 46, 50], ["PoG0", "GENE_OR_GENE_PRODUCT", 52, 56], ["MaG0 mice", "ORGANISM", 61, 70], ["mice", "SPECIES", 66, 70], ["mice", "SPECIES", 66, 70]]], ["The DC stock was then maintained by random selection of 1 male and 1 female from each of 20 breeding cages, with new mating cages set up by random pairing (except that brother\u00b1 sister mating is avoided).", [["DC", "ANATOMY", 4, 6], ["DC", "CELL_TYPE", 4, 6], ["The DC stock", "TREATMENT", 0, 12], ["new mating cages", "TREATMENT", 113, 129]]], ["Mice used for the studies reported here were at the sixth generation; each mouse should inherit about 25% of its genetic alleles from each of the 4 progenitor inbred lines, with each mouse receiving a different assortment of alleles.Analysis of health statusSerum samples were collected from representative wildcaught mice from each population shortly after arrival in the laboratory and sent to Charles River Breeding Laboratories for serological testing, to provide information about endemic infection in the natural habitat and to provide a baseline for comparison to the fosternursed G1 mice.", [["progenitor inbred lines", "ANATOMY", 148, 171], ["Serum samples", "ANATOMY", 258, 271], ["infection", "DISEASE", 494, 503], ["Mice", "ORGANISM", 0, 4], ["mouse", "ORGANISM", 75, 80], ["progenitor inbred lines", "CELL", 148, 171], ["mouse", "ORGANISM", 183, 188], ["Serum samples", "ORGANISM_SUBSTANCE", 258, 271], ["mice", "ORGANISM", 318, 322], ["mice", "ORGANISM", 591, 595], ["progenitor inbred lines", "CELL_LINE", 148, 171], ["alleles", "DNA", 225, 232], ["Mice", "SPECIES", 0, 4], ["mouse", "SPECIES", 75, 80], ["mouse", "SPECIES", 183, 188], ["mice", "SPECIES", 318, 322], ["mice", "SPECIES", 591, 595], ["mouse", "SPECIES", 75, 80], ["mouse", "SPECIES", 183, 188], ["mice", "SPECIES", 318, 322], ["mice", "SPECIES", 591, 595], ["the studies", "TEST", 14, 25], ["the 4 progenitor inbred lines", "TREATMENT", 142, 171], ["a different assortment of alleles", "TREATMENT", 199, 232], ["Serum samples", "TEST", 258, 271], ["serological testing", "TEST", 436, 455], ["endemic infection", "PROBLEM", 486, 503]]], ["Serum samples were also obtained from the CD-1 sentinel mice caged from birth to weaning with the G1 foster-nursed pups; at least 1, and more typically 2\u00b13, sentinel mice were tested from each foster-nursed G1 litter.", [["Serum samples", "ANATOMY", 0, 13], ["Serum samples", "ORGANISM_SUBSTANCE", 0, 13], ["mice", "ORGANISM", 56, 60], ["pups", "ORGANISM", 115, 119], ["mice", "ORGANISM", 166, 170], ["mice", "SPECIES", 56, 60], ["mice", "SPECIES", 166, 170], ["mice", "SPECIES", 56, 60], ["mice", "SPECIES", 166, 170], ["Serum samples", "TEST", 0, 13], ["the CD", "TEST", 38, 44]]], ["The serological panel included tests for evidence of prior exposure to Sendai, PVM (pneumonia virus of mice), MHV (mouse hepatitis virus; coronavirus), MVM (minute virus of mice), GD-7, Reo-3 (reovirus), Mycoplasma pulmonis, LCMV (lymphocytic choriomeningitis virus), ectromelia, K virus, polyoma virus, mouse adenovirus, and parvovirus.", [["pneumonia", "DISEASE", 84, 93], ["mouse hepatitis virus", "DISEASE", 115, 136], ["lymphocytic choriomeningitis virus", "DISEASE", 231, 265], ["polyoma virus", "DISEASE", 289, 302], ["parvovirus", "DISEASE", 326, 336], ["Sendai", "ORGANISM", 71, 77], ["PVM (pneumonia virus", "ORGANISM", 79, 99], ["mice", "ORGANISM", 103, 107], ["MHV (", "ORGANISM", 110, 115], ["mouse hepatitis virus; coronavirus", "ORGANISM", 115, 149], ["MVM (minute virus", "ORGANISM", 152, 169], ["mice", "ORGANISM", 173, 177], ["GD-7", "ORGANISM", 180, 184], ["Reo-3", "ORGANISM", 186, 191], ["reovirus", "ORGANISM", 193, 201], ["Mycoplasma pulmonis", "ORGANISM", 204, 223], ["LCMV (lymphocytic choriomeningitis virus", "ORGANISM", 225, 265], ["ectromelia, K virus", "ORGANISM", 268, 287], ["polyoma virus", "ORGANISM", 289, 302], ["mouse", "ORGANISM", 304, 309], ["adenovirus", "ORGANISM", 310, 320], ["parvovirus", "ORGANISM", 326, 336], ["mice", "SPECIES", 103, 107], ["MHV", "SPECIES", 110, 113], ["mouse", "SPECIES", 115, 120], ["hepatitis virus; coronavirus", "SPECIES", 121, 149], ["mice", "SPECIES", 173, 177], ["Mycoplasma pulmonis", "SPECIES", 204, 223], ["lymphocytic choriomeningitis virus", "SPECIES", 231, 265], ["K virus", "SPECIES", 280, 287], ["polyoma virus", "SPECIES", 289, 302], ["mouse", "SPECIES", 304, 309], ["mice", "SPECIES", 103, 107], ["MHV", "SPECIES", 110, 113], ["mouse hepatitis virus", "SPECIES", 115, 136], ["mice", "SPECIES", 173, 177], ["Reo-3", "SPECIES", 186, 191], ["Mycoplasma pulmonis", "SPECIES", 204, 223], ["LCMV", "SPECIES", 225, 229], ["lymphocytic choriomeningitis virus", "SPECIES", 231, 265], ["K virus", "SPECIES", 280, 287], ["polyoma virus", "SPECIES", 289, 302], ["mouse", "SPECIES", 304, 309], ["The serological panel", "TEST", 0, 21], ["tests", "TEST", 31, 36], ["prior exposure", "PROBLEM", 53, 67], ["Sendai", "TREATMENT", 71, 77], ["PVM (pneumonia virus of mice)", "PROBLEM", 79, 108], ["MHV (mouse hepatitis virus", "PROBLEM", 110, 136], ["coronavirus", "PROBLEM", 138, 149], ["MVM", "PROBLEM", 152, 155], ["GD", "TEST", 180, 182], ["Reo", "TEST", 186, 189], ["Mycoplasma pulmonis", "PROBLEM", 204, 223], ["LCMV", "PROBLEM", 225, 229], ["lymphocytic choriomeningitis virus", "PROBLEM", 231, 265], ["ectromelia", "PROBLEM", 268, 278], ["K virus", "PROBLEM", 280, 287], ["polyoma virus", "PROBLEM", 289, 302], ["mouse adenovirus", "PROBLEM", 304, 320], ["parvovirus", "PROBLEM", 326, 336], ["Sendai", "OBSERVATION", 71, 77], ["pneumonia", "OBSERVATION", 84, 93], ["MHV", "ANATOMY", 110, 113], ["Mycoplasma pulmonis", "ANATOMY", 204, 223], ["LCMV", "OBSERVATION", 225, 229], ["lymphocytic choriomeningitis", "OBSERVATION", 231, 259], ["parvovirus", "OBSERVATION", 326, 336]]], ["Sera from the WC mice were also tested for hantavirus to minimize possible risk to the health of the animal husbandry staff.", [["Sera", "ANATOMY", 0, 4], ["Sera", "ORGANISM_SUBSTANCE", 0, 4], ["WC mice", "ORGANISM", 14, 21], ["hantavirus", "ORGANISM", 43, 53], ["mice", "SPECIES", 17, 21], ["mice", "SPECIES", 17, 21], ["hantavirus", "SPECIES", 43, 53], ["Sera", "TEST", 0, 4], ["hantavirus", "PROBLEM", 43, 53]]], ["The caecum of sentinel animals was examined under a dissecting microscope to look for the presence of pinworms and pinworm eggs.", [["caecum", "ANATOMY", 4, 10], ["pinworms", "ANATOMY", 102, 110], ["eggs", "ANATOMY", 123, 127], ["caecum", "ORGAN", 4, 10], ["a dissecting microscope", "TEST", 50, 73], ["pinworms", "PROBLEM", 102, 110], ["pinworm eggs", "PROBLEM", 115, 127], ["caecum", "ANATOMY", 4, 10], ["sentinel animals", "OBSERVATION", 14, 30], ["pinworm eggs", "OBSERVATION", 115, 127]]], ["Skin samples from killed sentinel animals were allowed to cool overnight in a sterile dish, and then examined for the presence of mites.Analysis of health statusGross necropsy examinations were performed on small numbers of WC and G0 mice which were found dead, or culled from the colony because of illness.", [["Skin samples", "ANATOMY", 0, 12], ["colony", "ANATOMY", 281, 287], ["illness", "DISEASE", 299, 306], ["Skin samples", "CANCER", 0, 12], ["animals", "ORGANISM", 34, 41], ["mice", "ORGANISM", 234, 238], ["mice", "SPECIES", 234, 238], ["mice", "SPECIES", 234, 238], ["Skin samples", "TEST", 0, 12], ["Gross necropsy examinations", "TEST", 161, 188], ["dead", "PROBLEM", 256, 260], ["illness", "PROBLEM", 299, 306]]], ["Tissues saved for microscopic examination were \u00aexed in 10% buffered formalin, processed, and stained with haematoxylin and eosin.Onset of sexual maturityTen females from each of the 4 stocks were tested for vaginal patency as an index of sexual maturity; each group of 10 included members of 3\u00b14 different litters of different parentage.", [["Tissues", "ANATOMY", 0, 7], ["vaginal", "ANATOMY", 207, 214], ["formalin", "CHEMICAL", 68, 76], ["haematoxylin", "CHEMICAL", 106, 118], ["eosin", "CHEMICAL", 123, 128], ["Tissues", "ORGAN", 0, 7], ["formalin", "SIMPLE_CHEMICAL", 68, 76], ["haematoxylin", "SIMPLE_CHEMICAL", 106, 118], ["eosin", "SIMPLE_CHEMICAL", 123, 128], ["vaginal", "ORGANISM_SUBDIVISION", 207, 214], ["microscopic examination", "TEST", 18, 41], ["haematoxylin", "TREATMENT", 106, 118], ["sexual maturity", "PROBLEM", 138, 153], ["the 4 stocks", "TREATMENT", 178, 190], ["vaginal patency", "TREATMENT", 207, 222], ["sexual maturity", "PROBLEM", 238, 253], ["sexual maturity", "OBSERVATION", 138, 153], ["vaginal", "ANATOMY", 207, 214], ["patency", "OBSERVATION", 215, 222]]], ["Mice were restrained in a dorsal recumbent position while a sterile, saline-moistened swab was advanced into the vagina, and the procedure was repeated every 24 h until vaginal opening was noted.Faecal glucocorticoidsFaecal samples (4 pellets per mouse) were collected from each of 10 mice of each G1 stock (and PoG0) 24 h after routine cage changing.", [["dorsal", "ANATOMY", 26, 32], ["swab", "ANATOMY", 86, 90], ["vagina", "ANATOMY", 113, 119], ["vaginal", "ANATOMY", 169, 176], ["Faecal", "ANATOMY", 195, 201], ["Faecal samples", "ANATOMY", 217, 231], ["glucocorticoids", "CHEMICAL", 202, 217], ["Mice", "ORGANISM", 0, 4], ["vagina", "ORGAN", 113, 119], ["vaginal", "ORGANISM_SUBDIVISION", 169, 176], ["Faecal", "ORGANISM_SUBSTANCE", 195, 201], ["Faecal samples", "ORGANISM_SUBSTANCE", 217, 231], ["mouse", "ORGANISM", 247, 252], ["mice", "ORGANISM", 285, 289], ["Mice", "SPECIES", 0, 4], ["mouse", "SPECIES", 247, 252], ["mice", "SPECIES", 285, 289], ["mouse", "SPECIES", 247, 252], ["mice", "SPECIES", 285, 289], ["a dorsal recumbent position", "TREATMENT", 24, 51], ["a sterile, saline-moistened swab", "TREATMENT", 58, 90], ["the procedure", "TREATMENT", 125, 138], ["vaginal opening", "PROBLEM", 169, 184], ["Faecal glucocorticoids", "TREATMENT", 195, 217], ["Faecal samples", "TEST", 217, 231], ["routine cage changing", "TREATMENT", 329, 350], ["vagina", "ANATOMY", 113, 119], ["glucocorticoids", "OBSERVATION", 202, 217]]], ["Mice were 4\u00b15 months old at sampling, included equal numbers of males and females, and were drawn from 4 separate litters for each strain.", [["Mice", "ORGANISM", 0, 4], ["Mice", "SPECIES", 0, 4], ["each strain", "PROBLEM", 126, 137]]], ["Faecal samples were stored in 1.0 ml of 95% EtOH at 720 8C.", [["Faecal samples", "ANATOMY", 0, 14], ["EtOH", "CHEMICAL", 44, 48], ["EtOH", "CHEMICAL", 44, 48], ["Faecal samples", "ORGANISM_SUBSTANCE", 0, 14], ["EtOH", "SIMPLE_CHEMICAL", 44, 48], ["Faecal samples", "TEST", 0, 14]]], ["Each sample was extracted twice by boiling in 10 ml of 95% EtOH for 20 min.", [["sample", "ANATOMY", 5, 11], ["EtOH", "CHEMICAL", 59, 63], ["EtOH", "CHEMICAL", 59, 63], ["EtOH", "SIMPLE_CHEMICAL", 59, 63]]], ["The solvents from each extraction were combined in a glass culture tube and dried under air in a 35\u00b140 8C water bath in a fume hood.", [["The solvents", "TREATMENT", 0, 12], ["each extraction", "TREATMENT", 18, 33], ["a glass culture tube", "TREATMENT", 51, 71]]], ["After drying, each tube was rinsed with 1\u00b12 ml of a ethyl acetate:hexane solution (3:2 v/v), dried again, and the residue resuspended in 1.0 ml of 95% EtOH.", [["tube", "ANATOMY", 19, 23], ["ethyl acetate", "CHEMICAL", 52, 65], ["EtOH", "CHEMICAL", 151, 155], ["ethyl acetate", "CHEMICAL", 52, 65], ["hexane", "CHEMICAL", 66, 72], ["EtOH", "CHEMICAL", 151, 155], ["tube", "TISSUE", 19, 23], ["ethyl", "SIMPLE_CHEMICAL", 52, 57], ["acetate", "SIMPLE_CHEMICAL", 58, 65], ["hexane", "SIMPLE_CHEMICAL", 66, 72], ["EtOH", "SIMPLE_CHEMICAL", 151, 155], ["each tube", "TREATMENT", 14, 23], ["a ethyl acetate:hexane solution", "TREATMENT", 50, 81], ["the residue", "PROBLEM", 110, 121], ["tube", "OBSERVATION", 19, 23]]], ["Corticosterone concentration was determined using a commercially available radioimmunoassay kit (ICN Pharmaceuticals).", [["Corticosterone", "CHEMICAL", 0, 14], ["Corticosterone", "CHEMICAL", 0, 14], ["Corticosterone", "SIMPLE_CHEMICAL", 0, 14], ["Corticosterone concentration", "TREATMENT", 0, 28]]], ["The assay was validated using standard procedures for parallelism and quantitative recovery.Breeding performance under laboratory conditionsDuring the process of developing spf stocks from the mice trapped from Idaho, Majuro, and Pohnpei, we accumulated statistics on the proportion of mice in each generation that were able to bear (or to sire) a litter.", [["spf", "GENE_OR_GENE_PRODUCT", 173, 176], ["mice", "ORGANISM", 193, 197], ["mice", "ORGANISM", 286, 290], ["mice", "SPECIES", 193, 197], ["mice", "SPECIES", 286, 290], ["mice", "SPECIES", 193, 197], ["mice", "SPECIES", 286, 290], ["The assay", "TEST", 0, 9], ["standard procedures", "TREATMENT", 30, 49], ["spf stocks", "TREATMENT", 173, 183], ["Majuro", "TREATMENT", 218, 224], ["Pohnpei", "TREATMENT", 230, 237], ["spf stocks", "OBSERVATION", 173, 183]]], ["Table 1 records these data on breeding success.", [["breeding success", "TREATMENT", 30, 46]]], ["The results must be considered anecdotal, because they do not represent the outcome of a well-controlled study in which each test mouse was given access to proven partners at de\u00aened ages for de\u00aened intervals.", [["mouse", "ORGANISM", 130, 135], ["mouse", "SPECIES", 130, 135], ["mouse", "SPECIES", 130, 135], ["a well-controlled study", "TEST", 87, 110]]], ["Pairs of mice that were unsuccessful after~100 days, for example, were typically separated and re-paired with other partners in an effort to retain the maximal amount of genetic variation at each generation.", [["mice", "ORGANISM", 9, 13], ["mice", "SPECIES", 9, 13], ["mice", "SPECIES", 9, 13], ["mice", "ANATOMY", 9, 13], ["genetic variation", "OBSERVATION", 170, 187]]], ["Despite these uncertainties, the data do show that at least 55% of the wild-caught females and at least 77% of the wildcaught males were able to produce at least one litter of weaned pups.", [["pups", "ANATOMY", 183, 187], ["pups", "ORGANISM_SUBDIVISION", 183, 187], ["the data", "TEST", 29, 37], ["weaned pups", "OBSERVATION", 176, 187]]], ["There were no notable (or statistically signi\u00aecant) differences among the three varieties of WC animals, and no tendency for mice in the G0 (\u00aerst laboratory-born) generation to be either more or less successful than mice of the WC generation.", [["WC", "CHEMICAL", 93, 95], ["WC", "CHEMICAL", 228, 230], ["mice", "ORGANISM", 125, 129], ["mice", "ORGANISM", 216, 220], ["mice", "SPECIES", 125, 129], ["mice", "SPECIES", 216, 220], ["mice", "SPECIES", 125, 129], ["mice", "SPECIES", 216, 220], ["notable (or statistically signi\u00aecant) differences", "PROBLEM", 14, 63], ["no", "UNCERTAINTY", 11, 13], ["notable", "OBSERVATION_MODIFIER", 14, 21], ["no", "UNCERTAINTY", 109, 111]]], ["Although mice of the laboratory-derived DC stock were not formally tested in parallel with the WC and G0 mice, we note that approx.", [["DC", "ANATOMY", 40, 42], ["mice", "ORGANISM", 9, 13], ["DC", "CELL", 40, 42], ["G0 mice", "ORGANISM", 102, 109], ["DC", "CELL_TYPE", 40, 42], ["mice", "SPECIES", 9, 13], ["mice", "SPECIES", 105, 109], ["mice", "SPECIES", 9, 13], ["mice", "SPECIES", 105, 109]]], ["95% of females in DC breeding cages do produce progeny in their \u00aerst 100 days of mating, a success rate that is not met by females of the WC or G0 generations of any of the three wild-derived stocks.Breeding performance under laboratory conditionsThe mean number of pups per litter born to wildderived mice was much smaller than for mice of the DC stock (Fig. 1) .", [["DC", "ANATOMY", 18, 20], ["DC", "ANATOMY", 345, 347], ["pups", "ORGANISM_SUBDIVISION", 266, 270], ["mice", "ORGANISM", 302, 306], ["mice", "ORGANISM", 333, 337], ["DC", "CELL_TYPE", 18, 20], ["mice", "SPECIES", 302, 306], ["mice", "SPECIES", 333, 337], ["mice", "SPECIES", 302, 306], ["mice", "SPECIES", 333, 337], ["DC breeding cages", "TREATMENT", 18, 35], ["mean", "OBSERVATION_MODIFIER", 251, 255], ["number", "OBSERVATION_MODIFIER", 256, 262]]], ["Among WC mice, females of the MaWC stock tended to have slightly fewer pups per litter than females of the IdWC stock, but the statistical signi\u00aecance is marginal (P = 0.05) and may represent a chance effect in a series of multiple comparisons.", [["WC mice", "ORGANISM", 6, 13], ["MaWC", "ORGANISM", 30, 34], ["pups", "ORGANISM_SUBDIVISION", 71, 75], ["mice", "SPECIES", 9, 13], ["mice", "SPECIES", 9, 13], ["slightly fewer pups", "PROBLEM", 56, 75], ["marginal", "OBSERVATION_MODIFIER", 154, 162], ["may represent", "UNCERTAINTY", 178, 191]]], ["Litters born to mice of the G0 generation are not signi\u00aecantly larger or smaller than those born to WC mice.", [["WC", "CHEMICAL", 100, 102], ["mice", "ORGANISM", 16, 20], ["WC mice", "ORGANISM", 100, 107], ["mice", "SPECIES", 16, 20], ["mice", "SPECIES", 103, 107], ["mice", "SPECIES", 16, 20], ["mice", "SPECIES", 103, 107], ["larger", "OBSERVATION_MODIFIER", 63, 69], ["smaller", "OBSERVATION_MODIFIER", 73, 80]]], ["Each of the wild-derived stocks produces litters that are only about half as large as those born to laboratory-derived DC mice; the differences are in all cases highly signi\u00aecant (P < 0.01 after adjustment for multiple comparisons).Breeding performance under laboratory conditionsWeight gain trajectories Figure 2 shows mean body mass for mice of the WC stocks at the time of their arrival in the laboratory and again at approx.", [["DC", "ANATOMY", 119, 121], ["body", "ANATOMY", 325, 329], ["Weight gain", "DISEASE", 280, 291], ["WC", "CHEMICAL", 351, 353], ["mice", "ORGANISM", 122, 126], ["body", "ORGANISM_SUBDIVISION", 325, 329], ["mice", "ORGANISM", 339, 343], ["DC", "CELL_TYPE", 119, 121], ["mice", "SPECIES", 122, 126], ["mice", "SPECIES", 339, 343], ["mice", "SPECIES", 122, 126], ["mice", "SPECIES", 339, 343], ["Weight", "TEST", 280, 286], ["mean body mass", "PROBLEM", 320, 334], ["the WC stocks", "TREATMENT", 347, 360], ["mass", "OBSERVATION", 330, 334]]], ["135 days after arrival; this latter time point was chosen on the assumption that mice trapped at age 40\u00b160 days would be about 6 months old at this time.", [["mice", "ORGANISM", 81, 85], ["mice", "SPECIES", 81, 85], ["mice", "SPECIES", 81, 85]]], ["Both male and female mice of the IdWC stock were signi\u00aecantly larger at capture than mice of the MaWC and PoWC stocks, and these differences were maintained after 135 days under laboratory conditions.", [["mice", "ORGANISM", 21, 25], ["IdWC", "ORGANISM", 33, 37], ["mice", "ORGANISM", 85, 89], ["MaWC", "CELL", 97, 101], ["mice", "SPECIES", 21, 25], ["mice", "SPECIES", 85, 89], ["mice", "SPECIES", 21, 25], ["mice", "SPECIES", 85, 89], ["the IdWC stock", "TREATMENT", 29, 43], ["the MaWC and PoWC stocks", "TREATMENT", 93, 117], ["larger", "OBSERVATION_MODIFIER", 62, 68]]], ["These data are consistent with previous reports of low body mass in mice trapped on Pohnpei (Marshall, 1962) .Breeding performance under laboratory conditionsThese results are consistent with the idea that differences among these stocks in weight re\u00afect their genetic differences rather than adaptations to environmental differences among the trapping locations, although the Fig. 1 .", [["body", "ANATOMY", 55, 59], ["body", "ORGANISM_SUBDIVISION", 55, 59], ["mice", "ORGANISM", 68, 72], ["mice", "SPECIES", 68, 72], ["mice", "SPECIES", 68, 72], ["low body mass", "PROBLEM", 51, 64], ["consistent with", "UNCERTAINTY", 15, 30], ["low body", "OBSERVATION_MODIFIER", 51, 59], ["mass", "OBSERVATION", 60, 64], ["consistent with", "UNCERTAINTY", 176, 191]]], ["Litter sizes in wild-caught, wild-derived, and laboratory-derived mouse stocks.", [["mouse", "ORGANISM", 66, 71], ["mouse", "SPECIES", 66, 71], ["mouse", "SPECIES", 66, 71], ["sizes", "OBSERVATION_MODIFIER", 7, 12]]], ["Bars show the mean number of pups per litter using a calculation in which each successful dam received equal weight. n, number of dams that were successful in each of the seven stocks; WC stocks, mice caught in the \u00aeeld (ages of these mice were not known);domesticated' animals are not con\u00aened to mice.", [["WC", "CHEMICAL", 185, 187], ["Bars", "GENE_OR_GENE_PRODUCT", 0, 4], ["pups", "ORGANISM_SUBDIVISION", 29, 33], ["dams", "ORGANISM", 130, 134], ["mice", "ORGANISM", 196, 200], ["mice", "ORGANISM", 235, 239], ["animals", "ORGANISM", 270, 277], ["mice", "ORGANISM", 297, 301], ["mice", "SPECIES", 196, 200], ["mice", "SPECIES", 235, 239], ["mice", "SPECIES", 297, 301], ["mice", "SPECIES", 196, 200], ["mice", "SPECIES", 297, 301], ["a calculation", "TREATMENT", 51, 64]]], ["Wild-derived rats similarly exhibit smaller body size, reduced litter size, and greater age at sexual maturity than outbred laboratory stocks in routine experiments (Clark & Price, 1981) .DISCUSSIONThere are a number of situations in which higher lifespan, amongst individual members within a species, is associated with small body size.", [["body", "ANATOMY", 44, 48], ["body", "ANATOMY", 327, 331], ["rats", "ORGANISM", 13, 17], ["body", "ORGANISM_SUBDIVISION", 44, 48], ["litter", "ORGANISM_SUBDIVISION", 63, 69], ["body", "ORGANISM_SUBDIVISION", 327, 331], ["rats", "SPECIES", 13, 17], ["smaller body size", "PROBLEM", 36, 53], ["reduced litter size", "PROBLEM", 55, 74], ["small body size", "PROBLEM", 321, 336], ["smaller", "OBSERVATION_MODIFIER", 36, 43], ["body", "OBSERVATION_MODIFIER", 44, 48], ["size", "OBSERVATION_MODIFIER", 49, 53], ["reduced", "OBSERVATION_MODIFIER", 55, 62], ["litter", "OBSERVATION_MODIFIER", 63, 69], ["size", "OBSERVATION_MODIFIER", 70, 74], ["greater", "OBSERVATION_MODIFIER", 80, 87], ["small body", "OBSERVATION_MODIFIER", 321, 331], ["size", "OBSERVATION_MODIFIER", 332, 336]]], ["Sometimes an experimental manipulation \u00b1 restriction of available food calories (Weindruch & Walford, 1988) or of the amino acid methionine (Orentreich et al., 1993) \u00b1 produces a body size smaller than would be obtained if the test animals were allowed to eat all they wished of a nutritionally adequate diet.", [["body", "ANATOMY", 179, 183], ["amino acid", "CHEMICAL", 118, 128], ["methionine", "CHEMICAL", 129, 139], ["amino acid methionine", "CHEMICAL", 118, 139], ["amino acid", "AMINO_ACID", 118, 128], ["methionine", "SIMPLE_CHEMICAL", 129, 139], ["body", "ORGANISM_SUBDIVISION", 179, 183], ["the amino acid methionine", "TREATMENT", 114, 139]]], ["In other cases, such as the df/df and dw/dw dwarf mice (Brown-Borg et al., 1996) , and miniature poodles (Eigenmann, Patterson & Froesch, 1984) , the small body size re\u00afects a genetically determined alteration in endocrine state that interferes with growth despite free access to calories and nutrients.", [["body", "ANATOMY", 156, 160], ["endocrine", "ANATOMY", 213, 222], ["body", "ORGANISM_SUBDIVISION", 156, 160], ["endocrine", "ANATOMICAL_SYSTEM", 213, 222], ["calories", "SIMPLE_CHEMICAL", 280, 288], ["mice", "SPECIES", 50, 54], ["the small body size", "PROBLEM", 146, 165], ["alteration in endocrine state", "PROBLEM", 199, 228], ["small body", "OBSERVATION_MODIFIER", 150, 160], ["size", "OBSERVATION_MODIFIER", 161, 165]]], ["In these latter situations, small body size leads to diminished total food consumption, largely because fewer calories are needed to meet the needs \u00b1 thermal and metabolic homeostasis, and work output \u00b1 of smaller individuals.", [["body", "ANATOMY", 34, 38], ["body", "ORGANISM_SUBDIVISION", 34, 38], ["small body size", "PROBLEM", 28, 43], ["diminished total food consumption", "PROBLEM", 53, 86], ["thermal and metabolic homeostasis", "TREATMENT", 150, 183], ["work output", "TEST", 189, 200], ["smaller individuals", "PROBLEM", 206, 225], ["small", "OBSERVATION_MODIFIER", 28, 33], ["body", "OBSERVATION_MODIFIER", 34, 38], ["size", "OBSERVATION_MODIFIER", 39, 43], ["diminished", "OBSERVATION_MODIFIER", 53, 63], ["total", "OBSERVATION_MODIFIER", 64, 69], ["food consumption", "OBSERVATION", 70, 86], ["metabolic homeostasis", "OBSERVATION", 162, 183]]], ["It is possible, though unproven, that the associations between small stature and long lifespan in these various animal models may re\u00afect similar abnormalities in metabolic pathways or endocrine levels.", [["endocrine", "ANATOMY", 184, 193], ["endocrine", "ANATOMICAL_SYSTEM", 184, 193], ["small stature and long lifespan", "PROBLEM", 63, 94], ["similar abnormalities in metabolic pathways", "PROBLEM", 137, 180], ["endocrine levels", "TEST", 184, 200], ["small", "OBSERVATION_MODIFIER", 63, 68]]], ["Should our wild-derived mouse lines prove, as hypothesized, to exhibit exceptionally long lifespan, comparing them to dwarf and calorically restricted mice may provide key clues to the nature of the linkages between stature and longevity.DISCUSSIONIn general, differences among the three wild-derived stocks are less dramatic than those between any wildderived stock and the laboratory stock DC.", [["DC", "ANATOMY", 392, 394], ["stature", "DISEASE", 216, 223], ["mouse", "ORGANISM", 24, 29], ["lines", "CELL", 30, 35], ["mice", "ORGANISM", 151, 155], ["wild-derived mouse lines", "CELL_LINE", 11, 35], ["DC", "CELL_TYPE", 392, 394], ["mouse", "SPECIES", 24, 29], ["mice", "SPECIES", 151, 155], ["mouse", "SPECIES", 24, 29], ["mice", "SPECIES", 151, 155], ["dwarf and calorically restricted mice", "TREATMENT", 118, 155], ["less dramatic", "OBSERVATION_MODIFIER", 312, 325]]], ["IdWC mice are larger than PoWC and MaWC animals both at capture and after 4\u00b15 months of housing under laboratory conditions (Fig. 2) , and the IdG0 stock is larger at all ages than mice of the MaG0 or PoG0 stocks, consistent with the hypothesis.", [["IdWC mice", "ORGANISM", 0, 9], ["PoWC", "CELL", 26, 30], ["IdG0", "GENE_OR_GENE_PRODUCT", 143, 147], ["mice", "ORGANISM", 181, 185], ["MaG0", "GENE_OR_GENE_PRODUCT", 193, 197], ["PoG0", "GENE_OR_GENE_PRODUCT", 201, 205], ["mice", "SPECIES", 5, 9], ["mice", "SPECIES", 181, 185], ["mice", "SPECIES", 5, 9], ["mice", "SPECIES", 181, 185], ["the IdG0 stock", "TREATMENT", 139, 153], ["the hypothesis", "PROBLEM", 230, 244], ["larger", "OBSERVATION_MODIFIER", 14, 20], ["larger", "OBSERVATION_MODIFIER", 157, 163], ["consistent with", "UNCERTAINTY", 214, 229], ["hypothesis", "OBSERVATION", 234, 244]]], ["PoG0 and MaG0 mice are also signi\u00aecantly shorter than IdG0 animals, showing that the difference in body mass does not simply re\u00afect in increase in fat mass; possible differences in fat/lean ratios have not yet been examined.", [["body", "ANATOMY", 99, 103], ["fat mass", "ANATOMY", 147, 155], ["fat", "ANATOMY", 181, 184], ["PoG0", "GENE_OR_GENE_PRODUCT", 0, 4], ["MaG0 mice", "ORGANISM", 9, 18], ["body", "ORGANISM_SUBDIVISION", 99, 103], ["fat", "TISSUE", 147, 150], ["fat", "TISSUE", 181, 184], ["mice", "SPECIES", 14, 18], ["mice", "SPECIES", 14, 18], ["the difference in body mass", "PROBLEM", 81, 108], ["fat mass", "PROBLEM", 147, 155], ["fat/lean ratios", "TEST", 181, 196], ["shorter", "OBSERVATION_MODIFIER", 41, 48], ["difference", "OBSERVATION_MODIFIER", 85, 95], ["body", "ANATOMY", 99, 103], ["mass", "OBSERVATION", 104, 108], ["does not simply", "UNCERTAINTY", 109, 124], ["increase", "OBSERVATION_MODIFIER", 135, 143], ["fat mass", "OBSERVATION", 147, 155]]], ["These differences are consistent with the hypothesis that the aseasonal, predator-free conditions on Pohnpei and Majuro may have led to selection for genotypes that differ from those of our mice sampled from a mainland location, Idaho.", [["Pohnpei", "CHEMICAL", 101, 108], ["Majuro", "CHEMICAL", 113, 119], ["mice", "ORGANISM", 190, 194], ["mice", "SPECIES", 190, 194], ["mice", "SPECIES", 190, 194], ["the hypothesis", "PROBLEM", 38, 52], ["Pohnpei", "TREATMENT", 101, 108], ["consistent with", "UNCERTAINTY", 22, 37]]], ["On the other hand the available data do not suggest a difference among these three strains in mean litter size.", [["litter", "ORGANISM_SUBDIVISION", 99, 105], ["size", "OBSERVATION_MODIFIER", 106, 110]]], ["More detailed data will be needed to look for possible differences among these three wildderived strains in development of reproductive competence, inter-litter interval, and distribution of reproductive effort across the lifespan.DISCUSSIONUse of these mouse stocks for analyses of the genetics of life-history traits would have been complicated by the presence of infectious agents that might in\u00afuence maturation, fertility, immunity, weight gain, and longevity.", [["weight gain", "DISEASE", 437, 448], ["mouse", "ORGANISM", 254, 259], ["mouse", "SPECIES", 254, 259], ["mouse", "SPECIES", 254, 259], ["reproductive competence", "PROBLEM", 123, 146], ["reproductive effort", "PROBLEM", 191, 210], ["these mouse stocks", "TREATMENT", 248, 266], ["infectious agents", "TREATMENT", 366, 383], ["weight gain", "PROBLEM", 437, 448], ["distribution", "OBSERVATION_MODIFIER", 175, 187], ["reproductive effort", "OBSERVATION", 191, 210], ["infectious", "OBSERVATION", 366, 376]]], ["Although our sample size is quite small, we see no evidence for endemic infectious agents (except for MCMV) in either of the two island-trapped mouse stocks.", [["MCMV", "ORGANISM", 102, 106], ["mouse", "ORGANISM", 144, 149], ["mouse", "SPECIES", 144, 149], ["MCMV", "SPECIES", 102, 106], ["mouse", "SPECIES", 144, 149], ["our sample size", "TEST", 9, 24], ["endemic infectious agents", "PROBLEM", 64, 89], ["MCMV", "PROBLEM", 102, 106], ["size", "OBSERVATION_MODIFIER", 20, 24], ["small", "OBSERVATION_MODIFIER", 34, 39], ["no evidence for", "UNCERTAINTY", 48, 63], ["endemic", "OBSERVATION_MODIFIER", 64, 71], ["infectious", "OBSERVATION", 72, 82], ["two", "OBSERVATION_MODIFIER", 125, 128], ["island", "OBSERVATION_MODIFIER", 129, 135], ["trapped mouse stocks", "OBSERVATION", 136, 156]]], ["Our data are in marked contrast to those of a more comprehensive study of Mus domesticus trapped in 14 Australian sites, which revealed serologic evidence of MCMV, MHV (coronavirus), and rotavirus at all collection sites, and substantial evidence of reovirus, parvovirus, and adenovirus at some but not all sites (Smith, Singleton, Hansen & Shellam, 1993) .", [["reovirus, parvovirus", "DISEASE", 250, 270], ["Mus domesticus", "ORGANISM", 74, 88], ["MCMV", "ORGANISM", 158, 162], ["MHV (coronavirus", "ORGANISM", 164, 180], ["rotavirus", "ORGANISM", 187, 196], ["reovirus", "ORGANISM", 250, 258], ["parvovirus", "ORGANISM", 260, 270], ["adenovirus", "ORGANISM", 276, 286], ["Mus domesticus", "SPECIES", 74, 88], ["Mus domesticus", "SPECIES", 74, 88], ["MCMV", "SPECIES", 158, 162], ["MHV", "SPECIES", 164, 167], ["rotavirus", "SPECIES", 187, 196], ["adenovirus", "SPECIES", 276, 286], ["Our data", "TEST", 0, 8], ["a more comprehensive study", "TEST", 44, 70], ["Mus domesticus", "TEST", 74, 88], ["MCMV", "PROBLEM", 158, 162], ["MHV (coronavirus)", "PROBLEM", 164, 181], ["rotavirus at all collection sites", "PROBLEM", 187, 220], ["reovirus", "PROBLEM", 250, 258], ["parvovirus", "PROBLEM", 260, 270], ["adenovirus", "PROBLEM", 276, 286], ["serologic evidence of", "UNCERTAINTY", 136, 157], ["MCMV", "OBSERVATION", 158, 162], ["MHV", "OBSERVATION_MODIFIER", 164, 167], ["substantial evidence of", "UNCERTAINTY", 226, 249], ["reovirus", "OBSERVATION", 250, 258], ["parvovirus", "OBSERVATION", 260, 270], ["adenovirus", "OBSERVATION", 276, 286]]], ["It is possible that the relatively low incidence of viral infection in the island-derived mouse stocks re\u00afects their isolation from reservoirs of infection in larger, mainland populations.", [["viral infection", "DISEASE", 52, 67], ["infection", "DISEASE", 146, 155], ["mouse", "ORGANISM", 90, 95], ["mouse", "SPECIES", 90, 95], ["mouse", "SPECIES", 90, 95], ["viral infection", "PROBLEM", 52, 67], ["derived mouse stocks", "TREATMENT", 82, 102], ["infection", "PROBLEM", 146, 155], ["relatively", "OBSERVATION_MODIFIER", 24, 34], ["low", "OBSERVATION_MODIFIER", 35, 38], ["viral", "OBSERVATION_MODIFIER", 52, 57], ["infection", "OBSERVATION", 58, 67], ["mouse stocks", "OBSERVATION", 90, 102], ["reservoirs", "OBSERVATION_MODIFIER", 132, 142], ["infection", "OBSERVATION", 146, 155], ["larger", "OBSERVATION_MODIFIER", 159, 165], ["mainland", "OBSERVATION_MODIFIER", 167, 175], ["populations", "OBSERVATION_MODIFIER", 176, 187]]], ["Elimination of the few virus-infected IdWC mice, together with foster nursing of all G1 litters on spf CD-1 dams, seems to have produced stocks of IdG1, MaG1, and PoG1 mice that are free of known disease-associated microbial\u00afora, except for pinworm (which may well have been \u00aerst encountered in the vivarium itself ).DISCUSSIONThe consistently higher faecal corticosterone levels seen in all three of the wild-derived stocks, compared to the DC mice, are consistent with the idea that inadvertent selection for docility, timidity, and fertility in laboratory conditions may together lead to drastic alterations in endocrine regulation.", [["faecal", "ANATOMY", 351, 357], ["DC", "ANATOMY", 442, 444], ["endocrine", "ANATOMY", 614, 623], ["corticosterone", "CHEMICAL", 358, 372], ["corticosterone", "CHEMICAL", 358, 372], ["IdWC mice", "ORGANISM", 38, 47], ["IdG1", "GENE_OR_GENE_PRODUCT", 147, 151], ["MaG1", "GENE_OR_GENE_PRODUCT", 153, 157], ["PoG1 mice", "ORGANISM", 163, 172], ["faecal", "ORGANISM_SUBSTANCE", 351, 357], ["corticosterone", "SIMPLE_CHEMICAL", 358, 372], ["mice", "ORGANISM", 445, 449], ["endocrine", "ANATOMICAL_SYSTEM", 614, 623], ["DC", "CELL_TYPE", 442, 444], ["mice", "SPECIES", 43, 47], ["mice", "SPECIES", 168, 172], ["mice", "SPECIES", 445, 449], ["mice", "SPECIES", 43, 47], ["mice", "SPECIES", 168, 172], ["mice", "SPECIES", 445, 449], ["the few virus", "PROBLEM", 15, 28], ["MaG1", "TEST", 153, 157], ["known disease", "PROBLEM", 190, 203], ["associated microbial\u00afora", "PROBLEM", 204, 228], ["pinworm", "PROBLEM", 241, 248], ["The consistently higher faecal corticosterone levels", "TEST", 327, 379], ["docility", "PROBLEM", 511, 519], ["timidity", "TREATMENT", 521, 529], ["fertility in laboratory conditions", "PROBLEM", 535, 569], ["drastic alterations in endocrine regulation", "PROBLEM", 591, 634], ["few", "OBSERVATION_MODIFIER", 19, 22], ["virus", "OBSERVATION", 23, 28], ["disease", "OBSERVATION", 196, 203], ["higher", "OBSERVATION_MODIFIER", 344, 350], ["faecal corticosterone", "OBSERVATION", 351, 372], ["consistent with", "UNCERTAINTY", 455, 470]]], ["These differences do not re\u00afect the stresses of removal from natural to laboratory conditions, since all values were derived from mice born and raised in the laboratory.", [["mice", "ORGANISM", 130, 134], ["mice", "SPECIES", 130, 134], ["mice", "SPECIES", 130, 134], ["removal", "TREATMENT", 48, 55]]], ["We do not have any information on faecal corticosterone levels of mice living in their natural habitat, and thus cannot say whether the high levels seen in the Po, Ma, and Id stocks represent responses to elements of the laboratory environment that would not ordinarily be encountered in natural conditions; nor do we know whether these stocks differ in their endocrine responses to stressful situations such as restraint.", [["faecal", "ANATOMY", 34, 40], ["endocrine", "ANATOMY", 360, 369], ["corticosterone", "CHEMICAL", 41, 55], ["corticosterone", "CHEMICAL", 41, 55], ["faecal", "ORGANISM_SUBSTANCE", 34, 40], ["corticosterone", "SIMPLE_CHEMICAL", 41, 55], ["mice", "ORGANISM", 66, 70], ["Id", "GENE_OR_GENE_PRODUCT", 172, 174], ["endocrine", "ANATOMICAL_SYSTEM", 360, 369], ["mice", "SPECIES", 66, 70], ["mice", "SPECIES", 66, 70], ["faecal corticosterone levels", "TEST", 34, 62], ["restraint", "TREATMENT", 412, 421]]], ["Litter size of the PoWC and PoG0 mice is not less than that reported for pregnant mice trapped in Pohnpei (Marshall, 1962) , reported as 3.9 pre-term foetuses per dam, and weight of the PoWC and MaWC mice is greater than that of newly captured mice, suggesting that the stress levels that could contribute to the relative elevation in corticosterone levels do not lead to signi\u00aecant digestive or reproductive pathology.DISCUSSIONAnalysis of mice produced by crosses and backcrosses between DC and wild-derived mice should prove useful for estimation of the number of genetic loci that modulate body size, litter size, and possibly also rates of reproductive maturation.", [["digestive", "ANATOMY", 383, 392], ["DC", "ANATOMY", 490, 492], ["body", "ANATOMY", 594, 598], ["corticosterone", "CHEMICAL", 335, 349], ["corticosterone", "CHEMICAL", 335, 349], ["PoWC", "GENE_OR_GENE_PRODUCT", 19, 23], ["PoG0 mice", "ORGANISM", 28, 37], ["mice", "ORGANISM", 82, 86], ["foetuses", "ORGANISM", 150, 158], ["PoWC", "GENE_OR_GENE_PRODUCT", 186, 190], ["MaWC mice", "ORGANISM", 195, 204], ["mice", "ORGANISM", 244, 248], ["corticosterone", "SIMPLE_CHEMICAL", 335, 349], ["digestive", "ORGAN", 383, 392], ["mice", "ORGANISM", 441, 445], ["DC", "CELL", 490, 492], ["mice", "ORGANISM", 510, 514], ["body", "ORGANISM_SUBDIVISION", 594, 598], ["DC", "CELL_TYPE", 490, 492], ["mice", "SPECIES", 33, 37], ["mice", "SPECIES", 82, 86], ["mice", "SPECIES", 200, 204], ["mice", "SPECIES", 244, 248], ["mice", "SPECIES", 441, 445], ["mice", "SPECIES", 510, 514], ["mice", "SPECIES", 33, 37], ["mice", "SPECIES", 82, 86], ["mice", "SPECIES", 200, 204], ["mice", "SPECIES", 244, 248], ["mice", "SPECIES", 441, 445], ["mice", "SPECIES", 510, 514], ["weight", "TEST", 172, 178], ["the PoWC", "TEST", 182, 190], ["the stress levels", "TEST", 266, 283], ["the relative elevation in corticosterone levels", "PROBLEM", 309, 356], ["signi\u00aecant digestive or reproductive pathology", "PROBLEM", 372, 418], ["reproductive maturation", "PROBLEM", 645, 668], ["size", "OBSERVATION_MODIFIER", 7, 11], ["greater", "OBSERVATION_MODIFIER", 208, 215], ["elevation", "OBSERVATION", 322, 331], ["genetic loci", "OBSERVATION", 567, 579], ["body", "OBSERVATION_MODIFIER", 594, 598], ["size", "OBSERVATION_MODIFIER", 599, 603], ["litter", "OBSERVATION_MODIFIER", 605, 611], ["size", "OBSERVATION_MODIFIER", 612, 616]]], ["Measurement of these and other strain-speci\u00aec traits in the segregating populations should help to show whether these traits are under pleiotropic control of genes that in\u00afuence a range of life-history traits and set the stage for formal quantitative trait locus studies to map the relevant genetic polymorphisms.", [["formal quantitative trait locus studies", "PROBLEM", 231, 270]]], ["If life table analyses now in progress using G1 mice demonstrate that mice of one or more of these wild-derived stocks are particularly long-lived in comparison to DC and other laboratory-derived mouse stocks, they will be valuable tools for the genetic dissection of the genetic bases of longevity and for testing hypotheses about the physiological bases for inter-strain differences in lifespan.", [["DC", "ANATOMY", 164, 166], ["mice", "ORGANISM", 48, 52], ["mice", "ORGANISM", 70, 74], ["DC", "CELL", 164, 166], ["mouse", "ORGANISM", 196, 201], ["DC", "CELL_TYPE", 164, 166], ["mice", "SPECIES", 48, 52], ["mice", "SPECIES", 70, 74], ["mouse", "SPECIES", 196, 201], ["mice", "SPECIES", 48, 52], ["mice", "SPECIES", 70, 74], ["mouse", "SPECIES", 196, 201], ["life table analyses", "TEST", 3, 22], ["testing hypotheses", "TEST", 307, 325], ["dissection", "OBSERVATION", 254, 264]]]], "PMC7122465": [["IntroductionCoronaviruses of humans have been classified as a subfamily of the Coronaviridae family.", [["Coronaviruses", "GENE_OR_GENE_PRODUCT", 12, 25], ["humans", "ORGANISM", 29, 35], ["Coronaviridae", "GENE_OR_GENE_PRODUCT", 79, 92], ["Coronaviridae family", "PROTEIN", 79, 99], ["humans", "SPECIES", 29, 35], ["humans", "SPECIES", 29, 35]]], ["The viruses are roughly spherical, enveloped particles 120\u2013160 nm in diameter.", [["viruses", "OBSERVATION", 4, 11], ["roughly", "OBSERVATION_MODIFIER", 16, 23], ["spherical", "OBSERVATION_MODIFIER", 24, 33], ["enveloped", "OBSERVATION_MODIFIER", 35, 44], ["particles", "OBSERVATION_MODIFIER", 45, 54], ["160 nm", "OBSERVATION_MODIFIER", 59, 65], ["diameter", "OBSERVATION_MODIFIER", 69, 77]]], ["Their name derives from the characteristic \u201ccrown\u201d-like projections on their surface, approximately 20 nm long.", [["surface", "ANATOMY", 77, 84], ["surface", "CELLULAR_COMPONENT", 77, 84], ["20 nm", "OBSERVATION_MODIFIER", 100, 105]]], ["They are positive-sense, single-stranded RNA viruses, are sensitive to heat and lipid solvents, and have a distinct replication strategy common to other viruses in the order Nidovirales [1\u20133].", [["single-stranded RNA viruses", "PROBLEM", 25, 52], ["heat and lipid solvents", "TREATMENT", 71, 94], ["a distinct replication strategy", "TREATMENT", 105, 136], ["positive", "OBSERVATION", 9, 17], ["RNA viruses", "OBSERVATION", 41, 52]]], ["Coronaviruses have in the past been divided into three groups.", [["Coronaviruses", "PROBLEM", 0, 13]]], ["In part, because of increasing work on coronavirus discovery in the wake of the outbreak of severe acute respiratory syndrome (SARS) in 2003, a number of new coronaviruses of humans (hCoVs) have been identified.", [["acute respiratory syndrome", "DISEASE", 99, 125], ["SARS", "DISEASE", 127, 131], ["coronavirus", "ORGANISM", 39, 50], ["coronaviruses", "ORGANISM", 158, 171], ["humans", "ORGANISM", 175, 181], ["hCoVs", "CANCER", 183, 188], ["humans", "SPECIES", 175, 181], ["humans", "SPECIES", 175, 181], ["increasing work on coronavirus discovery", "PROBLEM", 20, 60], ["severe acute respiratory syndrome", "PROBLEM", 92, 125], ["coronavirus", "OBSERVATION", 39, 50], ["severe", "OBSERVATION_MODIFIER", 92, 98], ["acute", "OBSERVATION_MODIFIER", 99, 104], ["respiratory syndrome", "OBSERVATION", 105, 125], ["new", "OBSERVATION_MODIFIER", 154, 157], ["coronaviruses", "OBSERVATION", 158, 171]]], ["This has resulted in the three groups being reclassified as genera of the Coronavirinae subfamily.", [["Coronavirinae", "GENE_OR_GENE_PRODUCT", 74, 87], ["Coronavirinae subfamily", "PROTEIN", 74, 97]]], ["Before the SARS outbreak, while it was recognized that the coronavirus infected many different species, particularly domestic and laboratory animals, their extreme diversity in nature was not fully appreciated.", [["SARS", "DISEASE", 11, 15], ["coronavirus infected", "DISEASE", 59, 79], ["coronavirus", "ORGANISM", 59, 70], ["coronavirus", "SPECIES", 59, 70], ["the SARS outbreak", "PROBLEM", 7, 24], ["the coronavirus infected many different species", "PROBLEM", 55, 102], ["coronavirus", "OBSERVATION_MODIFIER", 59, 70], ["infected", "OBSERVATION", 71, 79], ["extreme", "OBSERVATION_MODIFIER", 156, 163], ["diversity", "OBSERVATION_MODIFIER", 164, 173]]], ["Although severe diseases of differing characteristics were known to occur in animals, in humans the viruses were thought to cause only acute respiratory infection which were generally mild.", [["respiratory", "ANATOMY", 141, 152], ["acute respiratory infection", "DISEASE", 135, 162], ["humans", "ORGANISM", 89, 95], ["humans", "SPECIES", 89, 95], ["humans", "SPECIES", 89, 95], ["severe diseases of differing characteristics", "PROBLEM", 9, 53], ["acute respiratory infection", "PROBLEM", 135, 162], ["severe", "OBSERVATION_MODIFIER", 9, 15], ["diseases", "OBSERVATION", 16, 24], ["viruses", "OBSERVATION", 100, 107], ["thought to cause", "UNCERTAINTY", 113, 129], ["acute", "OBSERVATION_MODIFIER", 135, 140], ["respiratory", "ANATOMY", 141, 152], ["infection", "OBSERVATION", 153, 162], ["mild", "OBSERVATION_MODIFIER", 184, 188]]], ["All this changed with the recognition that SARS was caused by a coronavirus (SARS-CoV).", [["SARS", "DISEASE", 43, 47], ["SARS", "DISEASE", 77, 81], ["coronavirus", "ORGANISM", 64, 75], ["SARS-CoV", "ORGANISM", 77, 85], ["SARS-CoV", "SPECIES", 77, 85], ["SARS", "PROBLEM", 43, 47], ["a coronavirus (SARS", "PROBLEM", 62, 81]]], ["This signaled that coronaviruses could produce lethal disease and encouraged more broadly based research on the agent and its prevention and control.", [["lethal disease", "DISEASE", 47, 61], ["coronaviruses", "ORGANISM", 19, 32], ["coronaviruses", "PROBLEM", 19, 32], ["lethal disease", "PROBLEM", 47, 61], ["the agent", "TREATMENT", 108, 117]]], ["In the process, two new respiratory or endemic coronaviruses have been identified as causing human infections, which appear to resemble in epidemiologic characteristics those previously known.", [["infections", "DISEASE", 99, 109], ["coronaviruses", "ORGANISM", 47, 60], ["human", "ORGANISM", 93, 98], ["human", "SPECIES", 93, 98], ["human", "SPECIES", 93, 98], ["two new respiratory or endemic coronaviruses", "PROBLEM", 16, 60], ["human infections", "PROBLEM", 93, 109], ["two", "OBSERVATION_MODIFIER", 16, 19], ["new", "OBSERVATION_MODIFIER", 20, 23], ["respiratory", "OBSERVATION_MODIFIER", 24, 35], ["endemic coronaviruses", "OBSERVATION", 39, 60], ["infections", "OBSERVATION", 99, 109]]], ["Very recently, MERS (Middle East respiratory syndrome) coronavirus, a novel human betacoronavirus lineage C virus, has been discovered zoonotically infecting humans in Middle Eastern countries.IntroductionIn light of the differences between the endemic respiratory and the SARS coronaviruses in terms of epidemiology and clinical expression, they will be covered separately in much of this chapter.Historical BackgroundCoronaviruses were first identified from domestic and laboratory animals before they were identified in humans.", [["Middle East respiratory syndrome) coronavirus", "DISEASE", 21, 66], ["SARS", "DISEASE", 273, 277], ["MERS (Middle East respiratory syndrome) coronavirus", "ORGANISM", 15, 66], ["human", "ORGANISM", 76, 81], ["betacoronavirus lineage C virus", "ORGANISM", 82, 113], ["humans", "ORGANISM", 158, 164], ["Coronaviruses", "GENE_OR_GENE_PRODUCT", 419, 432], ["humans", "ORGANISM", 523, 529], ["coronavirus", "SPECIES", 55, 66], ["human", "SPECIES", 76, 81], ["C virus", "SPECIES", 106, 113], ["humans", "SPECIES", 158, 164], ["humans", "SPECIES", 523, 529], ["Middle East respiratory syndrome) coronavirus", "SPECIES", 21, 66], ["human betacoronavirus lineage C virus", "SPECIES", 76, 113], ["humans", "SPECIES", 158, 164], ["SARS coronaviruses", "SPECIES", 273, 291], ["humans", "SPECIES", 523, 529], ["MERS (Middle East respiratory syndrome)", "PROBLEM", 15, 54], ["coronavirus", "PROBLEM", 55, 66], ["a novel human betacoronavirus lineage C virus", "PROBLEM", 68, 113], ["the SARS coronaviruses", "PROBLEM", 269, 291], ["Historical BackgroundCoronaviruses", "PROBLEM", 398, 432], ["respiratory syndrome", "OBSERVATION", 33, 53], ["Middle", "ANATOMY_MODIFIER", 168, 174], ["Coronaviruses", "OBSERVATION", 419, 432]]], ["Infectious bronchitis virus of chickens was actually isolated in embryonated eggs in the 1940s.", [["eggs", "ANATOMY", 77, 81], ["Infectious bronchitis virus", "DISEASE", 0, 27], ["Infectious bronchitis virus", "ORGANISM", 0, 27], ["chickens", "ORGANISM", 31, 39], ["chickens", "SPECIES", 31, 39], ["Infectious bronchitis virus", "SPECIES", 0, 27], ["chickens", "SPECIES", 31, 39], ["Infectious bronchitis virus of chickens", "PROBLEM", 0, 39], ["embryonated eggs", "PROBLEM", 65, 81]]], ["The late recognition of these viruses was, in large part, because of difficulty in recovering the human viruses using standard cell culture techniques [4].", [["cell", "ANATOMY", 127, 131], ["human", "ORGANISM", 98, 103], ["cell", "CELL", 127, 131], ["human", "SPECIES", 98, 103], ["human", "SPECIES", 98, 103], ["these viruses", "PROBLEM", 24, 37], ["difficulty in recovering the human viruses", "PROBLEM", 69, 111], ["standard cell culture techniques", "TREATMENT", 118, 150], ["late", "OBSERVATION_MODIFIER", 4, 8], ["viruses", "OBSERVATION", 30, 37]]], ["The first human coronaviruses were identified by different techniques in the United Kingdom and the United States at approximately the same time.", [["human", "ORGANISM", 10, 15], ["coronaviruses", "ORGANISM", 16, 29], ["human", "SPECIES", 10, 15], ["human coronaviruses", "SPECIES", 10, 29]]], ["The British Medical Research Council\u2019s Common Cold Research Unit had been studying fluids collected from persons with natural respiratory infections by standard cell culture isolation methods and by inoculating them into human volunteers.", [["respiratory", "ANATOMY", 126, 137], ["cell", "ANATOMY", 161, 165], ["respiratory infections", "DISEASE", 126, 148], ["persons", "ORGANISM", 105, 112], ["cell", "CELL", 161, 165], ["human", "ORGANISM", 221, 226], ["volunteers", "ORGANISM", 227, 237], ["persons", "SPECIES", 105, 112], ["human", "SPECIES", 221, 226], ["human", "SPECIES", 221, 226], ["studying fluids", "TREATMENT", 74, 89], ["natural respiratory infections", "PROBLEM", 118, 148], ["standard cell culture isolation methods", "TREATMENT", 152, 191], ["respiratory infections", "OBSERVATION", 126, 148]]], ["Rhinoviruses or other cytopathogenic agents could be recovered from a portion of the fluids [5].", [["Rhinoviruses", "DISEASE", 0, 12], ["Rhinoviruses", "PROBLEM", 0, 12], ["other cytopathogenic agents", "TREATMENT", 16, 43]]], ["There was an additional, substantial portion from which no agents could be isolated but that could still cause colds in the volunteers.", [["colds", "DISEASE", 111, 116], ["volunteers", "ORGANISM", 124, 134], ["agents", "TREATMENT", 59, 65], ["colds in the volunteers", "PROBLEM", 111, 134], ["substantial", "OBSERVATION_MODIFIER", 25, 36], ["portion", "OBSERVATION_MODIFIER", 37, 44], ["no agents", "UNCERTAINTY", 56, 65], ["colds", "OBSERVATION", 111, 116]]], ["Organ cultures of human embryonic trachea or nasal epithelium were then used in an effort to detect the recalcitrant viruses present.", [["Organ cultures", "ANATOMY", 0, 14], ["embryonic trachea", "ANATOMY", 24, 41], ["nasal epithelium", "ANATOMY", 45, 61], ["Organ cultures", "CELL", 0, 14], ["human", "ORGANISM", 18, 23], ["embryonic trachea", "MULTI-TISSUE_STRUCTURE", 24, 41], ["nasal epithelium", "TISSUE", 45, 61], ["human", "SPECIES", 18, 23], ["human", "SPECIES", 18, 23], ["Organ cultures", "TEST", 0, 14], ["nasal epithelium", "PROBLEM", 45, 61], ["the recalcitrant viruses", "PROBLEM", 100, 124], ["human", "ANATOMY_MODIFIER", 18, 23], ["embryonic", "ANATOMY_MODIFIER", 24, 33], ["trachea", "ANATOMY", 34, 41], ["nasal epithelium", "ANATOMY", 45, 61], ["recalcitrant", "OBSERVATION_MODIFIER", 104, 116], ["viruses", "OBSERVATION", 117, 124]]], ["A specimen, B814, that had been collected in 1960 from a boy with a common cold had not yielded a virus on inoculation into cell culture.", [["specimen", "ANATOMY", 2, 10], ["cell", "ANATOMY", 124, 128], ["boy", "ORGANISM", 57, 60], ["cell culture", "CELL", 124, 136], ["cell culture", "CELL_LINE", 124, 136], ["boy", "SPECIES", 57, 60], ["A specimen", "TEST", 0, 10], ["a virus", "PROBLEM", 96, 103], ["cell culture", "TEST", 124, 136], ["virus", "OBSERVATION", 98, 103]]], ["After the specimen had been passaged serially three times in human tracheal organ culture, it could still cause colds on inoculation into volunteers, which indicated that replication had taken place [6].", [["specimen", "ANATOMY", 10, 18], ["tracheal organ culture", "ANATOMY", 67, 89], ["colds", "DISEASE", 112, 117], ["human", "ORGANISM", 61, 66], ["volunteers", "ORGANISM", 138, 148], ["human", "SPECIES", 61, 66], ["human", "SPECIES", 61, 66], ["human tracheal organ culture", "TEST", 61, 89], ["colds", "PROBLEM", 112, 117], ["tracheal organ", "ANATOMY", 67, 81]]], ["In Chicago during the winter of 1962, five agents were isolated in primary human kidney cell cultures from specimens collected from medical students with common colds.", [["kidney cell cultures", "ANATOMY", 81, 101], ["specimens", "ANATOMY", 107, 116], ["colds", "DISEASE", 161, 166], ["human", "ORGANISM", 75, 80], ["kidney cell cultures", "CELL", 81, 101], ["specimens", "TISSUE", 107, 116], ["primary human kidney cell cultures", "CELL_LINE", 67, 101], ["human", "SPECIES", 75, 80], ["human", "SPECIES", 75, 80], ["primary human kidney cell cultures", "TEST", 67, 101], ["specimens", "TEST", 107, 116], ["common colds", "PROBLEM", 154, 166], ["kidney", "ANATOMY", 81, 87], ["cell", "OBSERVATION", 88, 92]]], ["The viruses were ultimately adapted to WI-38 cultures and exhibited a type of cytopathic effect (CPE) not previously seen.", [["WI-38 cultures", "CELL", 39, 53], ["WI-38 cultures", "CELL_LINE", 39, 53], ["The viruses", "PROBLEM", 0, 11], ["WI", "TEST", 39, 41], ["cultures", "TEST", 45, 53], ["cytopathic effect (CPE", "PROBLEM", 78, 100], ["viruses", "OBSERVATION", 4, 11], ["cytopathic effect", "OBSERVATION", 78, 95]]], ["A prototype strain, 229E, was selected for characterization and was found to be RNA containing, ether labile, and 89 nm in diameter but distinct serologically from any known ortho- or paramyxoviruses.", [["ether", "CHEMICAL", 96, 101], ["paramyxoviruses", "ORGANISM", 184, 199], ["A prototype strain", "PROBLEM", 0, 18], ["paramyxoviruses", "PROBLEM", 184, 199], ["RNA", "OBSERVATION", 80, 83], ["labile", "OBSERVATION_MODIFIER", 102, 108], ["89 nm", "OBSERVATION_MODIFIER", 114, 119], ["distinct", "OBSERVATION_MODIFIER", 136, 144], ["serologically", "OBSERVATION", 145, 158], ["paramyxoviruses", "OBSERVATION", 184, 199]]], ["Sera collected from the five medical students all exhibited a fourfold rise in neutralization antibody titer against 229E [7].", [["Sera", "ANATOMY", 0, 4], ["Sera", "ORGANISM_SUBSTANCE", 0, 4], ["Sera", "TEST", 0, 4], ["neutralization antibody titer", "TEST", 79, 108]]], ["It became clear that these \u201cnovel\u201d viruses were of more than passing significance when organ culture methods were added to standard cell culture techniques in a study of acute respiratory infections of adults conducted at the National Institutes of Health (NIH).", [["organ", "ANATOMY", 87, 92], ["cell", "ANATOMY", 132, 136], ["respiratory", "ANATOMY", 176, 187], ["respiratory infections", "DISEASE", 176, 198], ["organ", "ORGAN", 87, 92], ["cell", "CELL", 132, 136], ["these \u201cnovel\u201d viruses", "PROBLEM", 21, 42], ["organ culture methods", "TEST", 87, 108], ["standard cell culture techniques", "TEST", 123, 155], ["a study", "TEST", 159, 166], ["acute respiratory infections", "PROBLEM", 170, 198], ["acute", "OBSERVATION_MODIFIER", 170, 175], ["respiratory", "ANATOMY", 176, 187], ["infections", "OBSERVATION", 188, 198]]], ["Six viruses were found that grew in organ but not cell culture and were ether labile; on electron microscopy, the agents were shown to resemble avian infectious bronchitis virus (IBV) in structure, and these represented a distinct family of viruses [8].", [["organ", "ANATOMY", 36, 41], ["cell culture", "ANATOMY", 50, 62], ["infectious bronchitis virus", "DISEASE", 150, 177], ["ether", "CHEMICAL", 72, 77], ["organ", "ORGAN", 36, 41], ["cell culture", "CELL", 50, 62], ["avian infectious bronchitis virus", "ORGANISM", 144, 177], ["IBV", "ORGANISM", 179, 182], ["avian infectious bronchitis virus", "SPECIES", 144, 177], ["infectious bronchitis virus", "SPECIES", 150, 177], ["IBV", "SPECIES", 179, 182], ["Six viruses", "PROBLEM", 0, 11], ["cell culture", "TEST", 50, 62], ["electron microscopy", "TEST", 89, 108], ["the agents", "TREATMENT", 110, 120], ["avian infectious bronchitis virus", "PROBLEM", 144, 177], ["viruses", "OBSERVATION", 4, 11], ["infectious", "OBSERVATION_MODIFIER", 150, 160]]], ["The B814 and 229E strains were soon also demonstrated to have a similar structure on electron microscopy and to develop in infected cells by budding into cytoplasmic vesicles [9, 10].", [["cells", "ANATOMY", 132, 137], ["cytoplasmic vesicles", "ANATOMY", 154, 174], ["B814", "GENE_OR_GENE_PRODUCT", 4, 8], ["cells", "CELL", 132, 137], ["cytoplasmic", "ORGANISM_SUBSTANCE", 154, 165], ["vesicles", "CELLULAR_COMPONENT", 166, 174], ["infected cells", "CELL_TYPE", 123, 137], ["The B814 and 229E strains", "TEST", 0, 25], ["electron microscopy", "TEST", 85, 104], ["infected cells", "PROBLEM", 123, 137], ["infected cells", "OBSERVATION", 123, 137], ["cytoplasmic vesicles", "OBSERVATION", 154, 174]]], ["As a result of the similarity of the human agents to IBV and also to mouse hepatitis virus (MHV), they were collectively considered to represent a group of vertebrate viruses distinct from the myxoviruses antigenically and structurally [11].", [["mouse hepatitis virus", "DISEASE", 69, 90], ["human", "ORGANISM", 37, 42], ["IBV", "ORGANISM", 53, 56], ["mouse hepatitis virus", "ORGANISM", 69, 90], ["MHV", "ORGANISM", 92, 95], ["human", "SPECIES", 37, 42], ["mouse", "SPECIES", 69, 74], ["hepatitis virus", "SPECIES", 75, 90], ["human", "SPECIES", 37, 42], ["IBV", "SPECIES", 53, 56], ["mouse hepatitis virus", "SPECIES", 69, 90], ["MHV", "SPECIES", 92, 95], ["the human agents", "TREATMENT", 33, 49], ["IBV", "TREATMENT", 53, 56], ["mouse hepatitis virus", "PROBLEM", 69, 90], ["vertebrate viruses", "PROBLEM", 156, 174], ["vertebrate viruses", "OBSERVATION", 156, 174]]], ["The name coronavirus was eventually adopted for the group to describe the fringe of projections seen around them on electron microscopy [1].", [["coronavirus", "ORGANISM", 9, 20], ["The name coronavirus", "PROBLEM", 0, 20], ["electron microscopy", "TEST", 116, 135]]], ["Except for 229E, none of the human coronaviruses had been successfully propagated in a system other than organ culture.", [["organ culture", "ANATOMY", 105, 118], ["human", "ORGANISM", 29, 34], ["coronaviruses", "ORGANISM", 35, 48], ["organ", "ORGAN", 105, 110], ["human", "SPECIES", 29, 34], ["human coronaviruses", "SPECIES", 29, 48], ["the human coronaviruses", "PROBLEM", 25, 48], ["organ culture", "TEST", 105, 118]]], ["McIntosh et al. reported successful adaptation of two of the NIH isolates, OC (organ culture) 38 and OC43, to the brains of suckling mice [12].", [["organ culture", "ANATOMY", 79, 92], ["brains", "ANATOMY", 114, 120], ["OC", "CHEMICAL", 75, 77], ["organ culture) 38", "CELL", 79, 96], ["brains", "ORGAN", 114, 120], ["mice", "ORGANISM", 133, 137], ["mice", "SPECIES", 133, 137], ["mice", "SPECIES", 133, 137], ["the NIH isolates", "TEST", 57, 73], ["OC (organ culture", "TEST", 75, 92], ["OC43", "PROBLEM", 101, 105]]], ["These strains were shown to be essentially identical antigenically but quite distinct from MHV.", [["MHV", "ORGANISM", 91, 94], ["MHV", "SPECIES", 91, 94], ["These strains", "PROBLEM", 0, 13], ["MHV", "OBSERVATION", 91, 94]]], ["Only OC38 and OC43 could be so adapted; the other four OC strains resisted such attempts.", [["OC", "CHEMICAL", 55, 57], ["OC38", "GENE_OR_GENE_PRODUCT", 5, 9], ["OC43", "GENE_OR_GENE_PRODUCT", 14, 18], ["OC38", "DNA", 5, 9], ["OC43", "DNA", 14, 18]]], ["The IBV was known to exhibit hemagglutination under certain conditions, but no such phenomenon had been demonstrated for the human strains until OC38 and OC43 were adapted to mice.", [["IBV", "ORGANISM", 4, 7], ["human", "ORGANISM", 125, 130], ["OC38", "GENE_OR_GENE_PRODUCT", 145, 149], ["OC43", "GENE_OR_GENE_PRODUCT", 154, 158], ["mice", "ORGANISM", 175, 179], ["human", "SPECIES", 125, 130], ["mice", "SPECIES", 175, 179], ["IBV", "SPECIES", 4, 7], ["human", "SPECIES", 125, 130], ["OC38", "SPECIES", 145, 149], ["mice", "SPECIES", 175, 179], ["The IBV", "PROBLEM", 0, 7], ["hemagglutination under certain conditions", "PROBLEM", 29, 70], ["such phenomenon", "PROBLEM", 79, 94], ["the human strains", "PROBLEM", 121, 138], ["OC43", "PROBLEM", 154, 158], ["IBV", "OBSERVATION", 4, 7], ["known to exhibit", "UNCERTAINTY", 12, 28], ["hemagglutination", "OBSERVATION", 29, 45]]], ["Kaye and Dowdle found that the infected brain preparations would directly and specifically agglutinate red cells obtained from chickens, rats, and mice [13].", [["brain", "ANATOMY", 40, 45], ["red cells", "ANATOMY", 103, 112], ["brain", "ORGAN", 40, 45], ["red cells", "CELL", 103, 112], ["chickens", "ORGANISM", 127, 135], ["rats", "ORGANISM", 137, 141], ["mice", "ORGANISM", 147, 151], ["red cells", "CELL_TYPE", 103, 112], ["chickens", "SPECIES", 127, 135], ["rats", "SPECIES", 137, 141], ["mice", "SPECIES", 147, 151], ["chickens", "SPECIES", 127, 135], ["mice", "SPECIES", 147, 151], ["the infected brain preparations", "TREATMENT", 27, 58], ["red cells", "TEST", 103, 112], ["infected", "OBSERVATION", 31, 39]]], ["This technique greatly expanded the ability to do seroepidemiologic studies, since it was simple and reproducible.Historical BackgroundSubsequent developments included adaption of OC38 and OC43 to growth in cell monolayers; either mouse brain or organ culture material could be used as sources of virus [9].", [["cell monolayers", "ANATOMY", 207, 222], ["brain", "ANATOMY", 237, 242], ["organ culture", "ANATOMY", 246, 259], ["OC38", "GENE_OR_GENE_PRODUCT", 180, 184], ["OC43", "GENE_OR_GENE_PRODUCT", 189, 193], ["cell monolayers", "CELL", 207, 222], ["mouse", "ORGANISM", 231, 236], ["brain", "ORGAN", 237, 242], ["OC38", "DNA", 180, 184], ["OC43", "DNA", 189, 193], ["mouse", "SPECIES", 231, 236], ["mouse", "SPECIES", 231, 236], ["seroepidemiologic studies", "TEST", 50, 75], ["adaption of OC38", "TREATMENT", 168, 184], ["OC43", "TREATMENT", 189, 193], ["cell monolayers", "TREATMENT", 207, 222], ["mouse brain", "PROBLEM", 231, 242], ["organ culture material", "TREATMENT", 246, 268], ["virus", "PROBLEM", 297, 302], ["cell monolayers", "OBSERVATION", 207, 222], ["brain", "ANATOMY", 237, 242], ["organ", "ANATOMY", 246, 251]]], ["Not only was CPE available for reading of neutralization tests, but also the OC38 and OC43 viruses were found to hemadsorb red cells of rats and mice, making available a more precise means of evaluating endpoints in tests involving these organ culture-derived strains [14].", [["hemadsorb red cells", "ANATOMY", 113, 132], ["organ culture", "ANATOMY", 238, 251], ["OC38", "GENE_OR_GENE_PRODUCT", 77, 81], ["OC43 viruses", "ORGANISM", 86, 98], ["hemadsorb red cells", "CELL", 113, 132], ["rats", "ORGANISM", 136, 140], ["mice", "ORGANISM", 145, 149], ["hemadsorb red cells", "CELL_TYPE", 113, 132], ["rats", "SPECIES", 136, 140], ["mice", "SPECIES", 145, 149], ["mice", "SPECIES", 145, 149], ["CPE", "PROBLEM", 13, 16], ["neutralization tests", "TEST", 42, 62], ["the OC38 and OC43 viruses", "PROBLEM", 73, 98], ["tests", "TEST", 216, 221], ["these organ culture", "TEST", 232, 251]]], ["The other OC strains and B814 that could not be adapted to mouse brain resisted adaptation to cell culture as well; these distinct viruses have since been lost and may actually have been rediscovered recently.Historical BackgroundWork on the coronaviruses of humans proceeded slowly, with debate about how frequently the viruses caused lower rather than upper respiratory disease.", [["brain", "ANATOMY", 65, 70], ["cell culture", "ANATOMY", 94, 106], ["respiratory", "ANATOMY", 360, 371], ["OC", "CHEMICAL", 10, 12], ["respiratory disease", "DISEASE", 360, 379], ["B814", "CELL", 25, 29], ["mouse", "ORGANISM", 59, 64], ["brain", "ORGAN", 65, 70], ["cell", "CELL", 94, 98], ["coronaviruses", "ORGANISM", 242, 255], ["humans", "ORGANISM", 259, 265], ["mouse", "SPECIES", 59, 64], ["humans", "SPECIES", 259, 265], ["mouse", "SPECIES", 59, 64], ["humans", "SPECIES", 259, 265], ["The other OC strains", "PROBLEM", 0, 20], ["B814", "TREATMENT", 25, 29], ["cell culture", "TEST", 94, 106], ["these distinct viruses", "PROBLEM", 116, 138], ["the viruses", "PROBLEM", 317, 328], ["upper respiratory disease", "PROBLEM", 354, 379], ["distinct", "OBSERVATION_MODIFIER", 122, 130], ["viruses", "OBSERVATION", 131, 138], ["viruses", "OBSERVATION", 321, 328], ["respiratory disease", "OBSERVATION", 360, 379]]], ["The methodological problems of working with them were a major impediment, as was their apparent involvement only in a relatively mild disease.", [["a relatively mild disease", "PROBLEM", 116, 141], ["relatively", "OBSERVATION_MODIFIER", 118, 128], ["mild", "OBSERVATION_MODIFIER", 129, 133], ["disease", "OBSERVATION", 134, 141]]], ["All this changed when in 2002 SARS appeared first in China and then in other countries of the world.", [["SARS", "DISEASE", 30, 34]]], ["The near panic resulted because of its transmission characteristics, case fatality, and the fact that the agent was initially unknown.", [["panic", "DISEASE", 9, 14], ["The near panic", "PROBLEM", 0, 14]]], ["That last aspect was solved quickly with the identification of the causative agent as a new coronavirus.", [["coronavirus", "DISEASE", 92, 103], ["coronavirus", "ORGANISM", 92, 103], ["a new coronavirus", "PROBLEM", 86, 103]]], ["The knowledge that the virus emerged from a zoonotic reservoir spurred investigation of its possible source.", [["the virus", "PROBLEM", 19, 28], ["a zoonotic reservoir", "TREATMENT", 42, 62], ["zoonotic", "OBSERVATION_MODIFIER", 44, 52]]], ["Small mammals (civet cats) in live game-animal markets in Guangdong were identified carrying closely related viruses.", [["civet cats", "ORGANISM", 15, 25], ["cats", "SPECIES", 21, 25], ["Small mammals (civet cats", "PROBLEM", 0, 25], ["mammals", "OBSERVATION_MODIFIER", 6, 13]]], ["This led to the identification of these animals as amplifier hosts and to the game-animal wet markets as an interface where zoonotic infection of humans was being initiated [15].", [["zoonotic infection", "DISEASE", 124, 142], ["humans", "ORGANISM", 146, 152], ["humans", "SPECIES", 146, 152], ["humans", "SPECIES", 146, 152], ["zoonotic infection of humans", "PROBLEM", 124, 152]]], ["The natural reservoir was later identified to be Chinese horseshoe bats [16, 17].", [["Chinese horseshoe bats", "SPECIES", 49, 71], ["The natural reservoir", "TREATMENT", 0, 21], ["reservoir", "OBSERVATION_MODIFIER", 12, 21]]], ["The SARS epidemic ended following the use of various population control measures and unexpectedly has not recurred.", [["SARS", "DISEASE", 4, 8], ["The SARS epidemic", "PROBLEM", 0, 17], ["various population control measures", "TREATMENT", 45, 80], ["SARS", "OBSERVATION_MODIFIER", 4, 8]]], ["However, increased attention to the coronaviruses continued globally.", [["coronaviruses", "ORGANISM", 36, 49], ["increased", "OBSERVATION_MODIFIER", 9, 18]]], ["New coronaviruses were identified in various animal hosts, and two additional coronaviruses were identified in humans, the first since 229E and OC43.", [["coronaviruses", "ORGANISM", 4, 17], ["coronaviruses", "ORGANISM", 78, 91], ["humans", "ORGANISM", 111, 117], ["humans", "SPECIES", 111, 117], ["humans", "SPECIES", 111, 117], ["New coronaviruses", "PROBLEM", 0, 17], ["two additional coronaviruses", "PROBLEM", 63, 91], ["OC43", "PROBLEM", 144, 148], ["coronaviruses", "OBSERVATION", 4, 17], ["coronaviruses", "OBSERVATION", 78, 91]]], ["NL63 was identified in Amsterdam in 2004 from a 7-month-old child with febrile bronchiolitis [18].", [["febrile bronchiolitis", "DISEASE", 71, 92], ["NL63", "GENE_OR_GENE_PRODUCT", 0, 4], ["child", "ORGANISM", 60, 65], ["NL63", "PROTEIN", 0, 4], ["child", "SPECIES", 60, 65], ["febrile bronchiolitis", "PROBLEM", 71, 92], ["febrile", "OBSERVATION_MODIFIER", 71, 78], ["bronchiolitis", "OBSERVATION", 79, 92]]], ["The same virus was also isolated at almost the same time by the group in Rotterdam from an 8-month-old child with pneumonia [19].", [["pneumonia", "DISEASE", 114, 123], ["child", "ORGANISM", 103, 108], ["child", "SPECIES", 103, 108], ["The same virus", "PROBLEM", 0, 14], ["pneumonia", "PROBLEM", 114, 123], ["virus", "OBSERVATION", 9, 14], ["pneumonia", "OBSERVATION", 114, 123]]], ["The second virus, HKU1, was detected in a specimen collected from a 71-year-old man from China with pneumonia and then from another adult with the same diagnosis [20].", [["specimen", "ANATOMY", 42, 50], ["pneumonia", "DISEASE", 100, 109], ["HKU1", "GENE_OR_GENE_PRODUCT", 18, 22], ["man", "ORGANISM", 80, 83], ["man", "SPECIES", 80, 83], ["The second virus", "PROBLEM", 0, 16], ["a specimen", "TEST", 40, 50], ["pneumonia", "PROBLEM", 100, 109], ["virus", "OBSERVATION", 11, 16], ["pneumonia", "OBSERVATION", 100, 109]]], ["With the development of real-time PCR techniques for all four human respiratory coronaviruses, it has now become possible to identify them in many situations.", [["respiratory coronaviruses", "DISEASE", 68, 93], ["human", "ORGANISM", 62, 67], ["human", "SPECIES", 62, 67], ["human respiratory coronaviruses", "SPECIES", 62, 93], ["real-time PCR techniques", "TREATMENT", 24, 48], ["all four human respiratory coronaviruses", "PROBLEM", 53, 93], ["respiratory coronaviruses", "OBSERVATION", 68, 93]]], ["Such identification is now typically done not only for these viruses but also for a variety of other respiratory agents.", [["respiratory", "ANATOMY", 101, 112], ["these viruses", "PROBLEM", 55, 68], ["other respiratory agents", "TREATMENT", 95, 119]]], ["This has meant that coronaviruses are now detected as much in clinical settings as in epidemiologic studies.Sources of Mortality Data ::: MethodologyUntil the occurrence of SARS, coronaviruses of humans were not thought to cause death, except, possibly, in those with underlying conditions.", [["SARS", "DISEASE", 173, 177], ["death", "DISEASE", 229, 234], ["coronaviruses", "ORGANISM", 20, 33], ["coronaviruses", "ORGANISM", 179, 192], ["humans", "ORGANISM", 196, 202], ["humans", "SPECIES", 196, 202], ["humans", "SPECIES", 196, 202], ["coronaviruses", "PROBLEM", 20, 33], ["epidemiologic studies", "TEST", 86, 107], ["SARS", "PROBLEM", 173, 177], ["coronaviruses of humans", "PROBLEM", 179, 202], ["death", "PROBLEM", 229, 234], ["underlying conditions", "PROBLEM", 268, 289], ["coronaviruses", "OBSERVATION", 20, 33]]], ["This was in contrast to the situation in animals, where infections were sometimes fatal, depending on the particular virus.", [["infections", "DISEASE", 56, 66], ["infections", "PROBLEM", 56, 66], ["the particular virus", "PROBLEM", 102, 122], ["infections", "OBSERVATION", 56, 66]]], ["Since the SARS episode, the major change which has affected data on the respiratory coronaviruses has been more ready detection using the polymerase chain reaction (PCR) technique, so that infections are now recognized in those who might previously have not been studied.", [["SARS", "DISEASE", 10, 14], ["respiratory coronaviruses", "DISEASE", 72, 97], ["infections", "DISEASE", 189, 199], ["the SARS episode", "PROBLEM", 6, 22], ["the major change", "PROBLEM", 24, 40], ["the respiratory coronaviruses", "PROBLEM", 68, 97], ["the polymerase chain reaction", "TREATMENT", 134, 163], ["infections", "PROBLEM", 189, 199], ["major", "OBSERVATION_MODIFIER", 28, 33], ["change", "OBSERVATION", 34, 40], ["infections", "OBSERVATION", 189, 199]]], ["This has especially been the case in hospitalized individuals, particularly those who will likely experience severe outcomes, such as the immunocompromised.", [["severe outcomes", "PROBLEM", 109, 124], ["the immunocompromised", "PROBLEM", 134, 155]]], ["It is also known from earlier studies that coronavirus frequently infects small children and reinfects adults, including persons with chronic respiratory disease [21].", [["respiratory", "ANATOMY", 142, 153], ["chronic respiratory disease", "DISEASE", 134, 161], ["coronavirus", "ORGANISM", 43, 54], ["children", "ORGANISM", 80, 88], ["children", "SPECIES", 80, 88], ["persons", "SPECIES", 121, 128], ["earlier studies", "TEST", 22, 37], ["coronavirus", "PROBLEM", 43, 54], ["chronic respiratory disease", "PROBLEM", 134, 161], ["chronic", "OBSERVATION_MODIFIER", 134, 141], ["respiratory disease", "OBSERVATION", 142, 161]]], ["It would be logical to assume that deaths could occur in these most susceptible segments of the population, but they are probably not very frequent.Sources of Mortality Data ::: MethodologyA problem during SARS was in defining the specificity of infection, whether inapparent, mild, or fatal.", [["deaths", "DISEASE", 35, 41], ["SARS", "DISEASE", 206, 210], ["infection", "DISEASE", 246, 255], ["MethodologyA problem", "PROBLEM", 178, 198], ["infection", "PROBLEM", 246, 255], ["probably not", "UNCERTAINTY", 121, 133], ["infection", "OBSERVATION", 246, 255], ["mild", "OBSERVATION_MODIFIER", 277, 281], ["fatal", "OBSERVATION_MODIFIER", 286, 291]]], ["This was related to the lack of a readily available diagnostic test in many areas where outbreaks occurred.", [["diagnostic test", "TEST", 52, 67]]], ["To a large extent, cases were classified using a clinical case definition.", [["large", "OBSERVATION_MODIFIER", 5, 10], ["extent", "OBSERVATION_MODIFIER", 11, 17]]], ["In some cases that survived, there was an attempt at serological confirmation.Sources of Morbidity Data ::: MethodologySince the coronaviruses of humans, other than the SARS virus, usually produce illnesses indistinguishable from those caused by other respiratory viruses, it is not possible to define morbidity in the absence of laboratory identification.", [["SARS virus", "DISEASE", 169, 179], ["respiratory viruses", "DISEASE", 252, 271], ["coronaviruses", "ORGANISM", 129, 142], ["humans", "ORGANISM", 146, 152], ["SARS virus", "ORGANISM", 169, 179], ["humans", "SPECIES", 146, 152], ["humans", "SPECIES", 146, 152], ["SARS virus", "SPECIES", 169, 179], ["serological confirmation", "TEST", 53, 77], ["the SARS virus", "PROBLEM", 165, 179], ["illnesses", "PROBLEM", 197, 206], ["other respiratory viruses", "PROBLEM", 246, 271], ["laboratory identification", "TEST", 330, 355], ["Morbidity", "OBSERVATION", 89, 98], ["coronaviruses", "OBSERVATION", 129, 142], ["respiratory viruses", "OBSERVATION", 252, 271], ["not possible", "UNCERTAINTY", 279, 291]]], ["Before PCR became available, it was difficult directly to identify the infecting virus; thus, besides anecdotal reports, most of the epidemiologic studies were based on identifying rises in antibody titer.", [["PCR", "TEST", 7, 10], ["the infecting virus", "PROBLEM", 67, 86], ["the epidemiologic studies", "TEST", 129, 154], ["rises in antibody titer", "PROBLEM", 181, 204], ["antibody titer", "OBSERVATION", 190, 204]]], ["In contrast, since development of the PCR technique, direct identification has become relatively simple.", [["the PCR technique", "TEST", 34, 51], ["direct identification", "TEST", 53, 74], ["relatively", "OBSERVATION_MODIFIER", 86, 96], ["simple", "OBSERVATION_MODIFIER", 97, 103]]], ["However, this seeming advance has often been accompanied by the use of the method to determine the incidence of infection in population groups and to define characteristics of associated disease or even seasonality.", [["infection", "DISEASE", 112, 121], ["the method", "TREATMENT", 71, 81], ["infection in population groups", "PROBLEM", 112, 142], ["associated disease", "PROBLEM", 176, 194], ["infection", "OBSERVATION", 112, 121], ["disease", "OBSERVATION", 187, 194]]], ["The major problem is the short duration of many of the available studies and the concentration on hospitalized individuals.", [["the available studies", "TEST", 51, 72], ["major", "OBSERVATION_MODIFIER", 4, 9], ["problem", "OBSERVATION", 10, 17], ["short duration", "OBSERVATION_MODIFIER", 25, 39]]], ["As a result, while it is possible to say these viruses can sometimes cause hospitalization and to infer the particular clinical diagnoses they produce, it is difficult to estimate what proportion of overall illnesses are severe.", [["overall illnesses", "PROBLEM", 199, 216], ["illnesses", "OBSERVATION", 207, 216], ["severe", "OBSERVATION_MODIFIER", 221, 227]]], ["A small number of studies have been population based and have produced the only data available for determining the overall impact of illness [22\u201324].", [["illness", "DISEASE", 133, 140], ["small", "OBSERVATION_MODIFIER", 2, 7]]], ["While the older population-based studies were limited to 229E, OC43, or both, they are useful since there are few recent investigations that give the same information.", [["OC43", "GENE_OR_GENE_PRODUCT", 63, 67], ["based studies", "TEST", 27, 40], ["OC43", "TEST", 63, 67]]], ["In fact, almost no studies include all four recognized coronaviruses and cover more than a single year.", [["coronaviruses", "ORGANISM", 55, 68], ["studies", "TEST", 19, 26], ["coronaviruses", "OBSERVATION", 55, 68]]], ["Such studies are therefore of continuing interest, at least as background, in determining the long-term occurrence of the viruses.", [["Such studies", "TEST", 0, 12], ["the viruses", "PROBLEM", 118, 129], ["viruses", "OBSERVATION", 122, 129]]], ["These original investigations were typically broadly based, with coronavirus infection forming part of overall evaluations of the role of viruses in general in respiratory illnesses.", [["respiratory", "ANATOMY", 160, 171], ["coronavirus infection", "DISEASE", 65, 86], ["respiratory illnesses", "DISEASE", 160, 181], ["coronavirus", "ORGANISM", 65, 76], ["These original investigations", "TEST", 0, 29], ["coronavirus infection", "PROBLEM", 65, 86], ["overall evaluations", "TEST", 103, 122], ["viruses", "PROBLEM", 138, 145], ["respiratory illnesses", "PROBLEM", 160, 181], ["coronavirus infection", "OBSERVATION", 65, 86], ["viruses", "OBSERVATION", 138, 145], ["respiratory illnesses", "OBSERVATION", 160, 181]]], ["As indicated in the selected listing in Table 10.1, a variety of different open and closed populations were used for these studies.", [["different open and closed populations", "TREATMENT", 65, 102], ["these studies", "TEST", 117, 130]]], ["The 229E strain was originally isolated from medical students in Chicago as part of a long-term study of respiratory illnesses in young adults [7, 25].", [["respiratory", "ANATOMY", 105, 116], ["respiratory illnesses", "DISEASE", 105, 126], ["The 229E strain", "PROBLEM", 0, 15], ["a long-term study", "TREATMENT", 84, 101], ["respiratory illnesses", "PROBLEM", 105, 126], ["respiratory", "ANATOMY", 105, 116], ["illnesses", "OBSERVATION", 117, 126]]], ["Employee groups were the source of specimens in the NIH [26, 27] and in the studies at Charlottesville, Virginia [30].", [["specimens", "ANATOMY", 35, 44]]], ["Infection was also evaluated in children\u2019s homes [28] and boarding schools [5], among military recruits [34], and among children hospitalized for severe respiratory illnesses in various parts of the world [26].", [["respiratory", "ANATOMY", 153, 164], ["respiratory illnesses", "DISEASE", 153, 174], ["children", "ORGANISM", 32, 40], ["children", "ORGANISM", 120, 128], ["children", "SPECIES", 32, 40], ["children", "SPECIES", 120, 128], ["Infection", "PROBLEM", 0, 9], ["severe respiratory illnesses", "PROBLEM", 146, 174], ["respiratory", "ANATOMY", 153, 164], ["illnesses", "OBSERVATION", 165, 174]]], ["Serological methods were used to detect occurrence in persons with acute exacerbations of asthma [33] or chronic obstructive respiratory disease [21].", [["respiratory", "ANATOMY", 125, 136], ["asthma", "DISEASE", 90, 96], ["chronic obstructive respiratory disease", "DISEASE", 105, 144], ["persons", "ORGANISM", 54, 61], ["persons", "SPECIES", 54, 61], ["Serological methods", "TEST", 0, 19], ["acute exacerbations", "PROBLEM", 67, 86], ["asthma", "PROBLEM", 90, 96], ["chronic obstructive respiratory disease", "PROBLEM", 105, 144], ["acute", "OBSERVATION_MODIFIER", 67, 72], ["exacerbations", "OBSERVATION", 73, 86], ["asthma", "OBSERVATION", 90, 96], ["chronic", "OBSERVATION_MODIFIER", 105, 112], ["obstructive", "OBSERVATION_MODIFIER", 113, 124], ["respiratory disease", "OBSERVATION", 125, 144]]], ["Patterns of coronavirus infection were identified among the general population residing in the Tecumseh, Michigan, community as part of a longitudinal study of respiratory illness [31, 32].", [["respiratory", "ANATOMY", 160, 171], ["coronavirus infection", "DISEASE", 12, 33], ["respiratory illness", "DISEASE", 160, 179], ["coronavirus", "ORGANISM", 12, 23], ["coronavirus infection", "PROBLEM", 12, 33], ["a longitudinal study", "TEST", 136, 156], ["respiratory illness", "PROBLEM", 160, 179], ["coronavirus", "OBSERVATION_MODIFIER", 12, 23], ["infection", "OBSERVATION", 24, 33]]], ["Also included in Table 10.1 are more recent studies using PCR to identify infection.", [["infection", "DISEASE", 74, 83], ["recent studies", "TEST", 37, 51], ["PCR", "TEST", 58, 61], ["infection", "PROBLEM", 74, 83], ["infection", "OBSERVATION", 74, 83]]], ["The previous studies, based on serology, often did not characterize infections identified clinically; in fact, challenge studies of volunteers were employed early, to determine characteristics of illnesses, because of problems associated with direct isolation [35, 36].", [["infections", "DISEASE", 68, 78], ["volunteers", "ORGANISM", 132, 142], ["The previous studies", "TEST", 0, 20], ["serology", "TEST", 31, 39], ["infections", "PROBLEM", 68, 78], ["illnesses", "PROBLEM", 196, 205], ["infections", "OBSERVATION", 68, 78]]], ["The more recent studies were able to characterize the illnesses clinically but have other limitations as indicated above.", [["The more recent studies", "TEST", 0, 23], ["the illnesses", "PROBLEM", 50, 63]]]], "d677e64f99fe5097ce1d3244dacd29a8f325e952": [["INTRODUCTIONRespiratory infections in immunosuppressed patients account for significant morbidity and mortality.", [["infections", "DISEASE", 24, 34], ["immunosuppressed", "DISEASE", 38, 54], ["patients", "ORGANISM", 55, 63], ["patients", "SPECIES", 55, 63], ["INTRODUCTIONRespiratory infections", "PROBLEM", 0, 34], ["significant morbidity", "PROBLEM", 76, 97], ["infections", "OBSERVATION", 24, 34], ["immunosuppressed", "OBSERVATION", 38, 54], ["significant", "OBSERVATION_MODIFIER", 76, 87], ["morbidity", "OBSERVATION", 88, 97]]], ["1, 2 Immunosuppression and co-morbid disease predispose patients to pulmonary infiltrates from infectious and non-infectious aetiologies.", [["pulmonary", "ANATOMY", 68, 77], ["co-morbid disease", "DISEASE", 27, 44], ["patients", "ORGANISM", 56, 64], ["pulmonary", "ORGAN", 68, 77], ["patients", "SPECIES", 56, 64], ["co-morbid disease", "PROBLEM", 27, 44], ["pulmonary infiltrates", "PROBLEM", 68, 89], ["infectious and non-infectious aetiologies", "PROBLEM", 95, 136], ["co-morbid disease", "OBSERVATION", 27, 44], ["pulmonary", "ANATOMY", 68, 77], ["infiltrates", "OBSERVATION", 78, 89], ["infectious", "OBSERVATION_MODIFIER", 95, 105], ["non-infectious", "OBSERVATION_MODIFIER", 110, 124]]], ["1 Excluding infection is important in order to improve management of noninfectious aetiologies.", [["infection", "DISEASE", 12, 21], ["infection", "PROBLEM", 12, 21], ["noninfectious aetiologies", "PROBLEM", 69, 94], ["infection", "OBSERVATION", 12, 21], ["noninfectious", "OBSERVATION", 69, 82]]], ["Bronchoscopy with bronchoalveolar lavage (BAL) has improved the ability to detect infection in immunosuppressed patients, 2,3 but the timing and frequency of its use is often subject to variable institutional policies.", [["bronchoalveolar lavage", "ANATOMY", 18, 40], ["BAL", "ANATOMY", 42, 45], ["infection", "DISEASE", 82, 91], ["bronchoalveolar lavage", "MULTI-TISSUE_STRUCTURE", 18, 40], ["patients", "ORGANISM", 112, 120], ["patients", "SPECIES", 112, 120], ["Bronchoscopy", "TEST", 0, 12], ["bronchoalveolar lavage", "TEST", 18, 40], ["infection", "PROBLEM", 82, 91], ["bronchoalveolar lavage", "OBSERVATION", 18, 40], ["infection", "OBSERVATION", 82, 91]]], ["Patients who are too ill to undergo a BAL require alternative diagnostic strategies.INTRODUCTIONImmunosuppressed patients are at increased risk for more severe disease from respiratory viruses.", [["BAL", "ANATOMY", 38, 41], ["respiratory viruses", "DISEASE", 173, 192], ["Patients", "ORGANISM", 0, 8], ["patients", "ORGANISM", 113, 121], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 113, 121], ["a BAL", "TEST", 36, 41], ["alternative diagnostic strategies", "TREATMENT", 50, 83], ["more severe disease", "PROBLEM", 148, 167], ["respiratory viruses", "PROBLEM", 173, 192], ["severe", "OBSERVATION_MODIFIER", 153, 159], ["disease", "OBSERVATION", 160, 167], ["respiratory viruses", "OBSERVATION", 173, 192]]], ["[4] [5] [6] The incidence of lower respiratory tract viral infections is difficult to accurately identify because of varying diagnostic techniques, seasonal and geographic variations in viral infection, 7, 8 the lack of specific symptoms and radiographical findings, 9 and the fact that many viruses are difficult to culture ex vivo.", [["lower respiratory tract", "ANATOMY", 29, 52], ["respiratory tract viral infections", "DISEASE", 35, 69], ["viral infection", "DISEASE", 186, 201], ["lower", "ORGANISM_SUBDIVISION", 29, 34], ["respiratory tract", "ORGANISM_SUBDIVISION", 35, 52], ["lower respiratory tract viral infections", "PROBLEM", 29, 69], ["varying diagnostic techniques", "PROBLEM", 117, 146], ["seasonal and geographic variations in viral infection", "PROBLEM", 148, 201], ["specific symptoms", "PROBLEM", 220, 237], ["radiographical findings", "TEST", 242, 265], ["many viruses", "PROBLEM", 287, 299], ["lower", "ANATOMY_MODIFIER", 29, 34], ["respiratory tract", "ANATOMY", 35, 52], ["viral infections", "OBSERVATION", 53, 69], ["viral infection", "OBSERVATION", 186, 201], ["many", "OBSERVATION_MODIFIER", 287, 291], ["viruses", "OBSERVATION", 292, 299]]], ["10 Multiplex PCR testing can identify up to 15 respiratory viruses and three atypical bacteria.", [["respiratory viruses", "DISEASE", 47, 66], ["Multiplex PCR testing", "TEST", 3, 24], ["15 respiratory viruses", "PROBLEM", 44, 66], ["three atypical bacteria", "PROBLEM", 71, 94], ["atypical", "OBSERVATION_MODIFIER", 77, 85], ["bacteria", "OBSERVATION", 86, 94]]], ["4 The detection rate of symptomatic lower respiratory tract viral infections on BAL fluid has been reported to be as low as 3% using culture 11 and up to 12% via PCR.", [["lower respiratory tract", "ANATOMY", 36, 59], ["BAL fluid", "ANATOMY", 80, 89], ["respiratory tract viral infections", "DISEASE", 42, 76], ["lower respiratory", "ORGANISM_SUBDIVISION", 36, 53], ["tract", "ORGANISM_SUBDIVISION", 54, 59], ["BAL fluid", "ORGANISM_SUBSTANCE", 80, 89], ["The detection rate", "TEST", 2, 20], ["symptomatic lower respiratory tract viral infections", "PROBLEM", 24, 76], ["BAL fluid", "TEST", 80, 89], ["culture", "TEST", 133, 140], ["PCR", "TEST", 162, 165], ["symptomatic", "OBSERVATION_MODIFIER", 24, 35], ["lower", "OBSERVATION_MODIFIER", 36, 41], ["respiratory tract", "ANATOMY", 42, 59]]], ["12 Importantly, identification of respiratory viruses on PCR does not always indicate active infection.", [["respiratory viruses", "DISEASE", 34, 53], ["infection", "DISEASE", 93, 102], ["respiratory viruses", "PROBLEM", 34, 53], ["PCR", "TEST", 57, 60], ["active infection", "PROBLEM", 86, 102], ["respiratory viruses", "OBSERVATION", 34, 53], ["not always indicate", "UNCERTAINTY", 66, 85], ["active", "OBSERVATION_MODIFIER", 86, 92], ["infection", "OBSERVATION", 93, 102]]], ["There is often some uncertainty in the clinical significance of detection of certain viruses, such as rhinovirus, in the lower respiratory tract.", [["lower respiratory tract", "ANATOMY", 121, 144], ["rhinovirus", "ORGANISM", 102, 112], ["lower", "ORGANISM_SUBDIVISION", 121, 126], ["respiratory tract", "ORGANISM_SUBDIVISION", 127, 144], ["certain viruses", "PROBLEM", 77, 92], ["rhinovirus", "PROBLEM", 102, 112], ["some", "OBSERVATION_MODIFIER", 15, 19], ["uncertainty", "OBSERVATION_MODIFIER", 20, 31], ["viruses", "OBSERVATION", 85, 92], ["rhinovirus", "OBSERVATION", 102, 112], ["lower", "ANATOMY_MODIFIER", 121, 126], ["respiratory tract", "ANATOMY", 127, 144]]], ["13 Nasopharyngeal (NP) respiratory viral panel-PCR (RVP-PCR) can non-invasively detect viral infections.", [["Nasopharyngeal", "ANATOMY", 3, 17], ["viral infections", "DISEASE", 87, 103], ["Nasopharyngeal (NP) respiratory viral panel", "TEST", 3, 46], ["PCR", "TEST", 47, 50], ["RVP", "TEST", 52, 55], ["PCR", "TEST", 56, 59], ["viral infections", "PROBLEM", 87, 103], ["Nasopharyngeal", "ANATOMY", 3, 17], ["viral", "OBSERVATION_MODIFIER", 87, 92], ["infections", "OBSERVATION", 93, 103]]], ["14 There are sparse data on the ability of NP RVP-PCR to identify lower respiratory tract disease in immunosuppressed patients.", [["lower respiratory tract", "ANATOMY", 66, 89], ["respiratory tract disease", "DISEASE", 72, 97], ["lower", "ORGANISM_SUBDIVISION", 66, 71], ["respiratory tract", "ORGANISM_SUBDIVISION", 72, 89], ["patients", "ORGANISM", 118, 126], ["patients", "SPECIES", 118, 126], ["NP RVP", "TEST", 43, 49], ["PCR", "TEST", 50, 53], ["lower respiratory tract disease", "PROBLEM", 66, 97], ["immunosuppressed patients", "TREATMENT", 101, 126], ["sparse", "OBSERVATION_MODIFIER", 13, 19], ["lower", "ANATOMY_MODIFIER", 66, 71], ["respiratory tract", "ANATOMY", 72, 89], ["immunosuppressed", "OBSERVATION", 101, 117]]], ["Two studies reported differing false negative NP rates, 3 of 72 (4%) patients 15 compared with 17 of 81 (21%) patients.", [["patients", "ORGANISM", 69, 77], ["patients", "ORGANISM", 110, 118], ["patients", "SPECIES", 69, 77], ["patients", "SPECIES", 110, 118], ["Two studies", "TEST", 0, 11], ["NP rates", "TEST", 46, 54]]], ["16 Many clinical decisions, including antibiotic choices and whether to pursue BAL are based on initial NP RVP-PCR testing.", [["BAL", "ANATOMY", 79, 82], ["antibiotic choices", "TREATMENT", 38, 56], ["BAL", "TEST", 79, 82], ["initial NP RVP", "TEST", 96, 110], ["PCR testing", "TEST", 111, 122]]], ["Therefore, it is important to know the testing characteristics of NP RVP-PCR and its ability to identify lower respiratory tract disease.INTRODUCTIONIn this study, we aimed to better characterize NP RVP-PCR in comparison with BAL RVP-PCR testing by determining positive and negative predictive values, sensitivity, specificity and the false negative rate.", [["lower respiratory tract", "ANATOMY", 105, 128], ["respiratory tract disease", "DISEASE", 111, 136], ["lower", "ORGANISM_SUBDIVISION", 105, 110], ["respiratory tract", "ORGANISM_SUBDIVISION", 111, 128], ["NP RVP", "TEST", 66, 72], ["PCR", "TEST", 73, 76], ["lower respiratory tract disease", "PROBLEM", 105, 136], ["this study", "TEST", 152, 162], ["NP RVP", "TEST", 196, 202], ["PCR", "TEST", 203, 206], ["BAL RVP", "TEST", 226, 233], ["PCR testing", "TEST", 234, 245], ["sensitivity", "TEST", 302, 313], ["lower", "ANATOMY_MODIFIER", 105, 110], ["respiratory tract", "ANATOMY", 111, 128]]], ["17 We also determined whether there were any clinical variables that were significantly associated with a positive BAL RVP-PCR as well as determine the importance of the seasonal variability on RVP-PCR testing.", [["a positive BAL RVP", "PROBLEM", 104, 122], ["PCR", "TEST", 123, 126], ["the seasonal variability", "PROBLEM", 166, 190], ["RVP", "TEST", 194, 197], ["PCR testing", "TEST", 198, 209]]], ["Finally, we evaluated whether additional pathogens were identified in BAL fluid in patients who had NP testing.Patient testingWe conducted a retrospective chart review that evaluated immunosuppressed adults who underwent bronchoscopy in the Pulmonary Department at the University of Rochester Medical Center between January 2011 and June 2016.", [["BAL fluid", "ANATOMY", 70, 79], ["BAL fluid", "ORGANISM_SUBSTANCE", 70, 79], ["patients", "ORGANISM", 83, 91], ["adults", "ORGANISM", 200, 206], ["patients", "SPECIES", 83, 91], ["Patient", "SPECIES", 111, 118], ["additional pathogens", "PROBLEM", 30, 50], ["BAL fluid", "TEST", 70, 79], ["NP testing", "TEST", 100, 110], ["bronchoscopy", "TREATMENT", 221, 233], ["Pulmonary", "ANATOMY", 241, 250]]], ["Patients were included if they had a paired NP swab performed within 7 days prior to bronchoscopy.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["a paired NP swab", "TEST", 35, 51], ["bronchoscopy", "TEST", 85, 97]]], ["All patients underwent BAL because of concern for lower respiratory tract infection based on imaging and symptoms.", [["BAL", "ANATOMY", 23, 26], ["lower respiratory tract", "ANATOMY", 50, 73], ["respiratory tract infection", "DISEASE", 56, 83], ["patients", "ORGANISM", 4, 12], ["lower", "ORGANISM_SUBDIVISION", 50, 55], ["respiratory tract", "ORGANISM_SUBDIVISION", 56, 73], ["patients", "SPECIES", 4, 12], ["BAL", "TREATMENT", 23, 26], ["lower respiratory tract infection", "PROBLEM", 50, 83], ["imaging", "TEST", 93, 100], ["symptoms", "PROBLEM", 105, 113], ["lower", "ANATOMY_MODIFIER", 50, 55], ["respiratory tract", "ANATOMY", 56, 73], ["infection", "OBSERVATION", 74, 83]]], ["NP and BAL samples were analysed using FilmArray (Biofire Diagnostic Inc, Salt Lake City, UT, USA) multiplex PCR which detects adenovirus, coronavirus (four strains), human metapneumovirus, rhinovirus/enterovirus, influenza A (three strains), influenza B, respiratory syncytial virus (A and B), parainfluenza 1-4, Mycoplasma pneumoniae, Chlamydia pneumoniae and Bordetella pertussis.", [["BAL samples", "ANATOMY", 7, 18], ["human metapneumovirus", "DISEASE", 167, 188], ["rhinovirus/enterovirus", "DISEASE", 190, 212], ["influenza A", "DISEASE", 214, 225], ["influenza B", "DISEASE", 243, 254], ["respiratory syncytial virus", "DISEASE", 256, 283], ["parainfluenza 1-4,", "CHEMICAL", 295, 313], ["Mycoplasma pneumoniae", "DISEASE", 314, 335], ["Chlamydia pneumoniae", "DISEASE", 337, 357], ["Bordetella pertussis", "DISEASE", 362, 382], ["BAL samples", "CANCER", 7, 18], ["adenovirus", "ORGANISM", 127, 137], ["coronavirus", "ORGANISM", 139, 150], ["human", "ORGANISM", 167, 172], ["metapneumovirus", "ORGANISM", 173, 188], ["rhinovirus", "ORGANISM", 190, 200], ["enterovirus", "ORGANISM", 201, 212], ["influenza A", "ORGANISM", 214, 225], ["influenza B", "ORGANISM", 243, 254], ["respiratory syncytial virus", "ORGANISM", 256, 283], ["A and B", "ORGANISM", 285, 292], ["parainfluenza 1-4", "ORGANISM", 295, 312], ["Mycoplasma pneumoniae", "ORGANISM", 314, 335], ["Chlamydia pneumoniae", "ORGANISM", 337, 357], ["Bordetella pertussis", "ORGANISM", 362, 382], ["human", "SPECIES", 167, 172], ["metapneumovirus", "SPECIES", 173, 188], ["influenza B", "SPECIES", 243, 254], ["respiratory syncytial virus", "SPECIES", 256, 283], ["parainfluenza 1-4", "SPECIES", 295, 312], ["Mycoplasma pneumoniae", "SPECIES", 314, 335], ["Chlamydia pneumoniae", "SPECIES", 337, 357], ["Bordetella pertussis", "SPECIES", 362, 382], ["human metapneumovirus", "SPECIES", 167, 188], ["influenza A", "SPECIES", 214, 225], ["respiratory syncytial virus", "SPECIES", 256, 283], ["A", "SPECIES", 285, 286], ["Mycoplasma pneumoniae", "SPECIES", 314, 335], ["Chlamydia pneumoniae", "SPECIES", 337, 357], ["Bordetella pertussis", "SPECIES", 362, 382], ["BAL samples", "TEST", 7, 18], ["FilmArray", "TEST", 39, 48], ["multiplex PCR", "TEST", 99, 112], ["adenovirus", "PROBLEM", 127, 137], ["coronavirus", "PROBLEM", 139, 150], ["human metapneumovirus", "PROBLEM", 167, 188], ["rhinovirus", "PROBLEM", 190, 200], ["enterovirus", "PROBLEM", 201, 212], ["influenza", "PROBLEM", 214, 223], ["influenza B", "PROBLEM", 243, 254], ["respiratory syncytial virus", "PROBLEM", 256, 283], ["parainfluenza", "PROBLEM", 295, 308], ["Mycoplasma pneumoniae", "PROBLEM", 314, 335], ["Chlamydia pneumoniae", "PROBLEM", 337, 357], ["Bordetella pertussis", "PROBLEM", 362, 382], ["BAL", "ANATOMY", 7, 10], ["metapneumovirus", "OBSERVATION", 173, 188], ["respiratory syncytial", "ANATOMY", 256, 277], ["Mycoplasma pneumoniae", "OBSERVATION", 314, 335], ["Chlamydia pneumoniae", "OBSERVATION", 337, 357]]], ["Accepted culturing and PCR techniques were performed in our microbiology laboratory for bacterial, fungal and viral identification.Patient testingDemographic, clinical and microbiological data were collected.", [["Patient", "SPECIES", 131, 138], ["culturing", "TEST", 9, 18], ["PCR techniques", "TEST", 23, 37], ["bacterial, fungal and viral identification", "PROBLEM", 88, 130], ["Patient testing", "TEST", 131, 146], ["microbiological data", "TEST", 172, 192]]], ["Characteristics thought to be associated with viral infection included fever, cough, dyspnoea, hypoxia, leucopenia, lymphopenia and ground glass opacities on imaging (oedema).", [["viral infection", "DISEASE", 46, 61], ["fever", "DISEASE", 71, 76], ["cough", "DISEASE", 78, 83], ["dyspnoea", "DISEASE", 85, 93], ["hypoxia", "DISEASE", 95, 102], ["leucopenia", "DISEASE", 104, 114], ["lymphopenia", "DISEASE", 116, 127], ["oedema", "DISEASE", 167, 173], ["oedema", "PATHOLOGICAL_FORMATION", 167, 173], ["viral infection", "PROBLEM", 46, 61], ["fever", "PROBLEM", 71, 76], ["cough", "PROBLEM", 78, 83], ["dyspnoea", "PROBLEM", 85, 93], ["hypoxia", "PROBLEM", 95, 102], ["leucopenia", "PROBLEM", 104, 114], ["lymphopenia", "PROBLEM", 116, 127], ["ground glass opacities", "PROBLEM", 132, 154], ["imaging", "TEST", 158, 165], ["oedema", "PROBLEM", 167, 173], ["thought to be associated with", "UNCERTAINTY", 16, 45], ["viral", "OBSERVATION_MODIFIER", 46, 51], ["infection", "OBSERVATION", 52, 61], ["cough", "OBSERVATION", 78, 83], ["dyspnoea", "OBSERVATION", 85, 93], ["hypoxia", "OBSERVATION_MODIFIER", 95, 102], ["leucopenia", "OBSERVATION", 104, 114], ["lymphopenia", "OBSERVATION", 116, 127], ["ground glass opacities", "OBSERVATION", 132, 154], ["oedema", "OBSERVATION", 167, 173]]], ["18 Immunosuppression categories were defined as HIV/AIDS, haematological malignancy, solid organ transplantation or other immunosuppression (immunosuppressive chemotherapy, prednisone 40 mg daily, or two immunosuppressant agents).", [["haematological malignancy", "ANATOMY", 58, 83], ["organ", "ANATOMY", 91, 96], ["HIV/AIDS", "DISEASE", 48, 56], ["haematological malignancy", "DISEASE", 58, 83], ["prednisone", "CHEMICAL", 173, 183], ["prednisone", "CHEMICAL", 173, 183], ["organ", "ORGAN", 91, 96], ["prednisone", "SIMPLE_CHEMICAL", 173, 183], ["HIV", "SPECIES", 48, 51], ["HIV", "SPECIES", 48, 51], ["Immunosuppression categories", "TREATMENT", 3, 31], ["HIV/AIDS", "PROBLEM", 48, 56], ["haematological malignancy", "PROBLEM", 58, 83], ["solid organ transplantation", "TREATMENT", 85, 112], ["other immunosuppression", "TREATMENT", 116, 139], ["immunosuppressive chemotherapy", "TREATMENT", 141, 171], ["prednisone", "TREATMENT", 173, 183], ["two immunosuppressant agents", "TREATMENT", 200, 228], ["malignancy", "OBSERVATION", 73, 83]]], ["We defined winter and spring months as December through May for analysis of seasonal variability.Statistical analysisPositive predictive value, negative predictive value, sensitivity, specificity and the false negative rate were calculated by comparing RVP-PCR testing on NP and BAL samples.", [["BAL samples", "ANATOMY", 279, 290], ["seasonal variability", "PROBLEM", 76, 96], ["the false negative rate", "TEST", 200, 223], ["RVP", "TEST", 253, 256], ["PCR testing", "TEST", 257, 268], ["NP", "TEST", 272, 274], ["BAL samples", "TEST", 279, 290], ["seasonal variability", "OBSERVATION", 76, 96]]], ["Linear and logistic regression analyses were performed to determine whether associations existed between clinical variables and BAL RVP-PCR results.", [["logistic regression analyses", "TEST", 11, 39], ["clinical variables", "TEST", 105, 123], ["BAL RVP", "TEST", 128, 135], ["PCR", "TEST", 136, 139]]], ["Multivariable analyses were performed using a manual stepwise addition of independent variables.", [["Multivariable analyses", "TEST", 0, 22], ["a manual stepwise", "TREATMENT", 44, 61]]], ["All analyses were performed using SAS version 9.4 (SAS Institute Inc., Cary, NC, USA) with statistical significance defined as P < 0.05.CharacteristicsThree hundred immunosuppressed patients underwent bronchoscopy between January 2011 and June 2016.", [["patients", "ORGANISM", 182, 190], ["patients", "SPECIES", 182, 190], ["All analyses", "TEST", 0, 12], ["SAS version", "TEST", 34, 45], ["bronchoscopy", "TREATMENT", 201, 213]]], ["Eighty-nine patients had both NP and BAL RVP-PCR testing.", [["patients", "ORGANISM", 12, 20], ["patients", "SPECIES", 12, 20], ["both NP", "TREATMENT", 25, 32], ["BAL RVP", "TEST", 37, 44], ["PCR testing", "TEST", 45, 56]]], ["Radiographical abnormalities were present in all the patients and seventy-eight patients had either cough or shortness of breath.", [["cough", "DISEASE", 100, 105], ["shortness of breath", "DISEASE", 109, 128], ["patients", "ORGANISM", 53, 61], ["patients", "ORGANISM", 80, 88], ["patients", "SPECIES", 53, 61], ["patients", "SPECIES", 80, 88], ["Radiographical abnormalities", "PROBLEM", 0, 28], ["cough", "PROBLEM", 100, 105], ["shortness of breath", "PROBLEM", 109, 128], ["cough", "OBSERVATION", 100, 105]]], ["Eleven patients had fever without respiratory symptoms.", [["respiratory", "ANATOMY", 34, 45], ["fever", "DISEASE", 20, 25], ["respiratory symptoms", "DISEASE", 34, 54], ["patients", "ORGANISM", 7, 15], ["patients", "SPECIES", 7, 15], ["fever", "PROBLEM", 20, 25], ["respiratory symptoms", "PROBLEM", 34, 54]]], ["The median duration of time from symptom onset to NP testing was 3 days (range: 0-21 days) and the median of time duration from NP testing to BAL was 2 days (range: 0-7 days).", [["BAL", "ANATOMY", 142, 145], ["symptom", "PROBLEM", 33, 40], ["NP testing", "TEST", 50, 60], ["NP testing", "TEST", 128, 138], ["BAL", "TEST", 142, 145]]], ["Seven different virus strains were identified in 31 patients (35% positivity) ( Table 2) .", [["patients", "ORGANISM", 52, 60], ["patients", "SPECIES", 52, 60], ["Seven different virus strains", "PROBLEM", 0, 29], ["virus strains", "OBSERVATION", 16, 29]]], ["Of the four patients with influenza virus detected on BAL, three had received the influenza vaccine.Positive and negative predictive values, sensitivity, specificity and false negativityThe positive and negative predictive values of NP RVP-PCR for concordant BAL RVP-PCR testing were 88% and 89%, respectively ( Table 2 ).", [["BAL", "ANATOMY", 259, 262], ["influenza virus", "DISEASE", 26, 41], ["patients", "ORGANISM", 12, 20], ["influenza virus", "ORGANISM", 26, 41], ["BAL", "ORGANISM_SUBSTANCE", 54, 57], ["patients", "SPECIES", 12, 20], ["influenza virus", "PROBLEM", 26, 41], ["BAL", "TEST", 54, 57], ["the influenza vaccine", "TREATMENT", 78, 99], ["sensitivity", "TEST", 141, 152], ["specificity", "TEST", 154, 165], ["false negativity", "TEST", 170, 186], ["NP RVP", "TEST", 233, 239], ["PCR", "TEST", 240, 243], ["concordant BAL RVP", "TEST", 248, 266], ["PCR testing", "TEST", 267, 278], ["influenza virus", "OBSERVATION", 26, 41], ["negative", "OBSERVATION_MODIFIER", 113, 121], ["predictive values", "OBSERVATION_MODIFIER", 122, 139]]], ["The sensitivity and specificity of NP RVP-PCR testing were 75% and 95%, respectively.", [["The sensitivity", "TEST", 0, 15], ["NP RVP", "TEST", 35, 41], ["PCR testing", "TEST", 42, 53]]], ["The false negative rate of NP RVP-PCR was only 8%.Concordant NP and BAL RVP-PCR testingOf the 89 patients who had paired NP-BAL RVP-PCR testing, 21 had concordant NP-positive BAL-positive (NP(+)BAL(+)) PCR testing.", [["BAL", "ANATOMY", 175, 178], ["patients", "ORGANISM", 97, 105], ["patients", "SPECIES", 97, 105], ["NP RVP", "TEST", 27, 33], ["PCR", "TEST", 34, 37], ["Concordant NP", "TEST", 50, 63], ["BAL RVP", "TEST", 68, 75], ["PCR testingOf", "TEST", 76, 89], ["paired NP", "TEST", 114, 123], ["BAL RVP", "TEST", 124, 131], ["PCR testing", "TEST", 132, 143], ["NP", "TEST", 163, 165], ["NP", "TEST", 189, 191], ["BAL", "TEST", 194, 197], ["PCR testing", "TEST", 202, 213], ["false", "OBSERVATION_MODIFIER", 4, 9], ["negative", "OBSERVATION", 10, 18]]], ["Fifty-eight patients had concordant NP(\u2212)BAL(\u2212) RVP-PCR testing.", [["patients", "ORGANISM", 12, 20], ["patients", "SPECIES", 12, 20], ["RVP", "TEST", 48, 51], ["PCR testing", "TEST", 52, 63]]], ["The total concordance was 89% (Table 2) .", [["The total concordance", "TEST", 0, 21]]], ["Viruses detected by PCR are listed in Table 2 .", [["Viruses", "PROBLEM", 0, 7]]], ["Patient characteristics for positive results are listed in Table 2 .Discordant NP and BAL RVP-PCR testingTen patients had discordant tests.", [["BAL", "ANATOMY", 86, 89], ["patients", "ORGANISM", 109, 117], ["Patient", "SPECIES", 0, 7], ["patients", "SPECIES", 109, 117], ["Discordant NP", "TEST", 68, 81], ["BAL RVP", "TEST", 86, 93], ["PCR testing", "TEST", 94, 105], ["discordant tests", "TEST", 122, 138]]], ["Seven (8%) patients had samples that were NP test negative but BAL test positive (NP(\u2212)BAL(+)).", [["samples", "ANATOMY", 24, 31], ["patients", "ORGANISM", 11, 19], ["patients", "SPECIES", 11, 19], ["samples", "TEST", 24, 31], ["NP test", "TEST", 42, 49], ["BAL test", "TEST", 63, 71], ["BAL", "TEST", 87, 90]]], ["The viruses identified only on BAL testing are also listed in Table 2 .", [["BAL", "ORGANISM_SUBSTANCE", 31, 34], ["The viruses", "PROBLEM", 0, 11], ["BAL testing", "TEST", 31, 42], ["viruses", "OBSERVATION", 4, 11]]], ["Five of the patients had haematological malignancy and two had other immunosuppression.", [["haematological malignancy", "ANATOMY", 25, 50], ["malignancy", "DISEASE", 40, 50], ["patients", "ORGANISM", 12, 20], ["haematological malignancy", "CANCER", 25, 50], ["patients", "SPECIES", 12, 20], ["haematological malignancy", "PROBLEM", 25, 50], ["other immunosuppression", "TREATMENT", 63, 86], ["malignancy", "OBSERVATION", 40, 50], ["immunosuppression", "OBSERVATION", 69, 86]]], ["Three patients (3%) had samples that were NP(+)BAL(\u2212), with coronavirus found twice and rhinovirus once.", [["samples", "ANATOMY", 24, 31], ["patients", "ORGANISM", 6, 14], ["coronavirus", "ORGANISM", 60, 71], ["rhinovirus", "ORGANISM", 88, 98], ["patients", "SPECIES", 6, 14], ["samples", "TEST", 24, 31], ["NP", "TEST", 42, 44], ["BAL", "TEST", 47, 50], ["coronavirus", "PROBLEM", 60, 71], ["rhinovirus", "PROBLEM", 88, 98]]], ["One patient had a haematological malignancy, one had a solid organ transplant and one had other immunosuppression.Discordant NP and BAL RVP-PCR testingInfluenza was missed on NP testing in two patients who had received allogeneic stem cell transplants.", [["haematological malignancy", "ANATOMY", 18, 43], ["organ", "ANATOMY", 61, 66], ["BAL", "ANATOMY", 132, 135], ["stem cell", "ANATOMY", 230, 239], ["malignancy", "DISEASE", 33, 43], ["Influenza", "DISEASE", 151, 160], ["patient", "ORGANISM", 4, 11], ["organ", "ORGAN", 61, 66], ["patients", "ORGANISM", 193, 201], ["stem cell", "CELL", 230, 239], ["patient", "SPECIES", 4, 11], ["patients", "SPECIES", 193, 201], ["a haematological malignancy", "PROBLEM", 16, 43], ["a solid organ transplant", "TREATMENT", 53, 77], ["other immunosuppression", "TREATMENT", 90, 113], ["Discordant NP", "TEST", 114, 127], ["BAL RVP", "TEST", 132, 139], ["PCR testing", "TEST", 140, 151], ["Influenza", "PROBLEM", 151, 160], ["NP testing", "TEST", 175, 185], ["allogeneic stem cell transplants", "TREATMENT", 219, 251], ["haematological", "ANATOMY", 18, 32], ["malignancy", "OBSERVATION", 33, 43], ["transplant", "OBSERVATION", 67, 77], ["immunosuppression", "OBSERVATION", 96, 113], ["allogeneic stem cell transplants", "OBSERVATION", 219, 251]]], ["Only one had received the influenza vaccine prior to bronchoscopy.", [["the influenza vaccine", "TREATMENT", 22, 43], ["bronchoscopy", "TEST", 53, 65]]], ["Rapid influenza testing was only checked in the patient who did not receive the vaccine and was negative.Discordant NP and BAL RVP-PCR testingClinical variables associated with a positive BAL RVP-PCR sample Unadjusted logistic regression analyses showed that allogeneic bone marrow transplantation and testing performed between December and May were significantly associated with increased odds of having a positive viral BAL RVP-PCR (OR = 3.3, 95% CI: 1.19-9.12; and OR = 4.62, 95% CI: 1.64-12.99, respectively) ( Table 3) .", [["BAL", "ANATOMY", 123, 126], ["bone marrow", "ANATOMY", 270, 281], ["patient", "ORGANISM", 48, 55], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 270, 281], ["patient", "SPECIES", 48, 55], ["Rapid influenza testing", "TEST", 0, 23], ["the vaccine", "TREATMENT", 76, 87], ["Discordant NP", "TEST", 105, 118], ["BAL RVP", "TEST", 123, 130], ["PCR testing", "TEST", 131, 142], ["a positive BAL RVP", "TEST", 177, 195], ["PCR sample", "TEST", 196, 206], ["logistic regression analyses", "TEST", 218, 246], ["allogeneic bone marrow transplantation", "TREATMENT", 259, 297], ["testing", "TEST", 302, 309], ["a positive viral BAL RVP", "PROBLEM", 405, 429], ["PCR", "TEST", 430, 433], ["CI", "TEST", 449, 451], ["OR", "TEST", 468, 470], ["CI", "TEST", 483, 485], ["influenza", "OBSERVATION", 6, 15], ["allogeneic bone marrow transplantation", "OBSERVATION", 259, 297]]], ["No associations were identified between positive BAL RVP-PCR and other groups or subsets of immunosuppression or other clinical variables (Table 3) .", [["positive BAL RVP", "TEST", 40, 56], ["PCR", "TEST", 57, 60], ["immunosuppression", "TREATMENT", 92, 109]]], ["Multivariable logistic regression analyses demonstrated that both season and allogeneic bone marrow transplantation were independently associated with increased odds of having a positive viral BAL RVP-PCR (OR = 3.73, 95% CI: 1.23-11.29; OR = 5.03, 95% CI: 1.70-14.86, respectively).Viral testing and BAL positivity based on the monthForty-nine patients had paired RVP-PCR testing performed between December and May.", [["bone marrow", "ANATOMY", 88, 99], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 88, 99], ["patients", "ORGANISM", 344, 352], ["patients", "SPECIES", 344, 352], ["Multivariable logistic regression analyses", "TEST", 0, 42], ["allogeneic bone marrow transplantation", "TREATMENT", 77, 115], ["a positive viral BAL RVP", "PROBLEM", 176, 200], ["PCR", "TEST", 201, 204], ["CI", "TEST", 221, 223], ["OR", "TEST", 237, 239], ["CI", "TEST", 252, 254], ["Viral testing", "TEST", 282, 295], ["BAL positivity", "TEST", 300, 314], ["paired RVP", "TEST", 357, 367], ["PCR testing", "TEST", 368, 379], ["allogeneic bone marrow transplantation", "OBSERVATION", 77, 115]]], ["Twenty-two (45%) were BAL RVP-PCR positive (see Figs S1, S2, Supplementary Information, for testing positivity and viruses detected by month).", [["BAL", "ANATOMY", 22, 25], ["BAL RVP", "TEST", 22, 29], ["PCR", "TEST", 30, 33], ["testing positivity", "TEST", 92, 110], ["viruses", "PROBLEM", 115, 122]]], ["Six had negative NP RVP-PCR testing.", [["NP RVP", "TEST", 17, 23], ["PCR testing", "TEST", 24, 35]]], ["Forty paired tests were performed between June and November.", [["Forty paired tests", "TEST", 0, 18]]], ["There were six (15%) positive BAL RVP-PCR tests.", [["BAL", "ANATOMY", 30, 33], ["positive BAL RVP", "TEST", 21, 37], ["PCR tests", "TEST", 38, 47]]], ["One of these patients had a negative NP RVP-PCR test.Organisms isolated from BALThere was no difference in the detection of non-viral organisms found on BAL between the positive or negative NP RVP-PCR groups (P = 0.48 for bacteria and P = 0.60 for fungal species) ( Table 4 ).", [["BAL", "ANATOMY", 153, 156], ["patients", "ORGANISM", 13, 21], ["BAL", "ORGANISM_SUBSTANCE", 153, 156], ["patients", "SPECIES", 13, 21], ["NP RVP", "TEST", 37, 43], ["PCR test", "TEST", 44, 52], ["Organisms", "PROBLEM", 53, 62], ["non-viral organisms", "PROBLEM", 124, 143], ["BAL", "TEST", 153, 156], ["P", "TEST", 209, 210], ["bacteria", "TEST", 222, 230], ["P", "TEST", 235, 236], ["fungal species", "PROBLEM", 248, 262]]], ["The NP-positive group had three patients (12.5%) in which five bacterial species were isolated, whereas the NP-negative group had five patients (8%) in which six bacterial species were isolated.", [["patients", "ORGANISM", 32, 40], ["patients", "ORGANISM", 135, 143], ["patients", "SPECIES", 32, 40], ["patients", "SPECIES", 135, 143], ["The NP", "TEST", 0, 6], ["five bacterial species", "PROBLEM", 58, 80], ["the NP", "TEST", 104, 110], ["six bacterial species", "PROBLEM", 158, 179], ["bacterial species", "OBSERVATION", 63, 80], ["bacterial species", "OBSERVATION", 162, 179]]], ["In patients who had positive NP RVP-PCR testing, six patients (25%) had fungal species identified on BAL testing.", [["BAL", "ANATOMY", 101, 104], ["patients", "ORGANISM", 3, 11], ["patients", "ORGANISM", 53, 61], ["patients", "SPECIES", 3, 11], ["patients", "SPECIES", 53, 61], ["positive NP RVP", "PROBLEM", 20, 35], ["PCR testing", "TEST", 36, 47], ["fungal species", "PROBLEM", 72, 86], ["BAL testing", "TEST", 101, 112], ["fungal species", "OBSERVATION", 72, 86]]], ["In patients who had negative NP RVP-PCR testing, 20 patients (31%) had fungal species identified on BAL testing.DISCUSSIONImmunosuppressed patients are at risk for severe disease from respiratory viral infections.", [["BAL", "ANATOMY", 100, 103], ["respiratory viral infections", "DISEASE", 184, 212], ["patients", "ORGANISM", 3, 11], ["patients", "ORGANISM", 52, 60], ["patients", "ORGANISM", 139, 147], ["patients", "SPECIES", 3, 11], ["patients", "SPECIES", 52, 60], ["patients", "SPECIES", 139, 147], ["NP RVP", "TEST", 29, 35], ["PCR testing", "TEST", 36, 47], ["fungal species", "PROBLEM", 71, 85], ["BAL testing", "TEST", 100, 111], ["severe disease", "PROBLEM", 164, 178], ["respiratory viral infections", "PROBLEM", 184, 212], ["fungal species", "OBSERVATION", 71, 85], ["severe", "OBSERVATION_MODIFIER", 164, 170], ["disease", "OBSERVATION", 171, 178], ["respiratory", "ANATOMY", 184, 195], ["viral infections", "OBSERVATION", 196, 212]]], ["[4] [5] [6] Multiplex PCR has increased the detection of viruses but its role in the management of immunosuppressed patients remains unclear.", [["immunosuppressed", "DISEASE", 99, 115], ["patients", "ORGANISM", 116, 124], ["patients", "SPECIES", 116, 124], ["Multiplex PCR", "TEST", 12, 25], ["viruses", "PROBLEM", 57, 64], ["viruses", "OBSERVATION", 57, 64], ["immunosuppressed", "OBSERVATION", 99, 115]]], ["Our study was designed to better characterize the role of RVP-PCR in the diagnosis of viral infections in this vulnerable population.", [["viral infections", "DISEASE", 86, 102], ["Our study", "TEST", 0, 9], ["RVP", "TEST", 58, 61], ["PCR", "TEST", 62, 65], ["viral infections", "PROBLEM", 86, 102], ["viral", "OBSERVATION_MODIFIER", 86, 91], ["infections", "OBSERVATION", 92, 102]]], ["We found that RVP-PCR testing on NP samples has a high positive and negative predictive value of 88% and 89%, respectively, compared with BAL RVP-PCR testing.", [["NP samples", "ANATOMY", 33, 43], ["NP samples", "CANCER", 33, 43], ["RVP", "TEST", 14, 17], ["PCR testing", "TEST", 18, 29], ["NP samples", "TEST", 33, 43], ["BAL RVP", "TEST", 138, 145], ["PCR testing", "TEST", 146, 157]]], ["The overall concordance of NP and BAL RVP-PCR testing was 89% with a low false negativity rate of 8%.", [["NP", "TEST", 27, 29], ["BAL RVP", "TEST", 34, 41], ["PCR testing", "TEST", 42, 53], ["a low false negativity rate", "PROBLEM", 67, 94]]], ["This suggests that NP RVP-PCR testing is sufficient in diagnosing or excluding the most lower respiratory tract viral infections, and could be helpful when a patient is clinically unstable and cannot undergo bronchoscopy.", [["respiratory tract viral infections", "DISEASE", 94, 128], ["patient", "ORGANISM", 158, 165], ["patient", "SPECIES", 158, 165], ["NP RVP", "TEST", 19, 25], ["PCR testing", "TEST", 26, 37], ["the most lower respiratory tract viral infections", "PROBLEM", 79, 128], ["clinically unstable", "PROBLEM", 169, 188], ["bronchoscopy", "TEST", 208, 220], ["lower", "ANATOMY_MODIFIER", 88, 93], ["respiratory tract", "ANATOMY", 94, 111], ["viral infections", "OBSERVATION", 112, 128]]], ["There are limited data comparing positivity from multiplex PCR testing performed on both NP and BAL samples in immunosuppressed patients.", [["BAL samples", "ANATOMY", 96, 107], ["BAL samples", "CANCER", 96, 107], ["patients", "ORGANISM", 128, 136], ["patients", "SPECIES", 128, 136], ["multiplex PCR testing", "TEST", 49, 70], ["BAL samples", "TEST", 96, 107], ["immunosuppressed patients", "TREATMENT", 111, 136]]], ["Hakki et al. 15 reported detection of viruses in 25 of 72 patients (19 NP(+)BAL(+), 3 NP(+)BAL(\u2212) and 3 NP(\u2212)BAL(+)) yielding an overall positivity rate of 35%.", [["patients", "ORGANISM", 58, 66], ["patients", "SPECIES", 58, 66], ["viruses", "PROBLEM", 38, 45], ["NP", "TEST", 71, 73], ["BAL", "TEST", 76, 79], ["NP", "TEST", 86, 88], ["BAL", "TEST", 91, 94], ["BAL", "TEST", 109, 112], ["an overall positivity rate", "TEST", 126, 152]]], ["Azadeh et al. 16detected viruses in 35 of 81 patients (15 NP(+) BAL(+), 3 NP(+)BAL(\u2212) and 17(NP(\u2212)BAL(+)) yieldingan overall positivity rate of 43%.", [["BAL", "ANATOMY", 79, 82], ["patients", "ORGANISM", 45, 53], ["patients", "SPECIES", 45, 53], ["viruses", "TEST", 25, 32], ["NP", "TEST", 58, 60], ["BAL", "TEST", 64, 67], ["NP", "TEST", 93, 95], ["BAL", "TEST", 98, 101], ["overall positivity rate", "TEST", 117, 140]]], ["In this study, M. pneumoniae was only detected once in BAL fluid.", [["BAL fluid", "ANATOMY", 55, 64], ["M. pneumoniae", "ORGANISM", 15, 28], ["BAL fluid", "ORGANISM_SUBSTANCE", 55, 64], ["M. pneumoniae", "SPECIES", 15, 28], ["M. pneumoniae", "SPECIES", 15, 28], ["this study", "TEST", 3, 13], ["M. pneumoniae", "PROBLEM", 15, 28], ["BAL fluid", "TEST", 55, 64], ["pneumoniae", "OBSERVATION", 18, 28], ["BAL", "ANATOMY", 55, 58], ["fluid", "OBSERVATION", 59, 64]]], ["The overall concordance of NP and BAL testing reported by Hakki et al. 15 was significantly higher (92%) than that reported by Azadeh et al. (77%).", [["BAL testing", "TEST", 34, 45]]], ["16 However, in the subgroup of immunosuppressed patients (n = 61) reported by Azadeh et al. 16 the concordance was 82%, closer to the concordance rate reported by Hakki et al. 15 Our data show similar rates of viral positivity to both of the studies mentioned above.", [["immunosuppressed", "DISEASE", 31, 47], ["patients", "ORGANISM", 48, 56], ["patients", "SPECIES", 48, 56], ["Our data", "TEST", 179, 187], ["viral positivity", "PROBLEM", 210, 226], ["the studies", "TEST", 238, 249], ["immunosuppressed", "OBSERVATION", 31, 47], ["viral positivity", "OBSERVATION", 210, 226]]], ["In our study, 31 of 89 patients (35%) had positive viral PCR testing with an overall concordance of 89%.", [["patients", "ORGANISM", 23, 31], ["patients", "SPECIES", 23, 31], ["our study", "TEST", 3, 12], ["positive viral PCR testing", "PROBLEM", 42, 68], ["viral PCR", "OBSERVATION", 51, 60]]], ["We did not identify any of the atypical bacteria using PCR.detected viruses in 35 of 81 patients (15 NP(+) BAL(+), 3 NP(+)BAL(\u2212) and 17(NP(\u2212)BAL(+)) yieldingThe number of false negative NP RVP-PCR testing (NP(\u2212)BAL(+)) in our population was 7 patients (8%) which was significantly lower than the 17 patients (21%) reported by Azadeh et al. 16 The high false negative rate may have been due to several variables including the population of non-immunosuppressed patients, poor swabbing and handling technique, lower NP viral shedding, higher viral levels in the lower respiratory tract, seasonal variability of virus detection, treatment with neuraminidase inhibitors prior to testing for influenza or the presence of viral mutations.", [["lower respiratory tract", "ANATOMY", 560, 583], ["influenza", "DISEASE", 687, 696], ["patients", "ORGANISM", 88, 96], ["patients", "ORGANISM", 243, 251], ["patients", "ORGANISM", 299, 307], ["patients", "ORGANISM", 460, 468], ["lower", "ORGANISM_SUBDIVISION", 560, 565], ["respiratory tract", "ORGANISM_SUBDIVISION", 566, 583], ["patients", "SPECIES", 88, 96], ["patients", "SPECIES", 243, 251], ["patients", "SPECIES", 299, 307], ["patients", "SPECIES", 460, 468], ["the atypical bacteria", "PROBLEM", 27, 48], ["PCR", "TEST", 55, 58], ["viruses", "TEST", 68, 75], ["NP", "TEST", 101, 103], ["BAL", "TEST", 107, 110], ["NP", "TEST", 117, 119], ["BAL", "TEST", 122, 125], ["NP", "TEST", 136, 138], ["BAL", "TEST", 141, 144], ["NP RVP", "TEST", 186, 192], ["PCR testing", "TEST", 193, 204], ["BAL", "TEST", 211, 214], ["poor swabbing", "PROBLEM", 470, 483], ["handling technique", "TEST", 488, 506], ["lower NP viral shedding", "PROBLEM", 508, 531], ["higher viral levels in the lower respiratory tract", "PROBLEM", 533, 583], ["virus detection", "TREATMENT", 609, 624], ["neuraminidase inhibitors", "TREATMENT", 641, 665], ["testing", "TEST", 675, 682], ["influenza", "PROBLEM", 687, 696], ["viral mutations", "PROBLEM", 716, 731], ["atypical", "OBSERVATION_MODIFIER", 31, 39], ["bacteria", "OBSERVATION", 40, 48], ["viruses", "OBSERVATION", 68, 75], ["high", "OBSERVATION_MODIFIER", 347, 351], ["false negative rate", "OBSERVATION", 352, 371], ["viral", "OBSERVATION", 517, 522], ["viral levels", "OBSERVATION", 540, 552], ["lower", "ANATOMY_MODIFIER", 560, 565], ["respiratory tract", "ANATOMY", 566, 583], ["viral mutations", "OBSERVATION", 716, 731]]], ["19 If the majority of testing occurred in the summer and fall when there are fewer viruses circulating, there would be less of a chance for a virus to be found on BAL.", [["BAL", "ANATOMY", 163, 166], ["BAL", "ORGANISM_SUBSTANCE", 163, 166], ["testing", "TEST", 22, 29], ["fewer viruses circulating", "PROBLEM", 77, 102], ["a virus", "PROBLEM", 140, 147], ["BAL", "TEST", 163, 166]]], ["We used the same PCR testing as Azadeh et al. 16 with FilmArray (BioFire Diagnostics Inc), yet our findings were more similar to Hakki et al. 15 (4% false negative) who used xTAG analyser.", [["xTAG", "SIMPLE_CHEMICAL", 174, 178], ["xTAG", "PROTEIN", 174, 178], ["the same PCR testing", "TEST", 8, 28], ["Hakki et al.", "TEST", 129, 141], ["xTAG analyser", "TEST", 174, 187]]], ["This suggests that the brand of PCR testing does not necessarily influence the rate of PCR positivity.detected viruses in 35 of 81 patients (15 NP(+) BAL(+), 3 NP(+)BAL(\u2212) and 17(NP(\u2212)BAL(+)) yieldingIn our study, influenza was diagnosed four times through BAL.", [["influenza", "DISEASE", 214, 223], ["patients", "ORGANISM", 131, 139], ["influenza", "ORGANISM", 214, 223], ["patients", "SPECIES", 131, 139], ["the brand of PCR testing", "TEST", 19, 43], ["PCR positivity", "PROBLEM", 87, 101], ["viruses", "TEST", 111, 118], ["NP", "TEST", 144, 146], ["BAL", "TEST", 150, 153], ["BAL", "TEST", 184, 187], ["our study", "TEST", 203, 212], ["influenza", "PROBLEM", 214, 223], ["BAL", "TEST", 257, 260], ["viruses", "OBSERVATION", 111, 118]]], ["In two patients, influenza was detected on BAL but not NP testing.", [["BAL", "ANATOMY", 43, 46], ["influenza", "DISEASE", 17, 26], ["patients", "ORGANISM", 7, 15], ["influenza", "ORGANISM", 17, 26], ["BAL", "ORGANISM_SUBSTANCE", 43, 46], ["patients", "SPECIES", 7, 15], ["influenza", "PROBLEM", 17, 26], ["BAL", "TEST", 43, 46], ["NP testing", "TEST", 55, 65], ["influenza", "OBSERVATION", 17, 26]]], ["Azadeh et al. 16 also reported four patients in whom influenza was detected on BAL but not on NP testing.", [["influenza", "DISEASE", 53, 62], ["patients", "ORGANISM", 36, 44], ["BAL", "ORGANISM_SUBSTANCE", 79, 82], ["patients", "SPECIES", 36, 44], ["influenza", "PROBLEM", 53, 62], ["BAL", "TEST", 79, 82], ["NP testing", "TEST", 94, 104]]], ["This study, however, does not provide clinical or demographic data on these patients.", [["patients", "ORGANISM", 76, 84], ["patients", "SPECIES", 76, 84], ["This study", "TEST", 0, 10], ["demographic data", "TEST", 50, 66]]], ["The two patients in our study who had NP(\u2212)BAL(+) influenza had symptoms for less than 2 days and viral shedding in the upper respiratory tract should have been present.", [["upper respiratory tract", "ANATOMY", 120, 143], ["influenza", "DISEASE", 50, 59], ["patients", "ORGANISM", 8, 16], ["upper respiratory", "ORGANISM_SUBDIVISION", 120, 137], ["tract", "ORGANISM_SUBDIVISION", 138, 143], ["patients", "SPECIES", 8, 16], ["our study", "TEST", 20, 29], ["BAL", "TEST", 43, 46], ["influenza", "PROBLEM", 50, 59], ["symptoms", "PROBLEM", 64, 72], ["viral shedding in the upper respiratory tract", "PROBLEM", 98, 143], ["upper", "ANATOMY_MODIFIER", 120, 125], ["respiratory tract", "ANATOMY", 126, 143]]], ["20 False negative NP testing could again be due to variables mentioned above.", [["False negative NP testing", "TEST", 3, 28], ["negative", "OBSERVATION", 9, 17]]], ["The reason for the negative NP influenza testing in our patients remains unclear.detected viruses in 35 of 81 patients (15 NP(+) BAL(+), 3 NP(+)BAL(\u2212) and 17(NP(\u2212)BAL(+)) yieldingAnother important factor not addressed in the prior studies is the impact of influenza vaccination, which is recommended in immunosuppressed patients.", [["influenza", "DISEASE", 31, 40], ["patients", "ORGANISM", 56, 64], ["patients", "ORGANISM", 110, 118], ["patients", "ORGANISM", 320, 328], ["patients", "SPECIES", 56, 64], ["patients", "SPECIES", 110, 118], ["patients", "SPECIES", 320, 328], ["the negative NP influenza testing", "PROBLEM", 15, 48], ["viruses", "TEST", 90, 97], ["NP", "TEST", 123, 125], ["BAL", "TEST", 129, 132], ["NP", "TEST", 139, 141], ["BAL", "TEST", 144, 147], ["NP", "TEST", 158, 160], ["BAL", "TEST", 163, 166], ["the prior studies", "TEST", 221, 238], ["influenza vaccination", "TREATMENT", 256, 277], ["influenza", "OBSERVATION", 31, 40], ["viruses", "OBSERVATION", 90, 97]]], ["Influenza vaccination could potentially explain lower rates of viral shedding and thus false negative NP testing.", [["Influenza", "DISEASE", 0, 9], ["Influenza vaccination", "TREATMENT", 0, 21], ["viral shedding", "PROBLEM", 63, 77]]], ["Conversely, immunosuppressed patients are at risk for reduced immunogenicity 21 and thus may not be adequately protected from influenza infection.", [["influenza infection", "DISEASE", 126, 145], ["patients", "ORGANISM", 29, 37], ["patients", "SPECIES", 29, 37], ["reduced immunogenicity", "PROBLEM", 54, 76], ["influenza infection", "PROBLEM", 126, 145], ["immunosuppressed", "OBSERVATION", 12, 28], ["may not be", "UNCERTAINTY", 89, 99], ["influenza", "OBSERVATION", 126, 135]]], ["Three of the four patients diagnosed with influenza on BAL in our study had received the influenza vaccine prior to bronchoscopy.", [["influenza", "DISEASE", 42, 51], ["patients", "ORGANISM", 18, 26], ["patients", "SPECIES", 18, 26], ["influenza", "PROBLEM", 42, 51], ["BAL", "TREATMENT", 55, 58], ["our study", "TEST", 62, 71], ["the influenza vaccine", "TREATMENT", 85, 106], ["bronchoscopy", "TEST", 116, 128], ["influenza", "OBSERVATION", 42, 51]]], ["This finding would suggest that a high clinical suspicion for influenza should be maintained regardless of their immunization status and/or negative NP swab PCR testing.", [["influenza", "DISEASE", 62, 71], ["influenza", "PROBLEM", 62, 71], ["NP swab PCR testing", "TEST", 149, 168]]], ["Overall, 11 bacteria and 26 fungal samples were detected in BAL fluid.", [["samples", "ANATOMY", 35, 42], ["BAL fluid", "ANATOMY", 60, 69], ["BAL fluid", "ORGANISM_SUBSTANCE", 60, 69], ["11 bacteria", "PROBLEM", 9, 20], ["26 fungal samples", "TEST", 25, 42], ["BAL fluid", "TEST", 60, 69], ["11 bacteria", "OBSERVATION_MODIFIER", 9, 20], ["BAL fluid", "OBSERVATION", 60, 69]]], ["In patients who were NP positive, five bacterial species were identified in three patients and six fungal species were identified in six patients.", [["patients", "ORGANISM", 3, 11], ["patients", "ORGANISM", 82, 90], ["patients", "ORGANISM", 137, 145], ["patients", "SPECIES", 3, 11], ["patients", "SPECIES", 82, 90], ["patients", "SPECIES", 137, 145], ["NP positive", "PROBLEM", 21, 32], ["five bacterial species", "PROBLEM", 34, 56], ["six fungal species", "PROBLEM", 95, 113], ["bacterial species", "OBSERVATION", 39, 56], ["fungal species", "OBSERVATION", 99, 113]]], ["In patients who were NP negative, 6 bacterial species were identified in five patients and 16 fungal species, 13 being pneumocystis, were identified in 16 patients.", [["pneumocystis", "DISEASE", 119, 131], ["patients", "ORGANISM", 3, 11], ["patients", "ORGANISM", 78, 86], ["pneumocystis", "CANCER", 119, 131], ["patients", "ORGANISM", 155, 163], ["patients", "SPECIES", 3, 11], ["patients", "SPECIES", 78, 86], ["patients", "SPECIES", 155, 163], ["NP", "TEST", 21, 23], ["6 bacterial species", "PROBLEM", 34, 53], ["16 fungal species", "PROBLEM", 91, 108], ["pneumocystis", "PROBLEM", 119, 131], ["negative", "OBSERVATION", 24, 32], ["fungal species", "OBSERVATION", 94, 108], ["pneumocystis", "OBSERVATION", 119, 131]]], ["Four NP (\u2212) with Candida species only on culture were excluded from the table.", [["Candida species", "PROBLEM", 17, 32], ["culture", "TEST", 41, 48]]], ["The NP-positive group had two patients (rhinovirus and coronavirus) culture cytomegalovirus.", [["rhinovirus and coronavirus)", "DISEASE", 40, 67], ["cytomegalovirus", "DISEASE", 76, 91], ["patients", "ORGANISM", 30, 38], ["rhinovirus", "ORGANISM", 40, 50], ["coronavirus", "ORGANISM", 55, 66], ["cytomegalovirus", "ORGANISM", 76, 91], ["patients", "SPECIES", 30, 38], ["coronavirus", "SPECIES", 55, 66], ["The NP", "TEST", 0, 6], ["rhinovirus", "PROBLEM", 40, 50], ["coronavirus", "PROBLEM", 55, 66], ["culture cytomegalovirus", "TEST", 68, 91]]], ["The NP-negative group had three patients who were cytomegalovirus positive on viral culture and two patients who were positive for herpes simplex type 1 on viral culture.", [["herpes simplex type", "DISEASE", 131, 150], ["patients", "ORGANISM", 32, 40], ["cytomegalovirus", "ORGANISM", 50, 65], ["patients", "ORGANISM", 100, 108], ["herpes simplex type 1", "ORGANISM", 131, 152], ["patients", "SPECIES", 32, 40], ["patients", "SPECIES", 100, 108], ["herpes simplex", "SPECIES", 131, 145], ["The NP", "TEST", 0, 6], ["cytomegalovirus", "PROBLEM", 50, 65], ["viral culture", "TEST", 78, 91], ["herpes simplex type", "PROBLEM", 131, 150], ["viral culture", "TEST", 156, 169], ["cytomegalovirus", "OBSERVATION", 50, 65]]], ["Candida species were not thought to be pathologic in any of our patients..", [["Candida species", "ORGANISM", 0, 15], ["patients", "ORGANISM", 64, 72], ["patients", "SPECIES", 64, 72], ["Candida species", "PROBLEM", 0, 15], ["not thought to be", "UNCERTAINTY", 21, 38]]], ["We observed an increase in the detection of viruses between December and May (45%) and lower detection (15%) in the summer and fall months.", [["viruses", "PROBLEM", 44, 51], ["lower detection", "TEST", 87, 102], ["increase", "OBSERVATION_MODIFIER", 15, 23]]], ["During winter, NP viral PCR testing is less helpful at ruling out viral infections as five out of seven NP(\u2212)BAL(+) tests were performed on samples obtained between February and April.", [["samples", "ANATOMY", 140, 147], ["viral infections", "DISEASE", 66, 82], ["NP viral PCR testing", "TEST", 15, 35], ["viral infections", "PROBLEM", 66, 82], ["BAL(+) tests", "TEST", 109, 121], ["samples", "TEST", 140, 147]]], ["Therefore, bronchoscopy with repeat viral testing should be strongly considered in the case of a negative NP RVP-PCR test performed in the winter or spring months.detected viruses in 35 of 81 patients (15 NP(+) BAL(+), 3 NP(+)BAL(\u2212) and 17(NP(\u2212)BAL(+)) yieldingCo-pathogens are common in immunosuppressed patients with pulmonary infiltrates.", [["pulmonary infiltrates", "ANATOMY", 319, 340], ["patients", "ORGANISM", 192, 200], ["patients", "ORGANISM", 305, 313], ["pulmonary infiltrates", "PATHOLOGICAL_FORMATION", 319, 340], ["patients", "SPECIES", 192, 200], ["patients", "SPECIES", 305, 313], ["bronchoscopy", "TEST", 11, 23], ["repeat viral testing", "TEST", 29, 49], ["NP RVP", "TEST", 106, 112], ["PCR test", "TEST", 113, 121], ["viruses", "TEST", 172, 179], ["NP", "TEST", 205, 207], ["BAL", "TEST", 211, 214], ["NP", "TEST", 221, 223], ["BAL", "TEST", 226, 229], ["NP", "TEST", 240, 242], ["BAL", "TEST", 245, 248], ["yieldingCo-pathogens", "PROBLEM", 253, 273], ["pulmonary infiltrates", "PROBLEM", 319, 340], ["viruses", "OBSERVATION", 172, 179], ["immunosuppressed", "OBSERVATION", 288, 304], ["pulmonary", "ANATOMY", 319, 328], ["infiltrates", "OBSERVATION", 329, 340]]], ["22 Hakki et al. 15 reported six patients (8%) who had a positive BAL RVP-PCR and also had additional pathogens detected, five bacteria and one galactomannan, suggestive of invasive aspergillosis.", [["invasive aspergillosis", "ANATOMY", 172, 194], ["aspergillosis", "DISEASE", 181, 194], ["patients", "ORGANISM", 32, 40], ["aspergillosis", "CANCER", 181, 194], ["patients", "SPECIES", 32, 40], ["a positive BAL RVP", "PROBLEM", 54, 72], ["PCR", "TEST", 73, 76], ["additional pathogens", "PROBLEM", 90, 110], ["five bacteria", "PROBLEM", 121, 134], ["one galactomannan", "TEST", 139, 156], ["invasive aspergillosis", "PROBLEM", 172, 194], ["suggestive of", "UNCERTAINTY", 158, 171], ["invasive", "OBSERVATION_MODIFIER", 172, 180], ["aspergillosis", "OBSERVATION", 181, 194]]], ["23 Azadeh et al. 16 reported seven immunosuppressed patients (11%) who had a positive NP PCR who also had additional pathogens detected in BAL samples.", [["BAL samples", "ANATOMY", 139, 150], ["patients", "ORGANISM", 52, 60], ["BAL samples", "CANCER", 139, 150], ["patients", "SPECIES", 52, 60], ["a positive NP PCR", "PROBLEM", 75, 92], ["additional pathogens", "PROBLEM", 106, 126], ["BAL samples", "TEST", 139, 150]]], ["Here, we report eight patients (9%) who had a positive NP PCR test who also had additional pathogens isolated from BAL samples (Table 4) .", [["BAL samples", "ANATOMY", 115, 126], ["patients", "ORGANISM", 22, 30], ["BAL samples", "CANCER", 115, 126], ["patients", "SPECIES", 22, 30], ["a positive NP PCR test", "PROBLEM", 44, 66], ["additional pathogens", "PROBLEM", 80, 100], ["BAL samples", "TEST", 115, 126]]], ["These findings suggest bronchoscopy should be considered even in patients with positive RVP-PCR from NP sampling.", [["patients", "ORGANISM", 65, 73], ["patients", "SPECIES", 65, 73], ["bronchoscopy", "TREATMENT", 23, 35], ["positive RVP", "PROBLEM", 79, 91], ["PCR", "TEST", 92, 95], ["NP sampling", "TEST", 101, 112], ["bronchoscopy", "OBSERVATION", 23, 35]]], ["Our data also support the use of bronchoscopy in patients with negative NP RVP-PCR testing as additional pathogens were identified in BAL fluid.detected viruses in 35 of 81 patients (15 NP(+) BAL(+), 3 NP(+)BAL(\u2212) and 17(NP(\u2212)BAL(+)) yieldingWe acknowledge that our study has limitations inherent to observational studies.", [["BAL fluid", "ANATOMY", 134, 143], ["patients", "ORGANISM", 49, 57], ["BAL fluid", "ORGANISM_SUBSTANCE", 134, 143], ["patients", "ORGANISM", 173, 181], ["patients", "SPECIES", 49, 57], ["patients", "SPECIES", 173, 181], ["bronchoscopy", "TEST", 33, 45], ["NP RVP", "TEST", 72, 78], ["PCR testing", "TEST", 79, 90], ["additional pathogens", "PROBLEM", 94, 114], ["BAL fluid", "TEST", 134, 143], ["viruses", "TEST", 153, 160], ["NP", "TEST", 186, 188], ["BAL", "TEST", 192, 195], ["BAL", "TEST", 226, 229], ["our study", "TEST", 262, 271], ["observational studies", "TEST", 300, 321], ["BAL fluid", "OBSERVATION", 134, 143], ["viruses", "OBSERVATION", 153, 160]]], ["There is a small sample size within each group, which limits our statistical power.", [["a small sample size", "PROBLEM", 9, 28], ["small", "OBSERVATION_MODIFIER", 11, 16], ["sample", "OBSERVATION_MODIFIER", 17, 23], ["size", "OBSERVATION_MODIFIER", 24, 28], ["each group", "OBSERVATION_MODIFIER", 36, 46]]], ["We had no way to standardize the timing of when samples were collected relative to symptom onset or why patients underwent repeat testing, as there was no protocol at our institution for timing or work-up of immunosuppressed patients with pulmonary infiltrates.", [["samples", "ANATOMY", 48, 55], ["pulmonary", "ANATOMY", 239, 248], ["immunosuppressed", "DISEASE", 208, 224], ["pulmonary infiltrates", "DISEASE", 239, 260], ["patients", "ORGANISM", 104, 112], ["patients", "ORGANISM", 225, 233], ["pulmonary infiltrates", "PATHOLOGICAL_FORMATION", 239, 260], ["patients", "SPECIES", 104, 112], ["patients", "SPECIES", 225, 233], ["repeat testing", "TEST", 123, 137], ["protocol", "TREATMENT", 155, 163], ["pulmonary infiltrates", "PROBLEM", 239, 260], ["pulmonary", "ANATOMY", 239, 248], ["infiltrates", "OBSERVATION", 249, 260]]], ["There is the possibility that NP sample collection was not adequate, which could have contributed to the false negative rate.", [["sample", "ANATOMY", 33, 39], ["NP sample collection", "PROBLEM", 30, 50], ["possibility", "UNCERTAINTY", 13, 24], ["negative rate", "OBSERVATION", 111, 124]]], ["Lastly, BAL return was highly variable which also may have affected viral PCR positivity.detected viruses in 35 of 81 patients (15 NP(+) BAL(+), 3 NP(+)BAL(\u2212) and 17(NP(\u2212)BAL(+)) yieldingIn conclusion, viral PCR testing performed on samples obtained from the nasopharynx has a high concordance with viral PCR testing performed on BAL samples with a low false negative rate.", [["BAL", "ANATOMY", 8, 11], ["samples", "ANATOMY", 233, 240], ["nasopharynx", "ANATOMY", 259, 270], ["BAL samples", "ANATOMY", 330, 341], ["BAL", "ORGANISM_SUBSTANCE", 8, 11], ["patients", "ORGANISM", 118, 126], ["nasopharynx", "ORGAN", 259, 270], ["BAL samples", "CANCER", 330, 341], ["patients", "SPECIES", 118, 126], ["BAL return", "TEST", 8, 18], ["affected viral PCR positivity", "PROBLEM", 59, 88], ["viruses", "TEST", 98, 105], ["NP", "TEST", 131, 133], ["BAL", "TEST", 137, 140], ["NP", "TEST", 147, 149], ["BAL", "TEST", 152, 155], ["NP", "TEST", 166, 168], ["BAL", "TEST", 171, 174], ["viral PCR testing", "TEST", 202, 219], ["samples", "TEST", 233, 240], ["viral PCR testing", "TEST", 299, 316], ["BAL samples", "TEST", 330, 341], ["a low false negative rate", "PROBLEM", 347, 372], ["viruses", "OBSERVATION", 98, 105], ["nasopharynx", "ANATOMY", 259, 270], ["negative rate", "OBSERVATION", 359, 372]]], ["However, NP testing is heavily reliant on proper collection technique and has variability in the detection of certain viruses.", [["NP testing", "TEST", 9, 19], ["proper collection technique", "TEST", 42, 69], ["the detection", "TEST", 93, 106], ["certain viruses", "PROBLEM", 110, 125], ["viruses", "OBSERVATION", 118, 125]]], ["Non-invasive testing using NP RVP-PCR should be used if bronchoscopy is unable to be performed and is a reliable test both for diagnosing and excluding viral infections.", [["viral infections", "DISEASE", 152, 168], ["Non-invasive testing", "TEST", 0, 20], ["NP RVP", "TREATMENT", 27, 33], ["PCR", "TEST", 34, 37], ["bronchoscopy", "TEST", 56, 68], ["a reliable test", "TEST", 102, 117], ["diagnosing", "TEST", 127, 137], ["viral infections", "PROBLEM", 152, 168], ["infections", "OBSERVATION", 158, 168]]], ["Relying on the negative predictive value of NP viral PCR in patients with low clinical suspicion of infection could lead to cost savings by avoiding duplicate RVP testing.", [["infection", "DISEASE", 100, 109], ["patients", "ORGANISM", 60, 68], ["patients", "SPECIES", 60, 68], ["NP viral PCR", "PROBLEM", 44, 56], ["infection", "PROBLEM", 100, 109], ["duplicate RVP testing", "TEST", 149, 170], ["infection", "OBSERVATION", 100, 109]]], ["However, BAL remains an important tool in the evaluation of infiltrates in immunosuppressed patients, particularly during the winter and spring months because of discordance in testing and the high rates of co-infection.", [["BAL", "ANATOMY", 9, 12], ["co-infection", "DISEASE", 207, 219], ["patients", "ORGANISM", 92, 100], ["patients", "SPECIES", 92, 100], ["BAL", "TEST", 9, 12], ["the evaluation", "TEST", 42, 56], ["infiltrates", "PROBLEM", 60, 71], ["testing", "TEST", 177, 184], ["co-infection", "PROBLEM", 207, 219], ["BAL", "OBSERVATION", 9, 12], ["infiltrates", "OBSERVATION", 60, 71], ["immunosuppressed", "OBSERVATION", 75, 91], ["co-infection", "OBSERVATION", 207, 219]]], ["Ultimately, accurate and timely diagnosis (or exclusion) of viral infections via RVP-PCR testing of either NP or BAL samples will likely have an important clinical impact on immunosuppressed patients both through the rapid initiation of antiviral therapy and careful antibiotic stewardship.", [["BAL samples", "ANATOMY", 113, 124], ["viral infections", "DISEASE", 60, 76], ["patients", "ORGANISM", 191, 199], ["patients", "SPECIES", 191, 199], ["viral infections", "PROBLEM", 60, 76], ["RVP", "TEST", 81, 84], ["PCR testing", "TEST", 85, 96], ["BAL samples", "TEST", 113, 124], ["immunosuppressed patients", "TREATMENT", 174, 199], ["antiviral therapy", "TREATMENT", 237, 254], ["careful antibiotic stewardship", "TREATMENT", 259, 289], ["viral", "OBSERVATION_MODIFIER", 60, 65], ["infections", "OBSERVATION", 66, 76], ["antiviral therapy", "OBSERVATION", 237, 254]]]], "d92f84536aa2094b52e5ea171256f589d0b9669c": [["IntroductionThe Severe Acute Respiratory Syndrome Coronavirus type 2 (SARS-CoV-2) pandemic of 2020 demonstrates the devastating effect an emerging virus can have.", [["Acute Respiratory Syndrome Coronavirus", "DISEASE", 23, 61], ["SARS-CoV-2", "ORGANISM", 70, 80], ["Severe Acute Respiratory Syndrome Coronavirus type 2 (SARS-CoV-2", "SPECIES", 16, 80], ["The Severe Acute Respiratory Syndrome Coronavirus type 2", "PROBLEM", 12, 68], ["CoV", "TEST", 75, 78], ["pandemic", "PROBLEM", 82, 90], ["the devastating effect", "PROBLEM", 112, 134], ["an emerging virus", "PROBLEM", 135, 152], ["Severe", "OBSERVATION_MODIFIER", 16, 22], ["Acute", "OBSERVATION_MODIFIER", 23, 28], ["Respiratory Syndrome", "OBSERVATION", 29, 49], ["devastating", "OBSERVATION_MODIFIER", 116, 127], ["virus", "OBSERVATION", 147, 152]]], ["Although previous pandemics such as the Spanish Flu (1918) and Asian Flu (1957) resulted in a multitude of fatal cases, the SARS-CoV-2 pandemic exhibits an unprecedented impact on public health, the economy and society as a whole.", [["Flu", "CHEMICAL", 48, 51], ["Flu", "CHEMICAL", 69, 72], ["SARS", "DISEASE", 124, 128], ["SARS-CoV-2", "ORGANISM", 124, 134], ["CoV-2 pandemic", "SPECIES", 129, 143], ["SARS-CoV", "SPECIES", 124, 132], ["the SARS", "TEST", 120, 128]]], ["Metagenomic Next-Generation Sequencing (mNGS) enables hypothesis-free sequencing of all nucleic acids in a given sample, including genomes of pathogens.", [["sample", "ANATOMY", 113, 119], ["nucleic acids", "CHEMICAL", 88, 101], ["Metagenomic Next-Generation Sequencing", "TREATMENT", 0, 38], ["all nucleic acids", "TREATMENT", 84, 101], ["pathogens", "PROBLEM", 142, 151], ["pathogens", "OBSERVATION", 142, 151]]], ["All sequences are amplified, followed by classification of sequences based on a reference database.", [["All sequences", "TEST", 0, 13], ["a reference database", "TEST", 78, 98]]], ["While research applications are more common, mNGS is being introduced in clinical diagnostic laboratories as indicated by recently diagnosed cases of encephalitis [6] .", [["encephalitis", "DISEASE", 150, 162], ["encephalitis", "PROBLEM", 150, 162], ["encephalitis", "OBSERVATION", 150, 162]]], ["Implementation of mNGS in clinical diagnostics requires validation of metagenomic protocols.", [["mNGS", "DNA", 18, 22], ["clinical diagnostics", "TEST", 26, 46], ["metagenomic protocols", "TREATMENT", 70, 91]]], ["Metagenomic protocols and pipelines have been successfully used for detection of known pathogens [6] [7] [8] .", [["Metagenomic protocols", "TREATMENT", 0, 21], ["pipelines", "TREATMENT", 26, 35], ["known pathogens", "PROBLEM", 81, 96]]], ["However, detection and identification of novel, J o u r n a l P r e -p r o o f previously unknown emerging viruses presents a challenge due to the absence of their genome sequences in reference databases.IntroductionIn this study, we validated the identification of emerging coronaviruses by a viral metagenomic protocol, using clinical samples with SARS-CoV-2, and samples spiked with cultivated isolates SARS-CoV Frankfurt-1 (SARS-CoV) and MERS-CoV EMC/2012 (MERS-CoV).", [["samples", "ANATOMY", 337, 344], ["samples", "ANATOMY", 366, 373], ["coronaviruses", "ORGANISM", 275, 288], ["SARS-CoV Frankfurt-1", "ORGANISM", 406, 426], ["SARS-CoV", "ORGANISM", 428, 436], ["MERS-CoV EMC", "ORGANISM", 442, 454], ["MERS-CoV", "ORGANISM", 461, 469], ["genome sequences", "DNA", 164, 180], ["SARS-CoV", "SPECIES", 350, 358], ["SARS-CoV Frankfurt-1", "SPECIES", 406, 426], ["SARS-CoV", "SPECIES", 428, 436], ["MERS-CoV EMC/2012 (MERS-CoV", "SPECIES", 442, 469], ["emerging viruses", "PROBLEM", 98, 114], ["this study", "TEST", 219, 229], ["emerging coronaviruses", "PROBLEM", 266, 288], ["a viral metagenomic protocol", "TREATMENT", 292, 320], ["clinical samples", "TEST", 328, 344], ["SARS", "TEST", 350, 354], ["CoV", "TEST", 355, 358], ["samples", "TEST", 366, 373], ["cultivated isolates SARS", "TEST", 386, 410], ["CoV Frankfurt", "TEST", 411, 424], ["SARS", "TEST", 428, 432], ["viruses", "OBSERVATION", 107, 114]]], ["Identification of coronaviruses was tested using modified databases lacking SARS-CoV-2, SARS-CoV, and MERS-CoV, mimicking the situation at the time of virus discovery.", [["coronaviruses", "ORGANISM", 18, 31], ["SARS-CoV-2", "ORGANISM", 76, 86], ["SARS-CoV", "ORGANISM", 88, 96], ["MERS-CoV", "ORGANISM", 102, 110], ["SARS-CoV", "SPECIES", 76, 84], ["SARS-CoV", "SPECIES", 88, 96], ["MERS-CoV", "SPECIES", 102, 110], ["coronaviruses", "PROBLEM", 18, 31], ["modified databases", "TEST", 49, 67], ["SARS", "TEST", 76, 80], ["CoV", "TEST", 81, 84], ["SARS", "TEST", 88, 92], ["CoV", "TEST", 93, 96], ["coronaviruses", "OBSERVATION", 18, 31]]], ["Additionally, the efficacy of detection of novel coronaviruses using capture probes targeting vertebrate viruses [10] [11] known before the current pandemic was analyzed using a SARS-CoV-2 clinical sample.Sample selection and preparationNasopharyngeal swabs were obtained from two patients who tested positive for SARS-CoV-2 by realtime PCR targeting the SARS-CoV-2 E-gene [12] with Cq values of 20 and 30, respectively.", [["Nasopharyngeal swabs", "ANATOMY", 237, 257], ["coronaviruses", "ORGANISM", 49, 62], ["Nasopharyngeal swabs", "ORGANISM_SUBSTANCE", 237, 257], ["patients", "ORGANISM", 281, 289], ["SARS-CoV-2 E-gene", "DNA", 355, 372], ["patients", "SPECIES", 281, 289], ["SARS-CoV", "SPECIES", 314, 322], ["SARS-CoV", "SPECIES", 355, 363], ["novel coronaviruses", "PROBLEM", 43, 62], ["capture probes targeting vertebrate viruses", "PROBLEM", 69, 112], ["a SARS", "TEST", 176, 182], ["CoV", "TEST", 183, 186], ["Sample selection", "TEST", 205, 221], ["Nasopharyngeal swabs", "TEST", 237, 257], ["SARS", "PROBLEM", 314, 318], ["CoV", "TEST", 319, 322], ["realtime PCR", "TEST", 328, 340], ["the SARS", "TEST", 351, 359], ["CoV", "TEST", 360, 363], ["Cq values", "TEST", 383, 392]]], ["These PCRs Library preparation and sequencing were performed using a previously validated protocol [15] [16].Sample selection and preparationBriefly, 200\u03bcl of patient samples were spiked with equine arteritis virus (EAV) and phocid herpesvirus-1 (PhHV-1) prior to NA extraction using the Magnapure 96 DNA and Viral NA Small volume extraction kit on the MagnaPure 96 system (Roche, Basel, Switzerland) resulting in 100\u03bcL nucleic acid-containing eluate.", [["samples", "ANATOMY", 167, 174], ["equine arteritis", "DISEASE", 192, 208], ["NA", "CHEMICAL", 264, 266], ["patient", "ORGANISM", 159, 166], ["equine arteritis virus", "ORGANISM", 192, 214], ["EAV", "ORGANISM", 216, 219], ["phocid herpesvirus-1", "ORGANISM", 225, 245], ["PhHV-1", "ORGANISM", 247, 253], ["DNA", "CELLULAR_COMPONENT", 301, 304], ["patient", "SPECIES", 159, 166], ["equine arteritis virus", "SPECIES", 192, 214], ["phocid herpesvirus-1", "SPECIES", 225, 245], ["equine arteritis virus", "SPECIES", 192, 214], ["EAV", "SPECIES", 216, 219], ["phocid herpesvirus-1 (PhHV-1", "SPECIES", 225, 253], ["Magnapure 96", "SPECIES", 288, 300], ["sequencing", "TEST", 35, 45], ["a previously validated protocol", "TREATMENT", 67, 98], ["Sample selection", "TEST", 109, 125], ["preparationBriefly", "TEST", 130, 148], ["patient samples", "TEST", 159, 174], ["equine arteritis virus", "PROBLEM", 192, 214], ["phocid herpesvirus", "TEST", 225, 243], ["PhHV", "TEST", 247, 251], ["NA extraction", "TREATMENT", 264, 277], ["the Magnapure", "TEST", 284, 297], ["Viral NA", "TEST", 309, 317], ["Small volume extraction", "TREATMENT", 318, 341]]], ["Of this eluate, 50\u03bcl per sample was used as input for the library prep, utilizing the NEBNext Ultra II Directional RNA Library prep kit for Illumina (New England Biolabs, Ipswich, MA, USA), dual indexed NEBNext Multiplex Oligos for Illumina (1.5\u00b5M), and a protocol optimized for processing RNA and DNA simultaneously in a single tube [15] .Sample selection and preparationLibrary preps of the samples where processed both with and without enrichment for viruses using sequence capture probes (see below).", [["samples", "ANATOMY", 393, 400], ["DNA", "CELLULAR_COMPONENT", 298, 301], ["the library prep", "TREATMENT", 54, 70], ["the NEBNext Ultra II", "TREATMENT", 82, 102], ["Illumina", "PROBLEM", 140, 148], ["dual indexed NEBNext Multiplex Oligos", "TREATMENT", 190, 227], ["Illumina", "PROBLEM", 232, 240], ["a protocol", "TREATMENT", 254, 264], ["processing RNA", "TREATMENT", 279, 293], ["a single tube", "TREATMENT", 320, 333], ["Sample selection", "TEST", 340, 356], ["the samples", "TEST", 389, 400], ["viruses", "PROBLEM", 454, 461], ["sequence capture probes", "TEST", 468, 491]]], ["Subsequent sequence analysis was performed using aSequence read classification: CentrifugeAfter quality pre-processing using an in-house QC pipeline, Biopet version 0.9.0 [17] and removal of human reads after mapping them to human reference genome GRCh38 [18] with Bowtie2 version 2.3.4 [19] , the remaining sequencing reads were taxonomically classified using Centrifuge 1.0.2-beta [20]In-house virus discovery protocolPre-processed short reads were de novo assembled into contigs using SPAdes version 3.10.1 [22] .", [["human", "ORGANISM", 191, 196], ["human", "ORGANISM", 225, 230], ["human reads", "DNA", 191, 202], ["human reference genome", "DNA", 225, 247], ["Bowtie2 version", "DNA", 265, 280], ["-processed short reads", "DNA", 423, 445], ["human", "SPECIES", 191, 196], ["human", "SPECIES", 225, 230], ["human", "SPECIES", 191, 196], ["human", "SPECIES", 225, 230], ["Subsequent sequence analysis", "TEST", 0, 28], ["Biopet version", "TREATMENT", 150, 164], ["removal of human reads", "TREATMENT", 180, 202], ["Bowtie2 version", "TEST", 265, 280], ["Centrifuge", "TEST", 361, 371], ["In-house virus discovery protocol", "TREATMENT", 387, 420], ["SPAdes version", "TEST", 488, 502]]], ["All contigs were analyzed using the NCBI Basic Local Alignment Search Tool (BLAST 2.8.1) [23] using the BLAST NCBI's nucleotide (nt) database (accessed April 2018).", [["nucleotide", "CHEMICAL", 117, 127], ["nucleotide", "CHEMICAL", 117, 127], ["the BLAST NCBI's nucleotide", "TREATMENT", 100, 127]]], ["Only viral hits for contigs with a length of \u2265500bp were selected to identify the best shared homology to viruses.", [["viral hits", "OBSERVATION", 5, 15]]], ["A length of 500bp was taken to ensure coverage of the built contigs by at least 3 reads, to rule out any possible contamination.", [["built contigs", "DNA", 54, 67], ["A length", "TEST", 0, 8], ["contamination", "PROBLEM", 114, 127]]], ["Only hits dated prior to 2020 genomes were considered to mimic the virus discovery setting for SARS-CoV-2.Genome Detective: commercial classification and discovery toolAfter extraction of human reads, FASTQ files generated for SARS-CoV-2 samples (with and without viral enrichment) were uploaded for classification and de novo assembly by the commercial webbased tool Genome Detective v1.120 (www.genomedetective.com, accessed 2020-05-11) [9] , using a reference database (generated 2019-09-21).", [["SARS", "DISEASE", 95, 99], ["SARS-CoV-2", "ORGANISM", 95, 105], ["human", "ORGANISM", 188, 193], ["2020 genomes", "DNA", 25, 37], ["human reads", "DNA", 188, 199], ["FASTQ files", "DNA", 201, 212], ["human", "SPECIES", 188, 193], ["SARS-CoV", "SPECIES", 95, 103], ["human", "SPECIES", 188, 193], ["SARS-CoV", "SPECIES", 227, 235], ["SARS", "PROBLEM", 95, 99], ["CoV", "TEST", 100, 103], ["FASTQ files", "TEST", 201, 212], ["SARS", "PROBLEM", 227, 231], ["CoV-2 samples", "TEST", 232, 245], ["viral enrichment", "PROBLEM", 264, 280]]], ["In brief, after removal of low-quality reads and trimming by Trimmomatic [24] , candidate viral reads were identified using the protein-based alignment method DIAMOND [25] in combination with the Swissprot UniRef90 protein database followed by de novo assembly using metaSPAdes [26] .", [["candidate viral reads", "DNA", 80, 101], ["Swissprot UniRef90 protein", "PROTEIN", 196, 222], ["removal", "TREATMENT", 16, 23], ["viral reads", "TEST", 90, 101], ["the protein-based alignment method DIAMOND", "TREATMENT", 124, 166], ["the Swissprot UniRef90 protein database", "TREATMENT", 192, 231]]], ["Blastx and Blastn [23] were used to search for candidate reference sequences using the NCBI RefSeq virus database (accessed 2019-09-21).Genome Detective: commercial classification and discovery toolConsensus sequences were produced by joining de novo contigs using Advanced Genome Aligner [27] .", [["NCBI RefSeq virus", "SPECIES", 87, 104], ["Blastx", "TEST", 0, 6]]], ["Classification results of viral reads are shown in Figure 1 andVirus discovery: de novo assemblyResults of de novo assembly of all samples for contigs longer than 500bp are shown in Table 2 .Virus discovery: de novo assemblyBLASTn was used to search for hits with sequence homology.", [["Virus", "ORGANISM", 191, 196], ["assemblyBLASTn", "DNA", 216, 230], ["viral reads", "TEST", 26, 37], ["all samples", "TEST", 127, 138]]], ["Only viral hits with the lowest E-value of all matches identified that were submitted before the publication of SARS-CoV-2 genomes were considered.", [["SARS", "DISEASE", 112, 116], ["E-value", "DNA", 32, 39], ["SARS-CoV-2 genomes", "DNA", 112, 130], ["SARS-CoV", "SPECIES", 112, 120], ["viral hits", "PROBLEM", 5, 15], ["SARS", "PROBLEM", 112, 116], ["CoV", "TEST", 117, 120], ["viral hits", "OBSERVATION", 5, 15]]], ["BLASTn search results of the contigs with Coronaviridae hits are listed in Table 2 including the length of the longest contig for each sample.", [["Coronaviridae hits", "DNA", 42, 60], ["BLASTn search", "TEST", 0, 13], ["Coronaviridae hits", "TREATMENT", 42, 60]]], ["Additional BLAST alignment figures of the longest contigs of both the SARS-CoV and MERS-CoV samples can be found in Supplementary Figure 1 and 2, respectively.Virus discovery of SARS-CoV-2 by GenomeDetectiveGenomeDetective results of identification of SARS-CoV-2 sequences using a database created before the emergence of SARS-CoV-2 are shown in Figure 2 .", [["SARS", "DISEASE", 70, 74], ["SARS", "DISEASE", 178, 182], ["SARS", "DISEASE", 252, 256], ["SARS", "DISEASE", 322, 326], ["SARS-CoV", "ORGANISM", 70, 78], ["MERS-CoV", "ORGANISM", 83, 91], ["SARS-CoV-2", "ORGANISM", 178, 188], ["SARS-CoV-2", "ORGANISM", 252, 262], ["SARS-CoV-2 sequences", "DNA", 252, 272], ["SARS-CoV", "SPECIES", 70, 78], ["MERS-CoV", "SPECIES", 83, 91], ["SARS-CoV", "SPECIES", 178, 186], ["SARS-CoV", "SPECIES", 252, 260], ["SARS-CoV", "SPECIES", 322, 330], ["the SARS", "TEST", 66, 74], ["CoV samples", "TEST", 88, 99], ["SARS", "PROBLEM", 178, 182], ["CoV", "TEST", 183, 186], ["SARS", "TEST", 252, 256], ["a database", "TEST", 279, 289], ["SARS", "TEST", 322, 326], ["CoV", "TEST", 327, 330], ["BLAST alignment", "OBSERVATION", 11, 26], ["SARS", "OBSERVATION", 70, 74]]], ["SARS-CoV-2 sequences were identified as SARS-CoV, with nucleotide and amino acid identity of 80-81% and 83-85% respectively in combination with up to 98% genome coverage, being indicative for a novel finding.Virus discovery using capture probesThe efficacy of a metagenomic sequencing protocol using capture probes targeting vertebrate virus sequences designed before the emergence of SARS-CoV-2, was studied in the context of virus discovery.", [["nucleotide", "CHEMICAL", 55, 65], ["amino acid", "CHEMICAL", 70, 80], ["SARS", "DISEASE", 385, 389], ["nucleotide", "CHEMICAL", 55, 65], ["amino acid", "CHEMICAL", 70, 80], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 0, 10], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 40, 48], ["amino acid", "AMINO_ACID", 70, 80], ["Virus", "ORGANISM", 208, 213], ["SARS-CoV-2", "ORGANISM", 385, 395], ["SARS-CoV-2 sequences", "DNA", 0, 20], ["SARS-CoV", "DNA", 40, 48], ["vertebrate virus sequences", "DNA", 325, 351], ["SARS-CoV", "SPECIES", 40, 48], ["SARS-CoV", "SPECIES", 385, 393], ["SARS-CoV-2 sequences", "TEST", 0, 20], ["SARS-CoV", "TEST", 40, 48], ["nucleotide", "TEST", 55, 65], ["amino acid identity", "TEST", 70, 89], ["capture probes", "TREATMENT", 230, 244], ["a metagenomic sequencing protocol", "TREATMENT", 260, 293], ["vertebrate virus sequences", "PROBLEM", 325, 351], ["SARS-CoV", "TEST", 385, 393], ["virus", "OBSERVATION", 427, 432]]], ["We analyzed metagenomic data from the two SARS-CoV-2 positive samples prepared both with and without viral enrichment.", [["samples", "ANATOMY", 62, 69], ["SARS-CoV", "SPECIES", 42, 50], ["metagenomic data", "TEST", 12, 28], ["the two SARS", "TEST", 34, 46], ["CoV", "TEST", 47, 50], ["viral enrichment", "PROBLEM", 101, 117], ["without", "UNCERTAINTY", 93, 100], ["viral enrichment", "OBSERVATION", 101, 117]]], ["The total amount of contigs and the number of contigs matching genomes of viruses form Coronaviridae are shown in Table 2 and Reads mapping to the SARS-CoV-2 reference genome were used to visualize the difference in using capture probes as depicted in Figure 3 , where the SARS-CoV-2 genome is almost completely covered.", [["SARS-CoV-2 reference genome", "DNA", 147, 174], ["SARS-CoV-2 genome", "DNA", 273, 290], ["SARS-CoV", "SPECIES", 147, 155], ["SARS-CoV", "SPECIES", 273, 281], ["The total amount of contigs", "TREATMENT", 0, 27], ["viruses form Coronaviridae", "TREATMENT", 74, 100], ["the SARS", "TEST", 143, 151], ["CoV", "TEST", 152, 155], ["capture probes", "TEST", 222, 236], ["the SARS", "TEST", 269, 277], ["total", "OBSERVATION_MODIFIER", 4, 9], ["amount", "OBSERVATION_MODIFIER", 10, 16]]], ["The two largest contigs built by SPAdes that had a hit with the lowest E-value when BLASTed against genomes from Coronaviridae, were 4866bp and 5811bp in length for the two SARS-CoV-2 samples enriched using probes.DiscussionIn this study, we evaluated the performance of a metagenomic sequencing protocol for the identification of emerging viruses using clinical samples in combination with a simulated reference database.", [["samples", "ANATOMY", 363, 370], ["SPAdes", "DNA", 33, 39], ["E-value", "DNA", 71, 78], ["SARS-CoV", "SPECIES", 173, 181], ["Coronaviridae", "TREATMENT", 113, 126], ["bp", "TEST", 137, 139], ["bp", "TEST", 148, 150], ["length", "TEST", 154, 160], ["the two SARS", "TEST", 165, 177], ["CoV", "TEST", 178, 181], ["this study", "TEST", 227, 237], ["a metagenomic sequencing protocol", "TREATMENT", 271, 304], ["emerging viruses", "PROBLEM", 331, 347], ["clinical samples", "TEST", 354, 370], ["two", "OBSERVATION_MODIFIER", 4, 7], ["largest", "OBSERVATION_MODIFIER", 8, 15]]], ["High and low loads of SARS-CoV-2, SARS-CoV, and MERS-CoV in clinical samples could be detected as 'novel' viruses, using only reference sequences created before these viruses emerged.DiscussionSequence reads were assigned to the closest relatives of these viruses available at that time and assembled with heterologous sequences to 'novel' consensus genomes.", [["samples", "ANATOMY", 69, 76], ["SARS", "DISEASE", 22, 26], ["SARS-CoV-2", "ORGANISM", 22, 32], ["SARS-CoV", "ORGANISM", 34, 42], ["MERS-CoV", "ORGANISM", 48, 56], ["samples", "CANCER", 69, 76], ["heterologous sequences", "DNA", 306, 328], ["novel' consensus genomes", "DNA", 333, 357], ["SARS-CoV", "SPECIES", 22, 30], ["SARS-CoV", "SPECIES", 34, 42], ["MERS-CoV", "SPECIES", 48, 56], ["High and low loads of SARS", "PROBLEM", 0, 26], ["CoV", "TEST", 27, 30], ["SARS", "PROBLEM", 34, 38], ["CoV", "TEST", 39, 42], ["MERS", "PROBLEM", 48, 52], ["CoV in clinical samples", "TEST", 53, 76], ["novel' viruses", "PROBLEM", 99, 113], ["these viruses", "PROBLEM", 250, 263], ["heterologous sequences", "PROBLEM", 306, 328], ["low loads", "OBSERVATION_MODIFIER", 9, 18], ["viruses", "OBSERVATION", 167, 174]]], ["Low identity of these consensus genomes with genomes of closely related ones indicated a novel virus.", [["consensus genomes", "DNA", 22, 39], ["a novel virus", "PROBLEM", 87, 100]]], ["Additionally, J o u r n a l P r e -p r o o f probes targeting sequences of vertebrate viruses, available prior to the coronavirus pandemic of 2020, succeeded in the capture of nearly the full genome of SARS-CoV-2.", [["coronavirus", "DISEASE", 118, 129], ["SARS", "DISEASE", 202, 206], ["SARS-CoV-2", "ORGANISM", 202, 212], ["P r e -p r o o f probes", "DNA", 28, 51], ["SARS-CoV", "SPECIES", 202, 210], ["a l P r e -p r o o f probes targeting sequences", "TEST", 24, 71], ["vertebrate viruses", "PROBLEM", 75, 93], ["CoV", "TEST", 207, 210], ["vertebrate viruses", "OBSERVATION", 75, 93]]], ["It must be noted that the validation was performed using emerging viruses with nucleotide identity of over 76% to their closest known relatives and conclusions cannot be extended to novel viruses which are less closely related.", [["nucleotide", "CHEMICAL", 79, 89], ["nucleotide", "CHEMICAL", 79, 89], ["the validation", "TEST", 22, 36], ["nucleotide identity", "TEST", 79, 98], ["novel viruses", "PROBLEM", 182, 195], ["viruses", "OBSERVATION", 188, 195]]], ["Nucleotide (and amino acid) identities reported in literature with regard to novel human pathogenic viruses vary, for example 50% for older viruses like SARS-CoV [1] , 80% for MERS-CoV [14] , 88% for parts of the Human Metapneumovirus [28] and up to 97.2% for parts of SARS-CoV-2 [29] .DiscussionSeveral reports have shown an increase of 100-10.000 fold in sensitivity for detection of known viruses when using capture probes [10] , [30] and here we report the potential of using capture probes in the detection of novel viruses.", [["amino acid", "CHEMICAL", 16, 26], ["SARS", "DISEASE", 153, 157], ["SARS", "DISEASE", 269, 273], ["Nucleotide", "CHEMICAL", 0, 10], ["amino acid", "CHEMICAL", 16, 26], ["amino acid", "AMINO_ACID", 16, 26], ["human", "ORGANISM", 83, 88], ["SARS-CoV", "ORGANISM", 153, 161], ["MERS-CoV", "ORGANISM", 176, 184], ["Human", "ORGANISM", 213, 218], ["human", "SPECIES", 83, 88], ["Human", "SPECIES", 213, 218], ["human", "SPECIES", 83, 88], ["SARS-CoV", "SPECIES", 153, 161], ["MERS-CoV", "SPECIES", 176, 184], ["Human Metapneumovirus", "SPECIES", 213, 234], ["SARS-CoV", "SPECIES", 269, 277], ["Nucleotide (and amino acid)", "TREATMENT", 0, 27], ["novel human pathogenic viruses", "PROBLEM", 77, 107], ["older viruses", "PROBLEM", 134, 147], ["SARS", "TEST", 153, 157], ["CoV", "TEST", 158, 161], ["MERS", "TEST", 176, 180], ["CoV", "TEST", 181, 184], ["the Human Metapneumovirus", "TEST", 209, 234], ["SARS", "TEST", 269, 273], ["CoV", "TEST", 274, 277], ["known viruses", "PROBLEM", 386, 399], ["capture probes", "TREATMENT", 480, 494], ["novel viruses", "PROBLEM", 515, 528], ["Human", "ANATOMY", 213, 218], ["Metapneumovirus", "OBSERVATION", 219, 234], ["increase", "OBSERVATION_MODIFIER", 326, 334], ["viruses", "OBSERVATION", 392, 399]]], ["Sequence variation was addressed in the probe design by retaining mutant or variant sequences if sequences diverged by more than 90% [10] .", [["mutant or variant sequences", "DNA", 66, 93], ["Sequence variation", "TEST", 0, 18]]], ["Lipkin and colleagues describe the capture of conserved regions of a rodent hepacivirus isolate with 75% identity using VirSeqCap VERT, and even 40% for detection rather than whole genome sequencing is suggested [10] .", [["hepacivirus", "CANCER", 76, 87], ["VirSeqCap VERT", "DNA", 120, 134], ["rodent", "SPECIES", 69, 75], ["VirSeqCap VERT", "TREATMENT", 120, 134], ["whole genome sequencing", "TEST", 175, 198]]], ["The capture probes used in this study targeted sequences of several isolates of alpha-, beta-, gamma-, and deltacoronaviruses.", [["alpha-", "GENE_OR_GENE_PRODUCT", 80, 86], ["beta-", "GENE_OR_GENE_PRODUCT", 88, 93], ["gamma-", "GENE_OR_GENE_PRODUCT", 95, 101], ["deltacoronaviruses", "GENE_OR_GENE_PRODUCT", 107, 125], ["alpha-, beta-, gamma-, and deltacoronaviruses", "DNA", 80, 125], ["The capture probes", "TREATMENT", 0, 18], ["this study", "TEST", 27, 37], ["alpha-", "TEST", 80, 86], ["deltacoronaviruses", "PROBLEM", 107, 125]]], ["In this study the whole genome of SARS-CoV-2, with 76-100% overall nucleotide identity to the probe targets, was detected using these probes.DiscussionMetagenomic sequencing is increasingly being used in diagnostic laboratories as a hypothesis-free approach for suspected infectious diseases in undiagnosed cases.", [["nucleotide", "CHEMICAL", 67, 77], ["infectious diseases", "DISEASE", 272, 291], ["nucleotide", "CHEMICAL", 67, 77], ["SARS-CoV-2", "ORGANISM", 34, 44], ["SARS-CoV-2", "DNA", 34, 44], ["probe targets", "DNA", 94, 107], ["SARS-CoV", "SPECIES", 34, 42], ["this study", "TEST", 3, 13], ["SARS", "TEST", 34, 38], ["CoV", "TEST", 39, 42], ["diagnostic laboratories", "TEST", 204, 227], ["suspected infectious diseases in undiagnosed cases", "PROBLEM", 262, 312], ["infectious", "OBSERVATION", 272, 282]]], ["Metagenomic sequencing in diagnostic laboratories has resulted in the detection of pathogens present in the reference database but either not tested for by routine methods due to rare or unknown associations with a specific disease, or for which routine testing failed (e.g., due to primer mismatches).", [["Metagenomic sequencing", "TEST", 0, 22], ["diagnostic laboratories", "TEST", 26, 49], ["pathogens", "PROBLEM", 83, 92], ["a specific disease", "PROBLEM", 213, 231], ["routine testing", "TEST", 246, 261], ["primer mismatches", "PROBLEM", 283, 300], ["pathogens", "OBSERVATION", 83, 92]]], ["Additionally, mNGS enables the detection of novel pathogens not (yet) present in the databases.", [["mNGS", "PROTEIN", 14, 18], ["novel pathogens", "PROBLEM", 44, 59]]], ["Common bioinformatic classifiers are usually not designed for discovery purposes, so additional algorithms including a separate validation to assess the performance in a discovery setting are needed.", [["discovery purposes", "TEST", 62, 80], ["additional algorithms", "TEST", 85, 106], ["a separate validation", "TEST", 117, 138]]], ["Reports on specific J o u r n a l P r e -p r o o f bioinformatic discovery tools typically describe the algorithm and an in silico analysis and here we present validation studies on the performance of virus discovery tools using clinical samples.DiscussionImplementation of virus discovery protocols in diagnostic laboratories may contribute to increased vigilance for emerging viruses and therefore aids in surveillance and pandemic preparedness.Conflict of interestThe authors have no conflicts of interest.", [["samples", "ANATOMY", 238, 245], ["bioinformatic discovery tools", "TEST", 51, 80], ["the algorithm", "TEST", 100, 113], ["an in silico analysis", "TEST", 118, 139], ["validation studies", "TEST", 160, 178], ["clinical samples", "TEST", 229, 245], ["virus discovery protocols", "TREATMENT", 274, 299], ["diagnostic laboratories", "TEST", 303, 326], ["increased vigilance", "PROBLEM", 345, 364], ["emerging viruses", "PROBLEM", 369, 385]]], ["J o u r n a l P r e -p r o o f Table showing the total number of built contigs with a length >=500bp, the number of these contigs where the hit with the lowest E-value would be a hit to viruses, the number of contigs where the hit with the lowest E-value would be a hit to Coronaviridae and of this last group the length of the longest contig, the alignment length, identity match, taxonomic name of BLAST result and the release years of sequences belonging to the species and subjects found by BLAST.", [["a length", "TEST", 84, 92], ["bp", "TEST", 98, 100], ["a hit to viruses", "PROBLEM", 177, 193], ["Coronaviridae", "TREATMENT", 273, 286]]]], "PMC7471565": [["In December 2019, in Wuhan, China, the novel coronavirus \u2018severe acute respiratory syndrome 2\u2019 (SARS-CoV-2) was discovered as the cause of a pneumonia-like illness(1) and subsequently named coronavirus disease 2019 (COVID-19)(2).", [["coronavirus", "DISEASE", 45, 56], ["acute respiratory syndrome", "DISEASE", 65, 91], ["pneumonia", "DISEASE", 141, 150], ["coronavirus disease", "DISEASE", 190, 209], ["coronavirus \u2018severe acute respiratory", "ORGANISM", 45, 82], ["SARS-CoV-2", "ORGANISM", 96, 106], ["coronavirus", "SPECIES", 45, 56], ["coronavirus \u2018severe acute respiratory syndrome 2\u2019", "SPECIES", 45, 94], ["SARS-CoV-2", "SPECIES", 96, 106], ["the novel coronavirus", "PROBLEM", 35, 56], ["severe acute respiratory syndrome", "PROBLEM", 58, 91], ["SARS-CoV", "TEST", 96, 104], ["a pneumonia", "PROBLEM", 139, 150], ["coronavirus disease", "PROBLEM", 190, 209], ["COVID", "TEST", 216, 221], ["severe", "OBSERVATION_MODIFIER", 58, 64], ["acute", "OBSERVATION_MODIFIER", 65, 70], ["respiratory syndrome", "OBSERVATION", 71, 91], ["pneumonia", "OBSERVATION", 141, 150], ["coronavirus disease", "OBSERVATION", 190, 209]]], ["COVID-19 spread and is now a worldwide pandemic(3).", [["COVID-19", "CHEMICAL", 0, 8], ["COVID", "TEST", 0, 5], ["19 spread", "OBSERVATION_MODIFIER", 6, 15]]], ["Globally, SARS-CoV-2 has infected 20 ,439, 814 people and resulted in 744 ,385 deaths (13 August 2020)(4).", [["SARS", "DISEASE", 10, 14], ["deaths", "DISEASE", 79, 85], ["SARS-CoV-2", "ORGANISM", 10, 20], ["people", "ORGANISM", 47, 53], ["people", "SPECIES", 47, 53], ["SARS-CoV", "SPECIES", 10, 18], ["SARS", "TEST", 10, 14], ["CoV", "TEST", 15, 18], ["SARS", "OBSERVATION", 10, 14]]], ["In a retrospective Chinese multicentre cohort study, multivariable regression analysis determined that older age was associated with an increased odds of in-hospital death (OR 1\u22c510; 95% CI: 1\u22c503, 1\u22c517, per year increase; p= 0\u22c50043)(5).", [["death", "DISEASE", 166, 171], ["multivariable regression analysis", "TEST", 53, 86], ["CI", "TEST", 186, 188], ["increased", "OBSERVATION_MODIFIER", 136, 145]]], ["While older people do not appear to be at an increased risk of contracting COVID-19, they are more vulnerable to developing serious complications and have the highest mortality rate(5\u20137).", [["people", "ORGANISM", 12, 18], ["people", "SPECIES", 12, 18], ["serious complications", "PROBLEM", 124, 145]]], ["Many older people have comorbidities such as cardiovascular disease, diabetes and frailty that deplete their reserves and weaken their immune response(8).", [["cardiovascular", "ANATOMY", 45, 59], ["cardiovascular disease", "DISEASE", 45, 67], ["diabetes", "DISEASE", 69, 77], ["frailty", "DISEASE", 82, 89], ["people", "ORGANISM", 11, 17], ["people", "SPECIES", 11, 17], ["comorbidities", "PROBLEM", 23, 36], ["cardiovascular disease", "PROBLEM", 45, 67], ["diabetes", "PROBLEM", 69, 77], ["cardiovascular", "ANATOMY", 45, 59], ["disease", "OBSERVATION", 60, 67]]], ["Moreover, hospitalised patients with concomitant cardiac disease and COVID-19 have an extremely poor prognosis compared to those without a history of cardiac disease(9).", [["cardiac", "ANATOMY", 49, 56], ["cardiac", "ANATOMY", 150, 157], ["cardiac disease", "DISEASE", 49, 64], ["cardiac disease", "DISEASE", 150, 165], ["patients", "ORGANISM", 23, 31], ["cardiac", "ORGAN", 49, 56], ["cardiac", "ORGAN", 150, 157], ["patients", "SPECIES", 23, 31], ["concomitant cardiac disease", "PROBLEM", 37, 64], ["COVID", "TEST", 69, 74], ["cardiac disease", "PROBLEM", 150, 165], ["cardiac", "ANATOMY", 49, 56], ["disease", "OBSERVATION", 57, 64], ["cardiac", "ANATOMY", 150, 157], ["disease", "OBSERVATION", 158, 165]]]], "664563d8f7858aa1fe412414d4728b9243930e5a": [["R espiratory infection outbreaks in institutions housinglarge numbers of residents create an ideal environment for disease transmission (1) .", [["infection", "DISEASE", 13, 22], ["R espiratory infection", "PROBLEM", 0, 22], ["espiratory", "OBSERVATION_MODIFIER", 2, 12], ["infection", "OBSERVATION", 13, 22]]], ["Patients in long-term care facilities (LTCFs) for the elderly are more susceptible to respiratory infections and have a higher risk for complications (2, 3) .The StudyWe reviewed respiratory infection outbreaks registered with the Public Health Laboratory (PHL), Ontario Agency for Health Protection and Promotion dating back to October 2007 (Table 1) .", [["respiratory", "ANATOMY", 86, 97], ["respiratory infections", "DISEASE", 86, 108], ["respiratory infection", "DISEASE", 179, 200], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["respiratory infections", "PROBLEM", 86, 108], ["complications", "PROBLEM", 136, 149], ["respiratory infection outbreaks", "PROBLEM", 179, 210], ["Health Protection", "TREATMENT", 282, 299], ["respiratory", "ANATOMY", 86, 97], ["infections", "OBSERVATION", 98, 108], ["respiratory", "ANATOMY", 179, 190], ["infection", "OBSERVATION", 191, 200]]], ["Molecular detection methods were used for a subset of outbreaks registered during October 1, 2008 -April 19, 2009 .", [["Molecular detection methods", "TEST", 0, 27]]], ["After emergence of severe respiratory illness clusters in Mexico in early April, intensifi ed tracking of respiratory infection outbreaks in Ontario was undertaken.", [["respiratory", "ANATOMY", 26, 37], ["respiratory", "ANATOMY", 106, 117], ["respiratory illness", "DISEASE", 26, 45], ["respiratory infection", "DISEASE", 106, 127], ["severe respiratory illness clusters", "PROBLEM", 19, 54], ["respiratory infection outbreaks", "PROBLEM", 106, 137], ["severe", "OBSERVATION_MODIFIER", 19, 25], ["respiratory illness", "OBSERVATION", 26, 45], ["respiratory", "ANATOMY", 106, 117], ["infection", "OBSERVATION", 118, 127]]], ["Consequently, more information was available on outbreaks registered during the spring (April 20 to June 12, 2009); these data comprise the bulk of the study.The StudyRespiratory infection outbreaks in LTCFs were defi ned as any of the following: 2 cases of acute respiratory tract illness, 1 of which was laboratory-confi rmed; 3 cases of acute respiratory tract illness within 48 hours in a geographic area (e.g., unit, fl oor); and >2 units having a case of acute respiratory illness within a 48-hour period.", [["respiratory tract", "ANATOMY", 264, 281], ["respiratory tract", "ANATOMY", 346, 363], ["respiratory", "ANATOMY", 467, 478], ["infection", "DISEASE", 179, 188], ["LTCFs", "DISEASE", 202, 207], ["respiratory tract illness", "DISEASE", 264, 289], ["respiratory tract illness", "DISEASE", 346, 371], ["respiratory illness", "DISEASE", 467, 486], ["tract", "ORGANISM_SUBDIVISION", 276, 281], ["the study", "TEST", 148, 157], ["The StudyRespiratory infection outbreaks", "PROBLEM", 158, 198], ["acute respiratory tract illness", "PROBLEM", 258, 289], ["acute respiratory tract illness", "PROBLEM", 340, 371], ["acute respiratory illness", "PROBLEM", 461, 486], ["infection", "OBSERVATION", 179, 188], ["acute", "OBSERVATION_MODIFIER", 258, 263], ["respiratory tract", "ANATOMY", 264, 281], ["acute", "OBSERVATION_MODIFIER", 340, 345], ["respiratory tract", "ANATOMY", 346, 363], ["acute", "OBSERVATION_MODIFIER", 461, 466], ["respiratory illness", "OBSERVATION", 467, 486]]], ["Infl uenzalike-illness was defi ned as acute onset of respiratory illness with fever and cough with >1 of the following: sore throat, arthralgia, myalgia, or prostration.The StudyFrom April 20 through June 12, 2009, a total of 112 respiratory infection outbreaks were registered.", [["respiratory", "ANATOMY", 54, 65], ["uenzalike-illness", "DISEASE", 5, 22], ["respiratory illness", "DISEASE", 54, 73], ["fever", "DISEASE", 79, 84], ["cough", "DISEASE", 89, 94], ["sore throat", "DISEASE", 121, 132], ["arthralgia", "DISEASE", 134, 144], ["myalgia", "DISEASE", 146, 153], ["prostration", "DISEASE", 158, 169], ["respiratory infection", "DISEASE", 231, 252], ["illness", "PROBLEM", 15, 22], ["respiratory illness", "PROBLEM", 54, 73], ["fever", "PROBLEM", 79, 84], ["cough", "PROBLEM", 89, 94], ["sore throat", "PROBLEM", 121, 132], ["arthralgia", "PROBLEM", 134, 144], ["myalgia", "PROBLEM", 146, 153], ["prostration", "PROBLEM", 158, 169], ["The Study", "TEST", 170, 179], ["112 respiratory infection outbreaks", "PROBLEM", 227, 262], ["illness", "OBSERVATION", 15, 22], ["acute", "OBSERVATION_MODIFIER", 39, 44], ["respiratory", "ANATOMY", 54, 65], ["illness", "OBSERVATION", 66, 73], ["fever", "OBSERVATION", 79, 84], ["sore throat", "ANATOMY", 121, 132], ["arthralgia", "OBSERVATION", 134, 144], ["myalgia", "OBSERVATION", 146, 153], ["respiratory", "ANATOMY", 231, 242], ["infection", "OBSERVATION", 243, 252]]], ["Molecular testing was not used in 29 outbreaks (e.g., insuffi cient/inappropriate sample).", [["Molecular testing", "TEST", 0, 17]]], ["Most of the remaining 83 outbreaks submitted for molecular testing originated from LTCFs (91%); hospitals (2%), child care centers (2%), and psychiatric care facilities (1%) comprised the remainder.", [["LTCFs", "DISEASE", 83, 88], ["psychiatric", "DISEASE", 141, 152], ["molecular testing", "TEST", 49, 66]]], ["Mean age of persons tested as part of an outbreak investigation was 82 years (SD 13.96 years) and median age was 85 years; 95% were >57 years of age.The StudyTesting on the 589 specimens received from 161 outbreaks registered from October 1, 2008 through June 12, 2009 was performed by real-time reverse transcription-PCR (RT-PCR) for the infl uenza A virus matrix gene and the Luminex Respiratory Viral Panel (RVP) (Luminex Molecular Diagnostics, Toronto, Ontario, Canada) for other respiratory viruses.The StudyAn etiologic agent was identifi ed in 89% of the 161 outbreaks tested by molecular methods.", [["specimens", "ANATOMY", 177, 186], ["respiratory viruses", "DISEASE", 484, 503], ["persons", "ORGANISM", 12, 19], ["infl uenza A", "GENE_OR_GENE_PRODUCT", 339, 351], ["persons", "SPECIES", 12, 19], ["infl uenza A virus", "SPECIES", 339, 357], ["PCR", "TEST", 318, 321], ["RT-PCR", "TEST", 323, 329], ["the infl uenza A virus matrix gene", "TREATMENT", 335, 369], ["the Luminex Respiratory Viral Panel", "TEST", 374, 409], ["RVP", "TEST", 411, 414], ["other respiratory viruses", "PROBLEM", 478, 503], ["respiratory", "ANATOMY", 484, 495], ["viruses", "OBSERVATION", 496, 503]]], ["Two and 3 different pathogens were identifi ed in 24 (15%) and 6 (4%) outbreaks, respectively.", [["3 different pathogens", "PROBLEM", 8, 29]]], ["No etiologic agent was identifi ed in 18 (11%) of the outbreaks tested by molecular methods, which includes 1 specimen in which the result was indeterminate for coronavirus OC43.", [["specimen", "ANATOMY", 110, 118], ["coronavirus", "ORGANISM", 161, 172], ["coronavirus OC43", "PROTEIN", 161, 177], ["coronavirus", "SPECIES", 161, 172], ["coronavirus OC43", "SPECIES", 161, 177], ["etiologic agent", "PROBLEM", 3, 18], ["the outbreaks", "PROBLEM", 50, 63], ["coronavirus OC43", "PROBLEM", 161, 177], ["etiologic", "UNCERTAINTY", 3, 12], ["agent", "OBSERVATION_MODIFIER", 13, 18], ["indeterminate", "OBSERVATION_MODIFIER", 143, 156], ["coronavirus OC43", "OBSERVATION", 161, 177]]], ["A wide range of causative etiologic agents were detected for outbreaks by the RVP assay (Table 2) .", [["the RVP assay", "TEST", 74, 87], ["wide", "OBSERVATION_MODIFIER", 2, 6]]], ["Specimens from most patients were positive for enterovirus/rhinovirus (114 patients) followed by metapneumovirus (85) Co-infections were noted in 22 of the patients tested by the RVP assay.", [["Specimens", "ANATOMY", 0, 9], ["enterovirus/rhinovirus", "DISEASE", 47, 69], ["patients", "ORGANISM", 20, 28], ["enterovirus", "ORGANISM", 47, 58], ["rhinovirus", "ORGANISM", 59, 69], ["patients", "ORGANISM", 75, 83], ["metapneumovirus", "ORGANISM", 97, 112], ["patients", "ORGANISM", 156, 164], ["patients", "SPECIES", 20, 28], ["patients", "SPECIES", 75, 83], ["patients", "SPECIES", 156, 164], ["enterovirus/rhinovirus", "SPECIES", 47, 69], ["Specimens", "TEST", 0, 9], ["enterovirus", "PROBLEM", 47, 58], ["rhinovirus", "PROBLEM", 59, 69], ["metapneumovirus", "PROBLEM", 97, 112], ["Co-infections", "PROBLEM", 118, 131], ["the RVP assay", "TEST", 175, 188]]], ["In 1 LTCF outbreak, 2 patients had co-infection of an untypeable infl uenza A and enterovirus/rhinovirus on testing by RVP.", [["enterovirus/rhinovirus", "DISEASE", 82, 104], ["patients", "ORGANISM", 22, 30], ["infl uenza A", "CANCER", 65, 77], ["enterovirus", "ORGANISM", 82, 93], ["rhinovirus", "ORGANISM", 94, 104], ["patients", "SPECIES", 22, 30], ["enterovirus/rhinovirus", "SPECIES", 82, 104], ["co-infection", "PROBLEM", 35, 47], ["an untypeable infl uenza A", "PROBLEM", 51, 77], ["enterovirus", "PROBLEM", 82, 93], ["rhinovirus", "PROBLEM", 94, 104], ["testing", "TEST", 108, 115], ["RVP", "TEST", 119, 122], ["rhinovirus", "OBSERVATION", 94, 104]]], ["An infl uenza A real-time RT-PCR result was negative in both patients; 1 patient had a co-infection with respiratory syncytial virus B and enterovirus/ rhinovirus.", [["respiratory syncytial virus B", "DISEASE", 105, 134], ["enterovirus/ rhinovirus", "DISEASE", 139, 162], ["patients", "ORGANISM", 61, 69], ["patient", "ORGANISM", 73, 80], ["respiratory syncytial virus B", "ORGANISM", 105, 134], ["enterovirus", "ORGANISM", 139, 150], ["rhinovirus", "ORGANISM", 152, 162], ["patients", "SPECIES", 61, 69], ["patient", "SPECIES", 73, 80], ["respiratory syncytial virus", "SPECIES", 105, 132], ["enterovirus/ rhinovirus", "SPECIES", 139, 162], ["RT-PCR", "TEST", 26, 32], ["a co-infection", "PROBLEM", 85, 99], ["respiratory syncytial virus B", "PROBLEM", 105, 134], ["enterovirus", "PROBLEM", 139, 150], ["rhinovirus", "PROBLEM", 152, 162], ["co-infection", "OBSERVATION", 87, 99], ["respiratory", "ANATOMY", 105, 116], ["syncytial virus", "OBSERVATION", 117, 132], ["rhinovirus", "OBSERVATION", 152, 162]]], ["Co-infections with coronavirus subtypes 229E and NL63 were the most common, observed in 10 of the 22 patients (45%) infected with multiple pathogens.", [["Co-infections", "DISEASE", 0, 13], ["coronavirus subtypes 229E", "ORGANISM", 19, 44], ["NL63", "GENE_OR_GENE_PRODUCT", 49, 53], ["patients", "ORGANISM", 101, 109], ["coronavirus", "SPECIES", 19, 30], ["patients", "SPECIES", 101, 109], ["Co-infections", "PROBLEM", 0, 13], ["coronavirus subtypes", "TEST", 19, 39], ["multiple pathogens", "PROBLEM", 130, 148], ["multiple", "OBSERVATION_MODIFIER", 130, 138], ["pathogens", "OBSERVATION", 139, 148]]], ["Isolates from 1 patient were positive for 3 viruses (coronavirus subtypes 229E and NL63 and enterovirus/rhinovirus).The StudyOne Persons with laboratory-confi rmed pandemic (H1N1) 2009 infection tested at the PHL, Ontario Agency for Health Protection and Promotion, were younger than those tested as part of outbreak investigations.", [["enterovirus/rhinovirus", "DISEASE", 92, 114], ["pandemic (H1N1) 2009 infection", "DISEASE", 164, 194], ["patient", "ORGANISM", 16, 23], ["coronavirus subtypes 229E", "ORGANISM", 53, 78], ["enterovirus/rhinovirus", "ORGANISM", 92, 114], ["confi rmed pandemic", "ORGANISM", 153, 172], ["patient", "SPECIES", 16, 23], ["Persons", "SPECIES", 129, 136], ["Isolates", "TEST", 0, 8], ["3 viruses", "PROBLEM", 42, 51], ["coronavirus subtypes", "TEST", 53, 73], ["NL63", "TEST", 83, 87], ["enterovirus", "PROBLEM", 92, 103], ["rhinovirus", "PROBLEM", 104, 114], ["pandemic", "PROBLEM", 164, 172], ["H1N1", "PROBLEM", 174, 178], ["infection", "PROBLEM", 185, 194], ["Health Protection", "TREATMENT", 233, 250], ["outbreak investigations", "TEST", 308, 331]]], ["Mean and median ages were 21.5 and 16 years, respectively; only 10% were >46 years of age.ConclusionsThe number of respiratory infection outbreaks in institutions submitted to PHL may refl ect disease impact caused by respiratory viruses during the infl uenza season.", [["respiratory", "ANATOMY", 115, 126], ["respiratory infection", "DISEASE", 115, 136], ["PHL", "CHEMICAL", 176, 179], ["respiratory viruses", "DISEASE", 218, 237], ["Mean", "TEST", 0, 4], ["respiratory infection outbreaks", "PROBLEM", 115, 146], ["ect disease impact", "PROBLEM", 189, 207], ["respiratory viruses", "PROBLEM", 218, 237], ["respiratory", "OBSERVATION_MODIFIER", 115, 126], ["infection", "OBSERVATION", 127, 136], ["respiratory viruses", "OBSERVATION", 218, 237]]], ["Respiratory viruses during the 2007-08 season may have been more active than those of the 2008-09 season because the number of outbreaks registered with PHL decreased from 1 year to the next.", [["PHL", "DISEASE", 153, 156], ["Respiratory viruses", "PROBLEM", 0, 19], ["PHL", "PROBLEM", 153, 156], ["viruses", "OBSERVATION", 12, 19], ["active", "OBSERVATION_MODIFIER", 65, 71]]], ["Declaration of pandemic status for the novel (H1N1) virus has not infl uenced the reporting of respiratory infection outbreaks from institutions in Ontario because submission rates for the corresponding period in 2007-08 and 2008-09 are similar.", [["respiratory infection", "DISEASE", 95, 116], ["novel (H1N1) virus", "ORGANISM", 39, 57], ["the novel (H1N1) virus", "PROBLEM", 35, 57], ["respiratory infection", "PROBLEM", 95, 116], ["submission rates", "TEST", 164, 180], ["respiratory", "ANATOMY", 95, 106], ["infection", "OBSERVATION", 107, 116]]], ["Variation would not be expected because reporting is required by Ontario law (4) .ConclusionsRespiratory viruses detected in outbreaks in institutions refl ect those known to be major causes of acute respiratory disease in the community; prevalence varies based on geographic location, season, and detection methods (5) (6) (7) .", [["respiratory", "ANATOMY", 200, 211], ["Respiratory viruses", "DISEASE", 93, 112], ["acute respiratory disease", "DISEASE", 194, 219], ["Respiratory viruses", "PROBLEM", 93, 112], ["acute respiratory disease", "PROBLEM", 194, 219], ["Respiratory viruses", "OBSERVATION", 93, 112], ["acute", "OBSERVATION_MODIFIER", 194, 199], ["respiratory disease", "OBSERVATION", 200, 219]]], ["Free access to such institutions by members of the community (staff or visitors), in conjunction with communal close quarters of residents, creates an ideal environment for propagation of viral respiratory outbreaks (8) .ConclusionsCurrent guidelines for isolation during viral respiratory outbreaks are not tailored for the specifi c virus.", [["viral respiratory outbreaks", "DISEASE", 188, 215], ["viral respiratory outbreaks", "DISEASE", 272, 299], ["specifi c virus", "ORGANISM", 325, 340], ["viral respiratory outbreaks", "PROBLEM", 188, 215], ["isolation", "TREATMENT", 255, 264], ["viral respiratory outbreaks", "PROBLEM", 272, 299], ["the specifi c virus", "PROBLEM", 321, 340], ["viral respiratory outbreaks", "OBSERVATION", 188, 215]]], ["As shown in this study, multiplex molecular testing makes it possible to identify the virus causing most LTCF respiratory infection outbreaks.", [["respiratory infection", "DISEASE", 110, 131], ["this study", "TEST", 12, 22], ["multiplex molecular testing", "TEST", 24, 51], ["the virus", "PROBLEM", 82, 91], ["most LTCF respiratory infection outbreaks", "PROBLEM", 100, 141], ["infection", "OBSERVATION", 122, 131]]], ["Infection control guidelines for a specifi c outbreak could be modifi ed based on the incubation period and duration of viral shedding for the identifi ed virus (9) .ConclusionsThe most commonly identifi ed virus in our study was enterovirus/rhinovirus.", [["enterovirus/rhinovirus", "DISEASE", 230, 252], ["enterovirus", "ORGANISM", 230, 241], ["rhinovirus", "ORGANISM", 242, 252], ["enterovirus/rhinovirus", "SPECIES", 230, 252], ["Infection control guidelines", "TREATMENT", 0, 28], ["a specifi c outbreak", "PROBLEM", 33, 53], ["viral shedding", "PROBLEM", 120, 134], ["the identifi ed virus", "TREATMENT", 139, 160], ["ed virus", "PROBLEM", 204, 212], ["our study", "TEST", 216, 225], ["enterovirus", "PROBLEM", 230, 241], ["rhinovirus", "PROBLEM", 242, 252], ["rhinovirus", "OBSERVATION", 242, 252]]], ["Clinicians should be reminded that rhinovirus can cause severe lower respiratory tract infection, including death, as documented in several LTCF outbreaks (10, 11) .", [["lower respiratory tract", "ANATOMY", 63, 86], ["rhinovirus", "DISEASE", 35, 45], ["lower respiratory tract infection", "DISEASE", 63, 96], ["death", "DISEASE", 108, 113], ["rhinovirus", "ORGANISM", 35, 45], ["lower", "ORGANISM_SUBDIVISION", 63, 68], ["respiratory tract", "ORGANISM_SUBDIVISION", 69, 86], ["rhinovirus", "PROBLEM", 35, 45], ["severe lower respiratory tract infection", "PROBLEM", 56, 96], ["death", "PROBLEM", 108, 113], ["severe", "OBSERVATION_MODIFIER", 56, 62], ["lower", "ANATOMY_MODIFIER", 63, 68], ["respiratory tract", "ANATOMY", 69, 86], ["infection", "OBSERVATION", 87, 96]]], ["These data highlight the need for molecular capacity to diagnose rhinovirus infection because detection is otherwise limited to less sensitive viral culture systems.", [["rhinovirus infection", "DISEASE", 65, 85], ["rhinovirus", "ORGANISM", 65, 75], ["molecular capacity", "PROBLEM", 34, 52], ["diagnose rhinovirus infection", "PROBLEM", 56, 85], ["less sensitive viral culture systems", "PROBLEM", 128, 164], ["rhinovirus", "OBSERVATION", 65, 75]]], ["This review of outbreaks predominantly involving elderly persons in LTCFs highlights the sparing of older persons by pandemic (H1N1) 2009.", [["LTCFs", "DISEASE", 68, 73], ["pandemic", "DISEASE", 117, 125], ["persons", "ORGANISM", 57, 64], ["persons", "ORGANISM", 106, 113], ["persons", "SPECIES", 57, 64], ["persons", "SPECIES", 106, 113]]], ["Possible explanations include cross-protective antibodies from previous exposure to infl uenza A (H1N1) strains circulating before the antigenic shift of infl uenza A to subtype H2N2 in 1957 or minimal contact with those most likely to have imported the pandemic strain into Canada (young travelers) (12) .", [["infl uenza A (H1N1) strains", "ORGANISM", 84, 111], ["infl uenza A", "ORGANISM", 154, 166], ["subtype H2N2", "ORGANISM", 170, 182], ["cross-protective antibodies", "PROTEIN", 30, 57], ["infl uenza A (H1N1)", "SPECIES", 84, 103], ["infl uenza A", "SPECIES", 154, 166], ["cross-protective antibodies", "PROBLEM", 30, 57], ["A (H1N1) strains", "PROBLEM", 95, 111]]], ["In addition, older persons may have less contact with the age group (children 10-19 years of age), with most cases being in Ontario.", [["persons", "ORGANISM", 19, 26], ["persons", "SPECIES", 19, 26], ["children", "SPECIES", 69, 77]]], ["Our fi ndings support Centers for Disease Control and Prevention guidelines for vaccination with monovalent pandemic (H1N1) 2009 virus vaccine.", [["pandemic", "DISEASE", 108, 116], ["monovalent pandemic (H1N1) 2009 virus", "ORGANISM", 97, 134], ["H1N1) 2009 virus", "SPECIES", 118, 134], ["Disease Control", "TREATMENT", 34, 49], ["Prevention guidelines", "TREATMENT", 54, 75], ["vaccination with monovalent pandemic (H1N1)", "TREATMENT", 80, 123]]], ["These guidelines have not placed older persons in a high priority group for vaccination because increased rates of hospitalization and severe disease caused by pandemic (H1N1) 2009 have not been observed (13, 14) .", [["pandemic", "DISEASE", 160, 168], ["persons", "ORGANISM", 39, 46], ["persons", "SPECIES", 39, 46], ["vaccination", "TREATMENT", 76, 87], ["severe disease", "PROBLEM", 135, 149], ["pandemic (H1N1)", "PROBLEM", 160, 175], ["severe", "OBSERVATION_MODIFIER", 135, 141], ["disease", "OBSERVATION", 142, 149], ["pandemic", "OBSERVATION_MODIFIER", 160, 168]]], ["Investment in multiplex technologies to investigate respiratory outbreaks in LTCFs shortens time for pathogen detection, helps guide infection control and vaccination policies, and can potentially save resources spent on other investigations.", [["respiratory outbreaks", "DISEASE", 52, 73], ["infection", "DISEASE", 133, 142], ["respiratory outbreaks", "PROBLEM", 52, 73], ["pathogen detection", "TEST", 101, 119], ["infection control", "TREATMENT", 133, 150], ["vaccination policies", "TREATMENT", 155, 175], ["other investigations", "TEST", 221, 241]]]]}